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Increasing health care costs worldwide put the current health care systems under 
pressure. While many efforts have aimed to contain costs in medicine, only few have 
achieved substantial changes. Inflammatory bowel diseases (IBD) rank among the most 
costly of chronic diseases and physicians nowadays are increasingly engaged in health 
economic discussions. Value-Based Health Care (VBHC) has gained a lot of attention 
recently, and is thought to be the way forward to contain costs while maintaining quality. 
The key concept behind VBHC is to improve achieved outcomes per the encountered 
costs, and evaluate performance accordingly. Four main components need to be in place 
for the system to be effective: 1) accurate measurement of health outcomes and costs; 2) 
reporting of these outcomes and benchmarking against other providers; 3) identification 
of areas in need of improvement based on these data and adjusting the care delivery 
processes accordingly; and 4) rewarding well-performing participants. In this article we 
will explore the key components of VBHC, we will review available evidence focusing on 
inflammatory bowel diseases and we will present our own experience as a guide for other 
providers. 
Introduction 
Worldwide health care costs continue to increase at an alarming pace. Despite differences 
in care delivery and financial infrastructure, most countries cope with similar trends of 
increasing health expenditures. It seems to be a universal ‘unsolvable’ problem (Figure 
1.1a). Even more disturbingly, the expenditure increase is not consistently accompanied 
by an increase in quality and improved health outcomes (Figure 1.1b).1 Various factors 
have been implicated to contribute to the problem: ineffective care delivery, excessive 
administration costs, non-adherence to guidelines, uncoordinated care, practice of 
defensive medicine, lack of preventative care, and introduction of new technologies.2 One 
overarching notion that has emerged is that necessary preventative care is 
underdelivered, while unnecessary care is overdelivered. In Chapter 5 we show that 
guideline adherence in IBD care is poor as well: many unnecessary services are 
overdelivered, while preventative services are often lacking. Indeed, due to current fee-
for-service payment structure, physicians are incentivized to often deliver more care than 
is necessary. Patients are usually unaware since there is little reporting on quality and 
health outcomes by individual physicians or hospitals. 
Though reforms have addressed one or more of the abovementioned items, none have 
managed to achieve substantial savings that bend the overall cost curve. Solutions to 
reduce health care spending have frequently involved shifting costs around among 
participants: shifting costs from insurers to patients by increasing the annual premiums; 
shifting costs between insurers; or shifting costs towards providers by introducing 
capitated payments. But shifting costs around has not resulted in decreased overall 
spending in any way.3 Recently it has become accepted that a complete care redesign, 
involving all stakeholders, is warranted to solve the health care crisis. Moreover, the right 
incentives should be put in place for all participants in order to ensure sustainability. An 
area which is rapidly gaining ground is the area of value-based health care (VBHC) which 
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solely focuses on achieved health outcomes and associated cost-effectiveness. This review 
introduces the concepts and rationale behind VBHC and provides early results observed in 
the care for patients with IBD. 
Figure 1.1. Health care data for the U.S. and four European countries. a) Growth in health expenditure as % of 
GDP between 2002-2012. b) Relation between health expenditure and lifetime risk of maternal death. Source: 
The World Bank, Health Nutrition and Population Statistics. 
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Value-based health care 
The main concept of VBHC is to evaluate health outcomes and their associated costs at 
the condition level. Value in health care can be calculated by dividing health outcomes by 
the costs encountered.3,4 Four key components need to be addressed to achieve health 
value improvement. 1) accurate measurement of health outcomes and associated costs; 
2) transparent outcome reporting with a classification of performance level (e.g. excellent,
good, fair, poor); 3) subsequent improvement of care delivery in a coordinated care 
setting organized around a single disease; and 4) payment reform to create the proper 
incentives for health care participants (Figure 1.2). We will now discuss the rationale to 
use those four individual key VBHC components. 
Figure 1.2. The four components of value-based health care represented in a positive feedback loop on the 
provider level, which can be accelerated by rewarding high value care on a regulatory level: 1) measure value (i.e. 
outcomes and costs); 2) report and benchmark outcomes against other providers; 3) improve the care delivery 
process based on observed outcomes; and 4) reward high value care. 
I) Measurement of value
To measure value in health care both health outcomes (i.e. quality) as well as costs will 
need to be measured accurately. We will start by discussing the general theory on 
different ways to measure quality of care and outcomes in health care, and we will also 
discuss specific measurements used in IBD. Thereafter we will discuss costs measurement 
and discuss one particularly useful method: time-driven activity-based costing (TDABC). 
Quality 
Quality of care can be assessed using structure, process, or outcome measures.5 A 
structural measure is related to the structure of the care delivery, for example the number 
of gastroenterologists that work in a hospital. Process measures are related to the process 
of care delivery, for example the percentage of patients that were tested for tuberculosis 
prior to starting an anti-TNFα agent. Outcome measures are related to the outcomes of 
the delivered care, for example the quality of life of a patient after a certain procedure. 
Structure measures are usually easy to measure but are generally poorly correlated with 
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outcomes. Outcome measures on the other hand are what matters most to the patient. 
However, it can take a long time to assess outcomes, especially in chronic disease 
management, which generates delays in quality reporting. Process measures are easier to 
measure and represent the medical practice well. However, process measures should be 
closely correlated with outcomes in order to be meaningful.5,6 
To measure health value, Porter7 proposes to always measure value around what is 
important to the patient. Outcomes, or results, are what counts to patients and therefore 
he proposes to measure value based on achieved results, instead of using surrogate 
markers such as structure and process measures. However, while health outcomes should 
be used to assess value, process measures can be very useful to improve internal 
processes. Porter proposes to measure outcomes in 3 tiers: 1) health status achieved or 
retained, 2) the quality and time of the recovery process, and 3) the sustainability of the 
achieved health status.7 
 
Additionally, the use of patient reported outcomes (PROs) is an upcoming field. The U.S. 
Food and Drug Administration (FDA) requires the use of validated PROs in clinical trials for 
drugs and medical device labeling.8 In 2004, the National Institutes of Health (NIH) 
launched the Patient Reported Outcomes Measurement Information System (PROMIS) 
initiative (www.nihpromis.gov). This initiative aims to support progress in clinical research 
by building and validating common item banks of PROs that measure symptoms and 
outcomes applicable to a wide variety of diseases. This will facilitate straightforward 
interpretation of clinical trial data and make comparisons between different studies 
easier.9 
 
IBD Quality measures have been developed by the American Gastroenterology Association 
(AGA) in conjunction with the Crohn’s and Colitis Foundation America (CCFA) in 2011.10 
These are 10 process quality indicators (Qis) related to adherence to IBD practice 
guidelines, consisting of 8 outpatient Qis and 2 inpatient Qis. Additionally the CCFA 
developed a separate set of 10 process indicators, of which 5 overlap with the AGA Qi set. 
A set of 10 outcome measures was developed by the CCFA as well and include 
corticosteroid use, hospitalizations and emergency department (ED) visits, productivity, 
quality of life, malnutrition, anemia, nighttime bowel movements or leakage, 
incontinence, and narcotics use.6 Within the PROMIS framework a gastrointestinal (GI) 
symptom bank was developed as well. The GI symptom bank consists of scales applicable 
to both patients with a GI disease and to the general population. GI symptoms are 
measured in seven domains: gas/bloating flatulence, nausea/vomiting, diarrhea, 
constipation, bowel incontinence/soilage, heartburn/reflux, and disrupted swallowing.11  
 
At UCLA we are currently measuring all outcomes relevant to patients: disease control, 
quality of life (QoL) and (work) productivity.12 All three are used to 1) monitor achieved 
outcomes (tier 1); 2) estimate the time to recovery and the level of discomfort during 
flares (tier 2); and 3) measure relapse rate (tier 3). All outcomes are assessed on a regular 
basis to establish the performance of the implemented care program as well as to allow 
for early intervention in case of disease progression. Specific care scenarios with different 
frequencies of outcome monitoring are allocated based upon individual risk profiles. In 
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addition, the AGA process Qis are tracked internally in order to identify areas for process 
improvement. (Ho, A.D. et al, unpublished data) 
 
Chapter 2 discusses the development and validation of a simple score for remote 
monitoring of disease activity. The score consists of solely PROs and is specifically 
designed for implementation on a mobile application for patients. In Chapter 3 the impact 
of IBD on work productivity is assessed. Chapter 4 describes the development of a single 
quantifiable health outcome metric based on individual patients’ preferences. 
 
Costs 
For accurate value calculations, costs need to be measured in great detail. In most 
hospitals, accounting systems are designed for reimbursement purposes. Hence, costs are 
calculated using the charges on individual line items, and not always directly correlate 
with actual costs13. To truly understand what the costs of a treatment process are, the 
time-driven activity-based costing (TDABC) method can be used. This method calculates 
costs of a care process based on the amount of time spent for every step in the care 
process. This time is then multiplied with the costs per time-unit of the resources (e.g. 
personnel, space, equipment) involved.14 The use of TDABC offers the benefit of accurate 
cost measurement, and is simultaneously a way to get insight in how to make care 
delivery more cost effective. TDABC will help hospitals identify areas in the care process 
that can be delivered more efficiently, estimate the financial benefits of task 
differentiation between different providers, and calculate return on investment of quality 
improvement.14 
 
TDABC pilots have been run in a variety of centers in Belgium15,16, at the Cleveland clinic 
(U.S.A)17, the University of California Los Angeles (U.S.A.)18, the Boston Children’s Hospital 
(U.S.A.)19, and the University of Calgary (Canada)20. The Belgian study estimated costs 
using TDABC in 5 outpatient clinics and reported improvements in operations based on 
TDABC results. Through internal benchmarking times for procedure steps between 
different departments more effective methods were identified.16 The Cleveland Clinic 
used TDABC to map and cost two heart valve procedures. They were able to estimate 
accurate costs for each of the processes and found that calculated costs were 
approximately 10% lower than the costs calculated using the administrative data. 
Additionally the TDABC method helped them to identify redundancy in their processes, to 
reassign tasks in order to have everyone perform tasks at the top of their license, and to 
get a closer insight on non-billable activities.17 Using TDABC the Boston Children’s hospital 
was able to decrease total visit time for plagiocephalic care with 19.9% (7:29 minutes) due 
to workflow improvements. Costs increased by 7.7% ($8.22) per visit, but this was offset 
by the additional time available to see two extra patients per day.19 The UCLA department 
of Neurosurgery reports similar advantages using a continuous cycle of identification of 
variation, identifying the most cost-effective solution, and process improvement.18 
 
At UCLA we started to use the TDABC model to assess the costs associated with Qi 
implementation in clinic. We identified seven types of personnel involved in the Qi 
process in the GI clinic. For the IBD clinic total costs for general IBD measures including 
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vaccinations, documentation of disease activity and tobacco use were $80.33, addition of 
bone loss assessment increased the costs to $91.41, and addition of process costs for 
checking hepatitis B and tuberculosis prior to anti-TNFα therapy initiation was $108.76. 
(Ho, A.D. et al, unpublished data) In future efforts, radiology costs and lab costs will be 
estimated using TDABC as well for a more comprehensive value calculation. 
U.S. wide health care utilization and the costs associated with IBD care are evaluated in 
Chapter 5. When no reliable costs are available health care utilization can be a meaningful 
proxy for costs of care. Therefore, Chapter 6 evaluates health care utilization in IBD 
patients treated at the UCLA Center for IBD and compares it to a matched control group of 
IBD patients. IBD related indirect costs due to losses in work productivity are assessed in 
Chapter 3. 
 
II) Outcome reporting 
Outcome registries are thought to increase value by driving patient and physician 
improvements. If outcome registries are publicly available, patients can choose the best 
medical practice for their care and avoid physicians with bad outcomes. On the other 
hand, registries offer the potential for providers to benchmark themselves against other 
practitioners and identify areas where they are lagging behind and subsequently improve. 
The effect of health registries in Sweden was recently analyzed in depth by the Boston 
Consultancy Group (BCG). Sweden has had an interest in tracking outcomes since the 
1800s and implemented official registries covering a broad array of diseases in the 1970s. 
Sweden’s health outcomes are among the best in Europe, while costs are around average. 
BCG found that while reporting on acute lymphoblastic leukemia (ALL) survival rates, ALL 
treatments dramatically improved with an increase in survival rates from 12% in the early 
1970s to 89% in 2005. Similarly, side effects from cataract surgery decreased dramatically. 
Though no comparative studies were done, some indications of the impact of disease 
registries were found. Two hospitals with low outcomes in survival rates after a 
myocardial infarction changed their practice after public reporting and achieved a 50% 
reduction in 30-day mortality within two years of the report.21 
 
Disease specific examples are identified as well. A steady rise in in vitro fertilization (IVF) 
success rates was observed in the U.S., after the Centers for Disease Control and 
Prevention started publicly reporting in-vitro fertilization (IVF) outcomes. This can be 
illustrated by a decrease in the number of IVF cycles entailing the transfer of three or 
more embryos from 83% to 35%.22 Similarly, in the cardiac surgery field, a decrease was 
observed in mortality rates after coronary artery bypass graft (CABG) surgery from 3.2% in 
1996 to 2.2% in 2005 in the presence of a public reporting system.23 In a blog post for the 
Harvard Business Review, Toby Cosgrove, Chief Executive Officer of the Cleveland Clinic, 
reported a decrease in infections after surgery by 40% and a decrease of urinary tract 
infections by 50% after reporting of provider performance data.24 In Europe, several 
countries have implemented registries as well, measuring quality indicators, outcomes 
and/or patient satisfaction data.25 
 
Due to the nature of the available data, it remains hard to assess whether observed 
effects are directly caused by the registries or by progress in the medical sciences. A 
Chapter 1 
16 
literature review from the U.S. Agency for Healthcare Research and Quality analyzing 
97 qualitative and 101 quantitative studies, found overall substantial evidence that 
reporting leads to improvements in the quality measures and moderate evidence that 
reporting might lead to a reduction in mortality. They also showed that reporting 
requirements mainly drive changes in physician behavior rather than in patient behavior 
(e.g. choosing a different doctor based on reports).26 Furthermore, there is emerging 
evidence that introduction of public reporting systems leads to a reduction in costs. A 
recent retrospective controlled study found a decrease of 13.7% in CABG prices and 11.4% 
in percutaneous transluminal intervention (PTI) prices after introduction of a public 
reporting system.27 
 
IBD outcome registries are being built as well. As mentioned above the AGA developed a 
set of 10 Qi measures for IBD specifically.10 Reporting of 8 of the 10 AGA quality measures 
to the Centers for Medicare and Medicaid Services (CMS) is required in specific conditions 
in the U.S., and reporting of those measures to CMS is directly linked to 
reimbursements.18 In 2013, the British Society of Gastroenterology launched a national 
IBD specific registry as well, which includes information on number of patients, 
admissions, surgeries, and medication use for national benchmarking.28 
 
III) Care coordination 
In order to deliver high value care, the most accurate treatment should be chosen for the 
right patient at the right location at the right time. Practice guidelines have been installed 
by many physician associations. However, guidelines are not followed consistently. In a 
2010-2012 U.S. nationwide analysis we showed that 42% of Crohn’s disease patients was 
prescribed 5-ASA even though not supported by current guidelines, and steroid sparing 
medication was prescribed infrequently while 9% of all IBD patients used long term (>3 
months) steroids.29 Reasons for guideline non-adherence could be a lack of incentives for 
guideline adherence, lack of access to guidelines, or a lack of trust towards guidelines.30 
 
Care coordination has been proposed to be a key need in order to improve care quality. 
Care coordination includes the use of evidence based care pathways by a multidisciplinary 
care team ensuring continuity of care and engaging the patient in the care process.31 A 
study in an insurance claims database analyzing continuity of care, defined as the 
percentage of visits with the same provider, showed that moderate improvements in care 
continuity in patients with chronic diseases were associated with substantial 
improvements in outcomes and decreases in complications and costs.32 A review assessing 
the effect of care coordination systems in chronic disease management found positive 
effects on quality of life, functional status and health outcomes, satisfaction scores, 
guideline adherence, and compliance.31 Additionally, routine collection of PROs was 
shown to be beneficial for patient-provider communication and for monitoring of 
treatment response and detecting unrecognized problems in cancer patients.33 
Furthermore, it is shown that health care systems organized around primary care are 
associated with lower health care expenditures and that systems with a weak primary 
care infrastructure are associated with worse health outcomes.34 The U.S. patient-
centered medical home (PCMH) is a model that explores this further. PCMH can be 
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described as a model for care that includes primary care access, comprehensiveness, care 
coordination, and continuity of care. Hundreds of pilots have been initiated over the U.S. 
and the first controlled results suggest improved outcomes, reduced health care 
utilization, and cost savings due to initiation of a PCMH.35
For IBD specifically, the Royal Adelaide hospital in Australia found a significant decrease in 
costs and fewer hospitalizations after introduction of a coordinated care infrastructure in 
a controlled study.36 Hospitals in the UK, Italy, The Netherlands, Canada, and Austria have 
been working with integrated care models as well, though no outcomes are presented.37 
The UCLA Center for IBD, launched in 2012, uses an approach that combines all 
components of coordinated care and outcome measurements. Multidisciplinary care 
pathways for IBD were developed and implemented, which include evidence-based 
practice management, task differentiation and coordination between providers, and 
collection of outcomes. PROs are collected routinely using a patient facing mobile 
application, which is used for patient monitoring and outcome reporting. This is all 
supported by a solid IT infrastructure, with a provider portal and a patient facing mobile 
application (UCLA eIBD, available for iOS and Android). This infrastructure also facilitates 
patient-provider communication and education, and offers wellness programs. Health 
care providers can evaluate their patients’ outcomes, health care utilization and 
associated costs.12,38 A controlled analysis using a payer database of 49 UCLA IBD Center 
patients versus 245 IBD controls showed a significant decrease in corticosteroid use from 
31% to 12%, and 1.3-3.4 times more frequent biomarker testing. Non-significant 
decreases in emergency department (ED) visits (75% decrease), hospitalizations (89% 
decrease), and office visits (25% decrease) was observed as well39. Chapter 6 describes 
this evaluation in more detail. 
IV) Payment reform to reward value
Value based insurance design (VBID) is an approach to use insurance models that reward 
high value care. Initial efforts were mainly focused on cost sharing strategies, while the 
value component has only been added in pilots more recently. In the famous RAND health 
insurance experiment (1974-1982) it was shown already that health care is affected by a 
certain price elasticity, which is shown by a higher demand for medical care if co-
payments for patients are lower.40 However, nonspecific cost sharing strategies target 
necessary care as well as unnecessary care, which is why the introduction of value in 
insurance designs is important. The first area in which VBID was implemented is in the 
prescription drug arena. Incentives can be targeted to patients, health care professionals, 
or both. Throughout the Organisation for Economic Co-operation and Development 
(OECD) member countries, different approaches are already being utilized by 
governments to stimulate cost-effective drug use using cost sharing strategies. Strategies 
used to incentivize patients include lowering co-payments or waiving the maximum 
allowed payment cap for essential medications or generic variants of drugs. Strategies 
aimed at physicians include compulsory guideline-based prescribing and benchmarking 
against other physicians, coupled with either financial penalties or rewards.41 
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Patient-targeted approaches include policies that for example lower co-payments for 
high-value drugs specifically, to improve patient adherence. In a 2013 paper reviewing 13 
studies assessing the effect of reduced co-payments found an increase in quality but no 
reduction in health expenditure.42 The majority of studies assessed the effect of reducing 
co-payments on diabetes and hypertension medication. Reductions of 25%-100% in 
copayments were found to increase adherence by on average 3% after one year. As 
expected, an increase in prescription drug expenditure was observed for insurers, but 
overall health expenditure was generally not affected. Two studies evaluated health care 
utilization and found reduction in office visits, ED visits and hospitalizations. Furthermore, 
two studies that included disease management with the VBID did observe decreased 
overall expenditures.42 Another 2014 review, incorporating 10 studies (of which seven 
overlap with the previous review), had comparable conclusions and observed an 
improvement in medication adherence from 2-5 percentage points and found lack of 
evidence for changes in expenditure, outcomes, or health care utilization.43 A more in 
depth analysis of 76 VBID plans introduced by a large pharmacy benefit manager found 
increased adherence in VBID plans that offered more generous benefits, targeted high-risk 
patients, had wellness programs, and made benefits available only for mail orders. Plans 
including disease management programs had higher adherence rates, but interestingly 
enough, disease management programs had a consistently negative effect on adherence 
improvements after introduction of VBID. The authors conclude this effect might be 
explained by the fact that VBID and disease management both aim for the same goal, or 
because baseline adherence was relatively high in those programs and the effect we 
observe is a ceiling effect.44 A third review assessing the effect of drug insurance cost-
sharing strategies for patients with cardiovascular related chronic diseases confirmed 
positive effects on adherence rates, though effects on outcomes remained unclear.45 
Non-pharmacy patient-targeted VBID approaches, mostly targeted at preventative 
services, are thought to be of high value to the health care system. The 2010 U.S. Patient 
Protection and Affordable Care Act (ACA) or ‘Obamacare’ requires coverage without cost-
sharing of certain preventive health services. Among these services are women’s 
preventive health services. This includes vaccinations, screening, and preventive 
treatments for certain risk groups.46,47 Inclusion of secondary preventive services is 
theoretical of high value as well. An analysis from the University of Michigan’s Center for 
Value Based Insurance Design estimated that addition of certain secondary preventative 
services in high deductible health plans would lead to a 5.1-5.6% increase in premiums. 
Nevertheless, over the long term, including those services is thought to increase health 
value.48 
Programs targeting treating physicians are implemented as well. Initial efforts to 
incentivize performance and accountability for providers are pay for performance 
programs (P4P), where physicians are rewarded or penalized when reaching certain 
quality targets, which are usually process measures. Additionally, the ACA allows health 
care providers to form Accountable Care Organizations (ACOs). ACOs are provider 
organizations organized around primary care, in which all participants are accountable for 
the quality and outcomes of care. The provider group is eligible to share in health care 
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savings with the insurers when they reach certain quality targets. These quality targets are 
focused around four domains: patient/caregiver experience, care coordination and 
patient safety, preventive health, and care for at-risk populations.49 Similarly, in different 
European countries payment reforms are being pursued, including rewards for the 
introduction of disease management programs in Germany, and bundled payments for 
episodes of care in The Netherlands.50 The effect of P4P programs on costs and outcomes 
is unclear, because only few good quality studies are available.51 Studies mostly show 
either a null effect or a marginal positive effect. The experience with ACOs and bundled 
payments incorporating quality incentives is still limited. Reported results on quality, 
outcomes and costs are mixed, and nine out of 32 CMS ACO contracts were 
discontinued.51 Best results are thought to result from bundled payments for episodes of 
care coupled to quality targets.4 
 
In the field of gastroenterology there is interest for implementation of VBID as well. Saini 
et al. suggest as an example to introduce higher co-payment for upper endoscopies when 
the indication is gastroesophageal reflux disease (GERD) than when the indication is 
dysphagia.52 We propose to introduce VBID in a comprehensive structure that incentivizes 
all stakeholders involved in IBD care to utilize high value care, which includes incentives 
for insurers, physicians, and patients. Physicians should be rewarded for good 
performance on a disease specific level. Using a cost-sharing insurance design, physicians 
with better outcomes should be at low financial risk, while having large financial benefits, 
while physicians with worse outcomes would have high risks with low benefits. This would 
result in a model in which savings with excellent outcomes are rewarded with a large 
percentage of shared savings for the provider, while savings with suboptimal outcomes 
are only rewarded with a small percentage of the savings, and savings with bad outcomes 
are not rewarded at all. On the other side of the spectrum, physicians with high costs and 
bad outcomes would be penalized by a high percentage of sharing in financial losses, 
while high cost with better outcomes should only be penalized with a smaller percentage 
in shared losses, and in cases where the provider achieves excellent outcomes financial 
penalties should be forgiven (Figure 1.3). Expected outcomes should be risk-adjusted 
based on the population mix. This structure is similar to the structure used by the second 
arm of the Medicare Shared Savings Program.49 Furthermore, patients should be 
incentivized to participate in their care. At UCLA, we calculate individual participation 
scores based on whether patients participate in patient education, partake in home 
monitoring, and comply with scheduled visits, procedures, and tests. We propose that 
patients should be financially rewarded based on their participation score, which will 
stimulate better outcomes. In Chapter 4 we also discuss a method to incorporate patient 




The introduction of VBHC is inevitable, but approaches on how to achieve value in health 
care differ. The key concepts include 1) measurement of outcomes and costs; 2) 
benchmarking of outcomes and costs 3) implementation of a value-based clinical system; 
and 4) the introduction of incentives for delivery of high-value care. Although the 
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introduction of incentives is mainly in the hands of regulators and insurers, the first three 
concepts can be driven from within the medical community. Payment reforms are 
emerging worldwide, and the medical community should be closely involved in the 
development of these contracts. By implementing the first three components in their care 
practice, providers can improve their care delivery processes and ensure high-value care 
delivery. These efforts will be rewarded financially as well after the formal introduction of 
VBID programs. Results on the effects of value-based approaches are still very limited, but 
many pilot programs are running and initial results are encouraging. We described the 




Figure 1.3. Proposed VBID mechanism. Providers are incentivized to deliver high value care by increases is shared 
savings when delivering better outcomes at lower than expected costs (segment A). Conversely, providers are 
disincentivized to deliver low value care by increases in shared losses when delivering worse outcomes at higher 
than expected costs (segment B). When delivering better outcomes at higher than expected costs, shared losses 
will decrease (segment C), while shared savings will decrease when delivering worse outcomes at lower than 
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Background & aims 
Mobile health technologies are emerging rapidly and an increasing number of people use 
smartphones. Remote monitoring is thought to be of value for inflammatory bowel 
disease (IBD) management but no tools are currently available. We tested the ability of an 
IBD monitoring tool, which might be used with mobile technologies, to assess disease 
activity in patients with Crohn’s disease (CD) or ulcerative colitis (CD). 
 
Methods 
This prospective observational study consisted of a score development phase and a 
validation phase. IBD patients filled out a set of patient reported outcomes which were 
compared to clinical disease activity indices. Predictors for disease activity were identified 




In total, 110 Crohn’s disease (CD) and 109 ulcerative colitis (UC) patients were included in 
the development phase. The developed CD score consisted of liquid stool frequency, 
abdominal pain, well-being, and patient assessed disease control. The UC score included 
stool frequency, abdominal pain, rectal bleeding, and patient assessed disease control. 
The score was validated in 301 CD and 265 UC patients. The AUC of the ROC for detecting 
clinical disease activity was 0.90 for CD and 0.91 for UC; for endoscopic activity the AUC 
was 0.63 for CD and 0.82 for UC. Both scores were responsive to changes in disease 
activity (P<0.003); The ICC for test-retest reliability was 0.94 for both CD and UC. 
 
Conclusions 
We developed and validated a monitoring score for CD and UC patients for 
implementation on mobile technology. The score predicts clinical disease activity in both 




The shift from symptom-oriented to prevention-oriented care delivery has accelerated the 
development of mobile health (mHealth) technologies and is thought to radically 
transform health care delivery.1 Smartphone adoption is increasing rapidly, with 64% of 
Americans using smartphones in 2014 of which 62% used their phones to look up health 
information.2 Many health applications (apps) are available, most of which provide health 
information or support data collection.3 For IBD patients, apps are available that assist in 
tracking symptoms, logging meals, and managing medications.4,5 These apps can create 
reports for providers but do not allow for real-time interactions between patient and 
provider. 
 
Self-monitoring and self-management for chronic diseases is widely practiced in diabetes 
care6 and anticoagulation therapy7. Additionally, e-technologies for symptom reporting 
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between patients and providers are increasingly used in chronic diseases.8 One compelling 
example is the diabetes app WellDoc, a U.S. Food and Drug Administration (FDA) 
approved app which can only be used after prescription by a health care provider3,9. 
Several systems for online symptom reporting and disease management have been 
developed for IBD. In the Danish Constant-Care web system, UC patients filled out a 
clinical symptom score and logged fecal calprotectin levels weekly; based on these scores 
the system made real-time recommendations for adjusting mesalamine dosing. This 
approach was shown to empower patients and decrease relapse duration.10,11 Similarly, 
individualization of infliximab dosing in CD patients was reported to be practical and 
feasible.12 A study evaluating another home tele-management system in UC (UC-HAT) did 
not show significant differences in disease activity and quality of life (QoL) between users 
and controls, and more than 1/3 of the patients discontinued participation.13 An ongoing 
multicenter randomized controlled trial is testing the use of a mobile tele-management 
system using text messaging in IBD. This system sends personalized alerts and educational 
texts, and assesses symptoms and side-effects, based on which treatment can be 
modified.14 
 
Patient Reported Outcomes (PROs) are increasingly used to evaluate health status, and 
the importance of PROs in outcome measurement, symptom management, and quality 
improvement efforts is increasingly recognized.15 Furthermore, the use of PROs as primary 
outcome measures for evaluating effectiveness of IBD interventions is progressively 
supported by the FDA.16 Therefore, PROs are promising for use in mHealth apps. An 
example is the HealthPROMISE app which tracks patient reported QoL scores in IBD 
patients and provides decision support to physicians.17 However, accurate e-monitoring 
tools for disease activity in IBD are yet to be developed. Previous efforts have aimed to 
develop PRO questionnaires by adjusting existing scores.18-20 We aimed to identify the 
most optimal PRO score to use on an IBD disease-monitoring app. The best PROs were 
selected from an exhaustive list of PROs in a prospective cohort of IBD patients. 
Subsequently, the developed scores were tested prospectively in an independent cohort 






This was a prospective, observational study, which aimed to develop and validate a 
mHealth index (mHI) for CD and UC that accurately monitors IBD disease activity using 
PROs. The study consisted of two phases: a development phase and a validation phase. 
During the development phase the mHIs were developed using collected PROs and clinical 
disease activity indices. During the validation phase the developed mHIs were validated in 









IBD patients were identified during clinic visits between May 2013 and January 2014 at 
the University of California, Los Angeles (UCLA) Center for IBD. Patients with esophageal 
or anal CD involvement alone, patients with a pouch or stoma, and pregnant women were 
excluded. Eligible patients filled out disease-specific questionnaires assessing PROs of 
most common clinical disease activity indices (partial Mayo (pMayo), simple clinical colitis 
activity index (SCCAI), and modified Truelove and Witts index (MTWI) for UC; Harvey 
Bradshaw index (HBI) and Crohn’s disease activity index (CDAI), including a 7-day diary 
prior to the visit for CD). Additionally, patients were asked to assess their symptoms and 
perceived disease activity using visual analogue scales (VAS). The PROs were categorized 
into 10 domains: stool frequency, abdominal pain, general wellbeing, urgency, stool 
consistency, rectal bleeding, fever, anorexia, nausea/vomiting, and perceived disease 
activity (Table 2.1). 
 
During clinic visits, vital signs were measured and physicians collected the physician 
reported outcomes required for the clinical disease activity indices (Table 2.1). 
Hemoglobin (Hgb), hematocrit (Hct), white blood cell (WBC) count, platelets, albumin, 
C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were requested. 
Furthermore, stool testing for calprotectin was requested either at the patient’s preferred 
laboratory or using a free stool kit (Genova Diagnostics) picked up at the patient’s home. A 
dedicated study nurse (E.K.) followed up with patients via phone or e-mail to ensure lab 
and stool tests were performed. 
 
Validation phase 
Eligible IBD patients were identified during clinic and endoscopy visits between April 2014 
and March 2015 in three tertiary IBD referral centers (UCLA, USA; University of California, 
Irvine (UCI), USA; and Leiden University Medical Center (LUMC), The Netherlands). 
Patients who participated in the development phase of the study were excluded. For CD 
patients, the developed mHI-CD and HBI were completed during clinic visits; during 
endoscopic visits, the simple endoscopic score for CD (SES-CD) was additionally 
completed. For UC patients, the mHI-UC and pMayo were collected during clinic visits, and 
the Mayo endoscopic sub-score was additionally obtained during endoscopic visits. 
Patients at the LUMC, completed a Dutch version of the mHI-CD and mHI-UC. After 
translation to Dutch, the questionnaires were translated back to English by an 
independent translator; the Dutch questionnaire was then revised and re-tested. To 
assess sensitivity of the mHI to detect changes in clinical disease activity, a subset of 
patients was included a second time during scheduled follow-up visits. To assess test-test 
reliability, a subset of UCLA patients was asked to complete a second questionnaire at 
home after their clinic visit. 
 
Definitions 
For CD, clinical disease activity was defined as a HBI>4 or a CDAI>150. A change of ≥3 in 
HBI was considered a clinically relevant change.21 Endoscopic disease activity was defined 
as an SES-CD>3. For UC, clinical disease activity was defined as a pMayo>2, a MTWI>3, or a 
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Domain Question CD UC 
1. Stool 
frequency 
Number of liquid/very soft stools for each of the last 7 days X  
How many stools did you have yesterday during the day? X X 
How many stools did you have yesterday during the night? X X 
How many stools do you have normally during the day? X X 
How many stools do you have normally during the night? X X 
2. Abdominal 
pain 
Abdominal pain for each of the last 7 days (No  / Mild / Moderate / 
   Severe) X  
Abdominal pain (No / Mild / Moderate / Severe)  X 
Abdominal pain (No abdominal pain / With bowel actions / 
   Continuous) X X 
Rate your abdominal pain on a scale from 0 to 10 (VAS) X X 
3. General 
well-being 
General well-being for each of the last 7 days (Very Well / Slightly 
   below par / Poor / Very Poor / Terrible)  X 
General well-being (Very Well / Slightly below par / Poor / Very Poor / 
   Terrible) X  
General well-being (Perfect / Very good / Good / Average / Poor / 
   Terrible)  X 
Well-being (No impairment / Impaired, but able to continue activities / 
   Activities reduced / Unable to work) X X 
Rate your well-being on a scale from 0-10 (VAS) X X 
4. Urgency Urgency of defecation (No urgency / Hurry / Immediate / 
   Incontinence) X X 
5. Stool 
consistency 
Stool consistency (Normal or variably normal / Semi-formed / Liquid) X X 
Do you take opiates or lomotil/imodium for diarrhea? X X 
How often do you take anti-diarrheals? (0-10 VAS) X X 
6. Rectal 
bleeding 
What % of bowel movements contains visible blood? (None / Less 
   than 50% / 50% or more / Blood alone) X X 
Amount of blood in stool (None / Trace / Occasionally frank (bright 
   red) / Usually frank) X X 
How often do you experience rectal bleeding? (0-10 VAS) X X 
7. Fever Fever on each of the last 7 days X  
8. Anorexia Loss of appetite (Yes/No) X X 
9. Nausea/ 
vomiting 
Nausea and/or vomiting (Yes/No) X X 
10. Disease 
activity 
How well do you feel your disease is under control? (0-10 VAS) X X 
11. Clinical 
markers 
Temperature X X 
Weight and height X  
Pulse  X 
Abdominal tenderness  X 
Abdominal mass X  
Extra intestinal manifestations X X 
Physician global assessment of disease activity X X 
Hgb, Hct, WBC, platelets, albumin, CRP, ESR (blood) and calprotectin 
   (stool) X X 




SCCAI>2. A change of≥3 in the pMayo was considered a clinically relevant change.19 
Endoscopic disease activity was defined as a Mayo endoscopic subscore >1. 
 
Ethical considerations 
All patients consented to participate in this study. This study was approved by the IRBs of 
participating centers under the following protocol numbers: UCLA: IRB#13‐000402; UCI: 
HS# 2014-1231; LUMC: P14.158. 
 
Statistical analysis 
Descriptive statistics were used for clinical characteristics and demographic information. 
Numeric values are presented as mean and standard deviation or median and range. SAS 
version 9.2 was used for statistical analyses. 
 
Development phase 
Univariate logistic regression was performed using disease activity (HBI>4 for CD or 
pMayo>2 for UC) as the dependent variable and the PROs as independent variables. For 
each of the PROs, different cut-offs were used, which roughly created linear associations 
between the groups and the chance of active disease. Because different PROs represented 
the same domain (Table 2.1), the variables with the highest Wald χ-square value for 
predicting clinical disease activity were selected within each domain for inclusion in the 
multivariate logistic regression models. If two variables within the same domain had a 
similar predictive value (difference between Wald χ-square values <0.5), both were tried 
in separate models unless the question type was less preferable. Because of usability on a 
mobile application VAS, yes/no, or numeric questions were preferred over categorical 
questions; within those, questions with less response options were preferred. Variables 
with a p-value >0.1 in the univariate analysis were omitted from subsequent analyses. 
Stepwise forward multivariate logistic regression was performed with clinical disease 
activity as the dependent variable and the selected PROs as independent variables. A 
significance level of P<0.1 was required for entry in the model and a significance level of 
P<0.1 to stay in the model. Several models were performed using different clinical disease 
activity indices to define clinical disease activity as the dependent variable. 
 
Composite scores were created using the regression coefficients of independent 
predictors in the multivariate model. Spearman correlation coefficients were estimated 
between the newly developed mHIs and clinical disease activity indices. Receiver-operator 
characteristics (ROC) curves were used to assess the capability of the mHI to discriminate 
active versus non-active disease using different clinical disease activity indices, and the 
areas under the curves (AUC) were calculated. The composite score with overall highest 
AUC using different gold standards was selected.  
 
Because the main aim of the developed score was to identify patients at risk for active 
disease, we defined the optimal cutoff for disease activity as a negative predictive value 
(NPV) of ≥95% and a sensitivity of ≥85% while maintaining maximum specificity. The 
overall prevalence of active disease was estimated at 22% based on cross sectional cohort 
data from UCLA. 
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Validation phase 
To validate the mHI against clinical and endoscopic disease activity indices, the mHI-UC 
was compared to the pMayo and the endoscopic subscore of the Mayo; the mHI-CD was 
compared to the HBI and SES-CD. Spearman correlation coefficients between the scores 
were calculated and ROC curves to assess the ability to predict clinical and endoscopic 
disease activity were generated. To assess sensitivity to change, we compared patients 
who clinically improved, remained stable, and deteriorated. A Kruskal-Wallis test was used 
to compare groups. Test-retest reliability was assessed by the intra-class correlation 
coefficient (ICC). The performance of the VAS for patient-reported disease activity (DA-






In total, 219 patients (110 CD and 109 UC) were included in the development phase of the 
study (Figure 2.1a, Table 2.2). In 108 out of 110 CD patients the HBI was calculated, while 
the CDAI could only be calculated in 93 out of 110. The pMayo, SCCAI, and MTWI were 
calculated in all UC patients. Complete lab and stool tests were obtained from only 48% of 
patients. Despite intensive follow-up by a dedicated research nurse (E.K.), 39% of patients 
did not perform stool testing and 13% did not have labs drawn. Additionally, 14% of 
patients had blood drawn, but lab sets were incomplete due to protocol deviations. 
 
Univariate logistic regression was performed for PROs and blood and stool tests (Table 2.3 
and 2.4). Stool frequency, abdominal pain, general well-being, urgency, and patient-
reported disease activity were all strong predictors for clinical disease activity in both CD 
and UC (P<0.0001). Incontinence was only present in 3% of patients and did not predict 
disease activity in either CD (P=0.54) or UC (P=0.99). In CD the use of anti-diarrheals was 
predictive for disease activity (P=0.019) but not in UC (P=0.96), while the VAS assessing 
frequency of anti-diarrheal use was a predictor for neither CD (P=1.00) nor UC (P=0.26). 
Rectal bleeding was a predictor for disease activity in both UC (P<0.0001) and CD 
(P=0.019). Anorexia was predictive in both CD (P=0.019) and UC (P=0.0025), while nausea 
and vomiting predicted only CD disease activity (P=0.035) and not UC disease activity 
(P=0.14). High CRP (P=0.0009), high ESR (P=0.0022), low Hgb (P=0.022), and low albumin 
(P=0.034) were predictors for clinical disease activity in CD. High calprotectin was not a 
significant predictor for CD disease activity (P=0.054), though calprotectin as continuous 
variable had predictive value (P=0.011). Low platelets (P=0.98), low Hct (P=0.28), and high 
WBC (P=0.11) were not predictive in CD (Table 2.3). In UC high CRP (P=0.0067), high 
calprotectin (P=0.022), high WBC (P=0.013), high ESR (P=0.028), and low Hct (P=0.0047) 
were all predictive for clinical disease activity. Low albumin (P=0.98) was not predictive for 
clinical activity in UC, though albumin as continuous variable was (P=0.02). Low platelets 
(P=0.99) and low Hgb (P=0.13) were not predictive for disease activity in UC, while Hgb as 






      
Figure 2.1 Inclusion flowcharts for development phase (a) and validation phase (b). 
 
The most representative PROs were selected for inclusion in the multivariate regression 
model (Table 2.3 and 2.4). Because of low completion rates of lab testing despite intensive 
follow-up, lab tests were initially excluded from the multivariate analysis and score 
development. In CD four composite scores were evaluated (Table 2.5); In UC 11 composite 
scores were evaluated (Table 2.6). Addition of lab variables to the selected models 
decreased the sample size and therefore the power of the regression models; addition of 
the lab variables to the model did not result in inclusion of these variables in the models, 
because they did not reach the required significance level of P<0.1 for entry in the model. 
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Development phase Validation phase 
CD UC CD UC 
n 110 109 301 265 
Age (years), median (range) 33 (19-79) 35 (18-81) 33 (18-75) 42 (18-86) 
Male, n (%) 56 (51) 57 (52) 144 (48) 132 (50)a 
Smoking, n (%) 9 (8) 7 (6)a 19 (6)c 12 (5)d 
Age at diagnosis (years), median (range) 24 (8-68) 28 (10-81) 25 (8-66) 29 (2-76) 
Disease duration (years), median (range) 8 (0-46) 6 (0-52) 8 (0-52) 7 (0-59) 
Surgical history, n (%) 48 (44) 1 (1) 132 (44)b 13 (5)b 
Fistulizing disease (CD only), n (%) 5 (5)a - 59 (20)a - 
Active disease (HBI>4 /pMayo>2), n (%) 32 (30)a 37 (34) 82 (27) 82 (31) 
Table 2.2. Demographics of included patients in development and validation phase of the study. 
an=1 unknown; bn=2 unknown; cn=8 unknow; dn=9 unknown. 
Table 2.3 and 2.4 on page 36 – 41. 







HBI CDAI HBI CDAI 
HBI 
1 V1.1; V3 0.981 0.912 0.903 0.739 
2 V1.2; V3; V10 0.956 0.898 0.750 0.702 
CDAI 
1 V1.1; V3; V4; V10 0.951 0.963 0.837 0.830 
2 V3; V4; V10 0.900 0.942 0.731 0.771 
Table 2.5. Development and evaluation of composite scores for CD. 
*see Table 2.3 for full details on each variable; V1.1 number of liquid/very soft stools per day; V1.2 total number 
of stools per day; V3 abdominal pain; V4 well-being VAS; V10 disease control VAS. 







pMayo SCCAI MTWI pMayo SCCAI MTWI 
pMayo 
1, 2 V1.1; V3; V7; V8; V10 0.960 0.865 0.849 0.769 0.769 0.703 
1, 2# V1.1; V3; V7; V10 0.957 0.879 0.883 0.797 0.803 0.762 
3 V1.2; V3; V7; V8; V10 0.964 0.908 0.890 0.808 0.812 0.748 
3
#
 V1.2; V3; V7; V10 0.960 0.915 0.913 0.820 0.832 0.790 
4 V1.2; V 4.2; V7; V10 0.956 0.920 0.909 0.809 0.838 0.787 
SCCAI 
1 V2; V4.1; V5; V7 0.872 0.974 0.896 0.711 0.907 0.836 
2, 4 V2; V3; V4.2; V5; V7; V10 0.904 0.971 0.883 0.765 0.911 0.810 
3 V1.2; V2; V4.1; V5; V7 0.885 0.981 0.923 0.721 0.914 0.869 
MTWI 
1 unbalanced model - - - - - - 
2 V1.1; V2; V6; V7; V8 0.928 0.879 0.937 0.801 0.806 0.855 
3 V1.2; V2; V4.1 0.880 0.907 0.984 0.712 0.797 0.933 
4 V1.2; V2; V4.2; V7; V8 0.906 0.894 0.950 0.777 0.810 0.866 
Table 2.6. Development and evaluation of composite scores for UC.  
*see Table 2.3 for full details on each variable; V1.1 and V1.2 number of stools per day; V2 number of stools at 
night; V3 abdominal pain VAS; V4.1 general well-being; V4.2 well-being VAS; V5 Urgency of defecation; V6 stool 
consistency; V7 rectal bleeding VAS, V8 Anorexia; V10 disease control VAS. 
#in these models loss of appetite was excluded as independent variable because of a clinically irrelevant negative 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For CD the selected composite score (Table 2.7) had an AUC of >0.95 for predicting clinical 
disease activity using both CDAI and HBI as gold standards (0.951 and 0.963, respectively). 
The Spearman correlation coefficients were 0.837 and 0.830, respectively (Table 2.5). The 
optimal cutoff for the mHI-CD to predict clinical disease activity was ≥5.5, resulting in a 
NPV of 96%, positive predictive value (PPV) of 63%, sensitivity of 88% and specificity of 
85%. For UC the selected composite score (Table 2.8) had an AUC of >0.91 to predict 
disease activity using pMayo, SCCAI, and MTWI as gold standards (0.960, 0.915, and 0.913, 
respectively). The Spearman correlation coefficients were 0.820, 0.832, and 0.790, 
respectively (Table 2.6). The optimal cutoff for the mHI-UC to predict clinical disease 
activity was ≥4.99, resulting in a NPV of 97%, PPV of 72%, sensitivity of 89%, and 
specificity of 90%. 
 
mHI-CD Questions Answer Score 







Abdominal pain No Yes 
0.0000 
2.3868 
Rate your well-being on a scale from 0 to 10 
(0=worst, 10=best) 
8 - 10 
4 - 7 




How well do you feel your disease is under control 







Total score (SUM) 
Table 2.7. Calculation of the mHI-CD 
 
mHI-UC Questions Answer Score 
How many stools did you have yesterday? 
≤2 





Rate your abdominal pain on a scale from 0 to 10 
(0=none, 10=worst) 
0 - 2 
3 - 6 




How often do you experience rectal bleeding? 
(0=none, 10=always) 
0 - 3 
4 - 10 
0.0000 
2.2019 
How well do you feel your disease is under control 
(0=no disease activity, 10=worst disease activity) 
0 - 2 
3 - 5 




Total score (SUM)   
Table 2.8. Calculation of the mHI-CD 
 
Validation phase 
A total of 301 CD patients (UCLA n=127; UCI n=82; LUMC n=92) and 265 UC patients (UCLA 
n=119; UCI n=67; LUMC n=79) were analyzed in the validation phase (Figure 1b, Table 
2.2). For CD the Spearman correlation coefficient was 0.75 (P<0.0001) between HBI and 
mHI-CD, the AUC of the ROC for predicting clinical disease activity was 0.90, and a  
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Figure 2.2 Performance of the developed mHI scores to detect disease activity in CD (a, c, e) and UC (b, e, f). ROC 
curves of the mHI to predict clinical and endoscopic disease activity (a+b), scatter plot of the mHI versus clinical 
disease activity scores (c+d) and endoscopic disease activity scores (e+f). 
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sensitivity of 94% and specificity of 67% were achieved using a cutoff of ≥5.5 (Figure 2.2a 
and 2.2c). To achieve the optimal NPV of 95% and sensitivity of 85%, the cutoff in this 
cohort would be ≥6.38, which would result in 85% sensitivity, 80% specificity, 95% NPV, 
and 55% PPV. The mHI-CD was poorly correlated with the SES-CD (ρ=0.30, P=0.0039), with 
an AUC of 0.63 (Figure 2a and 2e). 
 
For UC the Spearman correlation coefficient was 0.72 (P<0.0001) between pMayo and 
mHI-UC, the AUC of the ROC for predicting clinical disease activity was 0.91, and a 
sensitivity of 73% and specificity of 90% specificity were achieved using a cutoff of ≥4.99 
(Figure 2.2b and 2.2d). The optimal cutoff in this cohort would be ≥3.2, which would result 
in 85% sensitivity, 80% specificity, 95% NPV, and 55% PPV. The mHI-UC was strongly 
correlated with the Mayo endoscopic subscore (ρ=0.60, P<0.0001), with an AUC of 0.82 
(Figure 2.2b and 2.2f). 
 
Sensitivity to change was assessed in a subset of 50 CD patients and 44 UC patients. 
Median time between questionnaires was 46 days (range 2-352) for CD and 57.5 days 
(range 3-275) for UC. Four (8%) CD patients deteriorated, 31 (62%) had stable disease 
activity, and 15 (30%) improved. Of the UC patients, 5 (11%) deteriorated, 27 (61%) 
remained stable, and 12 (27%) improved. There was a significant difference in mHI 
between patients who clinically improved, remained stable, or worsened in both CD 
(P=0.0030) and UC (P=0.0025, Figure 2.3a and 2.3b). Test-retest reliability was assessed in 
a subset of 40 CD and 37 UC patients. The median time to second questionnaire 
completion was 21 hours (range 7-36) for the mHI-CD and 23 hours (range 11-144) for the 
mHI-UC. The ICC was 0.94 (confidence limits 0.89-0.97) for the mHI-CD and 0.94 
(confidence limits 0.89-0.97) for the mHI-UC (Figure 2.3c and 2.3d). 
 
One question in both the mHI-CD and the mHI-UC assessed patient reported disease 
activity using a VAS (DA-VAS). In CD patients (n=301) the DA-VAS had a Spearman 
correlation of 0.63 (P<0.0001) with the HBI, and the AUC for predicting clinical disease 
activity was 0.83 (compared to ρ=0.75 and AUC=0.90 for the full mHI-CD). The CD DA-VAS 
was weakly correlated with the SES-CD (ρ=0.21, P=0.040), and had an AUC to predict 
endoscopic disease activity of 0.59 (compared to ρ=0.30 and AUC=0.63 for the full mHI-
CD). The DA-VAS was not significantly different between patients who deteriorated, 
remained stable, or improved (P=0.12). In UC patients (n=265) the DA-VAS had a 
Spearman correlation of 0.67 (P<0.0001) with the pMayo, and the AUC for predicting 
clinical disease activity was 0.86 (compared to ρ=0.72 and AUC=0.91 for the full mHI-UC). 
The UC DA-VAS was also correlated with the endoscopic component of the Mayo score 
(ρ=0.55, P<0.0001), and had an AUC to predict endoscopic disease activity of 0.79 
(compared to ρ=0.60 and AUC=0.82 for the full mHI-UC). A significant difference between 
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Discussion 
We developed two four-item questionnaires consisting solely of PROs for remote 
monitoring of IBD patients, which can be employed on mobile technology. The 
questionnaires were validated in a multi-center validation study and showed excellent 
characteristics to monitor clinical disease activity as well as symptom changes. As 
previously shown, UC clinical disease activity highly correlates with endoscopic disease 
activity, while correlation between CD symptoms and endoscopic findings is poor.22 
 
 
Figure 2.3. Sensitivity to change (a+b) and test-retest reliability (c+d) of the mHI-CD (a+c) and mHI-UC (b+d). 
 
Although previous studies have aimed to identify PROs for disease monitoring either by 
adjusting existing questionnaires18, or by using sub-components of existing 
questionnaires19,20, we were able to prospectively identify PROs relevant for clinical 
disease monitoring and validate those in an independent cohort. Interestingly, patient 
reported disease activity was shown to be an independent predictor for clinical disease 
activity in both UC and CD patients, even after inclusion of common IBD symptoms such as 
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stool frequency and abdominal pain. Patient reported disease activity alone had a 
comparable performance to the complete mHI in both CD and UC for detecting clinical 
and endoscopic activity, though responsiveness to changes in disease activity was reduced 
in particular in CD patients. 
 
A limitation of this study is the potential for recall bias in CDAI calculation. Though 7-day 
diary forms were sent out in advance, we did not log whether diaries were filled out daily 
of by recall. Additionally, in the validation cohort, optimal cutoffs of the mHI for detection 
of disease activity were higher than expected for CD and lower than expected for UC. This 
might be due to the reduction of questionnaire items from >20 PROs to just four, or due 
to differences in the patient population. The validation phase of the study most accurately 
represents the real-life situation. Therefore, we implemented the cutoff for optimal 
sensitivity and specificity as observed in the validation cohort in clinical practice. 
 
This study was not primarily designed to evaluate correlations between PROs and 
endoscopic healing. In at-risk patients, clinical assessments remain warranted, which may 
lead to further endoscopic evaluation. This tool offers an optimal screening method to 
monitor and evaluate disease activity in and outside of clinical practice with a high NPV. 
The mHIs are currently implemented in the UCLA eIBD patient app (Figure 2.4) and 





Figure 2.4. Screenshots of the mHI as implemented in the UCLA eIBD patient app available to patients treated at 
the UCLA IBD Center. 
 
The calculation of the mHI is complex; however, simplifying the score would most likely 
result in loss of accuracy. Since the index is meant to be automated and implemented on 
digital platforms, we feel that using the more complex calculations is justified. 
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Cloud-based health technologies are predicted to revolutionize care delivery and patient 
engagement. Patients can participate in their care by signaling meaningful health 
outcomes during year-round monitoring. Barriers for more widespread implementation of 
mHealth in IBD care include policies affecting reimbursement and regulatory 
requirements23, as well as privacy and security concerns.1 
 
In summary, we developed the mHI-CD and mHI-UC for remote monitoring of CD and UC 
patients. The scores are specifically designed for implementation on a mobile application 
and are currently available to IBD patients treated at the UCLA Center for IBD. Prospective 
randomized studies will need to assess the effect of remote monitoring on disease 
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Indirect costs associated with impaired productivity at work (presenteeism) due to 
inflammatory bowel disease (IBD) are a major contributor to health expenditures. Studies 
estimating indirect costs for IBD in the United States did not take presenteeism into 
account. We aimed to quantify work limitations and presenteeism and its associated costs 




We performed a prospective study at a tertiary IBD center. During clinic visits, work 
productivity, work-related problems and adjustments, quality of life, and disease activity 
were assessed in patients with IBD. Work productivity and impairment were assessed in a 
control population as well. Indirect costs associated with lost work hours (absenteeism) 
and presenteeism were estimated, as well as the effect of disease activity on those costs. 
 
Results 
Of the 440 included patients with IBD, 35.6% were unemployed. Significantly more 
presenteeism was detected in patients with IBD (62.9%) compared with controls (27.3%, 
P=0.004), with no significant differences in absenteeism. Patients in remission 
experienced significantly more presenteeism than controls (54.7% versus 27.3%, 
respectively, P<0.01), and indirect costs were significantly higher for remissive patients 
versus controls ($17,766 per year versus $9,179 per year, respectively, P=0.03). Only 
34.3% had made adjustments to battle work-related problems such as fatigue, irritability, 
and decreased motivation. 
 
Conclusions 
Patients with IBD in clinical remission still cope with significantly more presenteeism and 
work limitations than controls; this translates in higher indirect costs and decreased 




A decrease in work productivity is commonly seen in patients suffering from chronic 
diseases.1 This impairment is usually described in terms of presenteeism or absenteeism. 
Presenteeism is defined as the lost productivity that occurs when employees come to 
work but perform below par due to their illness. Absenteeism represents time missed 
from work due to their disease. Activity impairment is the effect of illness on regular 
everyday activities. The associated indirect costs are a major contributor to health 
expenditures. It was reported that 76% of medical costs in chronic diseases are due to 
indirect medical costs, of which 83% (63% of total costs) is due to presenteeism.2 
 
The IBD are chronic, frequently progressive, conditions often with complications leading 
to disabilities.3 The prevalence of Crohn’s disease (CD) is 201 per 100,000 adults and 238 
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per 100,000 adults for ulcerative colitis (UC) in the U.S. population.4 Impairment due to 
IBD has been shown to affect educational and employment prospects,5-8 triggering a 
socioeconomic burden on the economy and the patient.5,9 Patients with symptomatic IBD 
are less likely to have obtained a graduate or a professional degree than non-symptomatic 
patients.10 Patients with IBD experience significant longer periods of unemployment8 and 
have lower employment percentages5-7. Also, IBD-associated problems can result in job 
loss, missed school days, or reduced employment offers.9 Even if patients with IBD do go 
to work, their productivity is frequently impaired because of diminished motivation, 
irritability, avoidance of social activities, and less participation during meetings.11 
Published estimates showed that 43% of employees with IBD need time off work due to 
the disease, averaging 7.2 days per employee with IBD per year.12 This translates into a 
cost of $138 million per year for the U.S. The indirect cost of missed work time to IBD in 
1998 or 1999 was more than $3.6 billion U.S. dollars (USD) or $5228 USD per person with 
IBD and symptoms.10 Fortunately, more effective IBD therapies have resulted in improved 
health outcomes, which has been associated with improvements in employment status, 
hours worked, and productivity.13-15 
 
So far, studies estimating the indirect costs for IBD in the U.S. did not take presenteeism 
into account.16-19 Since presenteeism is the major contributor to indirect medical costs2, 
the actual costs are probably underestimated. Therefore, in addition to confirming IBD 
work-related problems in a prospective, high volume, single IBD center study, we aimed to 
(1) quantify presenteeism, (2) determine its associated costs, and (3) generate 





Design and Population 
We performed a prospective study at a tertiary IBD center in Los Angeles, California 
between March 2013 and February 2014. All included patients were above the age of 18 
and participated in the Value-based Care Program20 at the UCLA Center for Inflammatory 
Bowel Diseases. Consecutive patients were asked to participate in this study during clinic 
visits. In November 2013, a de-identified web-based questionnaire accessible through a 
128-bit SSL encrypted link was sent out to patients who had not visited our clinic in the 
past year. Patients who could not be reached through e-mail were approached by 
telephone. Included patients were approached by e-mail to ask anyone they know (e.g. a 
family member or friend), above the age of 18 and without IBD, to serve as our control 
group. The study was approved by the UCLA IRB under protocol number 13-001507. 
 
Questionnaires and Data Collection 
The following questionnaires were administered: (1) the Work Productivity and Activity 
Impairment (WPAI)21 questionnaire, (2) the short-IBD questionnaire for quality of life 
(QoL) assessment22, and (3) disease activity (DA) scores (Harvey Bradshaw index for CD23 
and partial Mayo score for UC24). Additionally, we developed a work impact questionnaire 
based on the IMPACT11 study to assess work-related problems. Finally, we included 
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questions about job-lock into the questionnaire (Figure 3.1). Job-lock is defined as the 
propensity of patients to stay in a job to retain insurance coverage. Data about race, 
ethnicity, initial symptoms, initial disease location, specific colon locations, fistula, extra-
intestinal manifestations, disease duration, surgeries, smoking and alcohol use were 
collected from the medical charts. 
 
 
Work Impact Questionnaire 
 
 
1. What industry do you work in? 
□ Real estate, renting, leasing 
□ State and Local Government 
□ Finance and insurance 
□ Health/social care 
□ Manufacturing 
□ Retail trade 
□ Wholesale trade 
□ Federal Government 
□ Information 
□ Arts, entertainment  
□ Construction 
□ Waste services 
□ Other services 
□ Utilities 
□ Mining 
□ Corporate management 
□ Education services 
□ Agriculture
□ Other, please specify: ………………………………………… 
 
2. Who is currently providing you with health insurance? 
□ Employer Æ proceed to next question 
□ Other, please specify and proceed to question 5 
……………………………………………………………………………………………… 
 
3. Would you like to change your job? 
□ Yes Æ proceed to next question 
□ No Æ proceed to question 5 
 
4. Is the risk of losing employer-provided health insurance your reason for not changing jobs? 
□ Yes 
□ No, please specify: ………………………………………………………………………………… 
  
5. Have you been on disability in the past year? If yes please specify for how long 
□ Yes, for ………………….. months Æ proceed to next question 
□ No    Æ proceed to question 7 
 
6. What was the reason you were on disability? 
□ Fatigue 
□ Hospitalization/Surgery 
□ Other, please specify: ……………………………………………………………………………………. 
 
7. Which of the following adjustments have you made in your work to avoid taking sick days off from work 
due to your IBD? 
□ Working from home 
□ Working part-time 
□ Working flexible hours 
□ I have not made any such adjustments 
□ I do not have the possibility to make 
such an adjustment 





Figure 3.1. The questionnaire used for data collection 
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8. If you have missed work due to your IBD, what was the reason? Check all that apply. 
□ Hospital/emergency department visit 
□ Doctor appointment 
□ Incontinence or fear of incontinence 
□ Abdominal pain or cramping 
□ Fear of frequent stools or bowel movements interfering with work activities 
□ Fear of frequent stools or bowel movements bringing attention to my condition from colleagues 
□ Fatigue, and/or not enough energy to get through the day 
□ Worry about gas pressure, discomfort 
□ Worry/fear of potential for embarrassment 
□ Rectal/anal pain or burning 
□ Volume of blood in bleeding episode 
□ I have never been absent from work due to IBD 
□ Not applicable/other: ……………………………………………………………………………………. 
 
9. Have any of your superiors and/or colleagues complained or made unfair remarks about your performance 
at work in relation to your IBD? 
□ Yes □ No 
 
10. Do you think you have been discriminated in the workplace as a direct consequence of your IBD? 
□ Yes □ No 
11. How does IBD affect your performance at work 
□ I am quiet or quieter during meetings 
□ I cancel my attendance at meetings at the last minute 
□ I do not participate in work social activities 
□ I am irritable at work 
□ I am less motivated in my work 
□ My IBD does not affect my behavior at work 
□ I am fatigued 
□ Not applicable/other 
 
How much do you agree with the following statements? 
12. I believe that IBD has negatively affected my career path, opportunities for advancement, income and/or 
earning potential 
□ Strongly agree 
□ Agree 




13. Because of my IBD, I have lost a job or had to quit /leave a job 
□ Strongly agree 
□ Agree 
□ Neither agree nor disagree 
□ Disagree 
□ Strongly disagree 
 
 
These questions were based on surveys and adapted for this study from the European Federation of Crohn’s and 
Ulcerative Colitis Associations and The National Association for Colitis and Crohn’s Disease. 
 
Figure 3.1 – continued. The questionnaire used for data collection 
 
Controls filled out a general health version of the WPAI and a modified version of the 
work impact questionnaire, assessing the effect of general health problems on work 
productivity. To classify patients by type of employment, we used the categorization of 




The WPAI calculates absenteeism, presenteeism, and activity impairment independent of 
work status. Absenteeism is calculated based on the numbers of hours missed from work 
due to disease as a percentage of the total amount of hours worked in a week. 
Presenteeism and activity impairment are assessed on an 11-point Likert scale, where 0 
was no effect of the disease, and 10 was full impairment due to disease. Prevalence of 
absenteeism, presenteeism, and activity impairment in our cohort were defined as any 
absenteeism, presenteeism, or activity impairment; no threshold was imposed. Job-lock is 
defined as not being able to change employment because of employer-provided health 
insurance and fear of loss of employee benefits. Remission of IBD was defined as a Harvey 
Bradshaw index of ≤4 for CD and a partial Mayo score ≤2 for UC, with higher scores 
indicating active disease. 
 
Outcomes 
Absenteeism, presenteeism, and work limitations were analyzed, and differences between 
patients with IBD and controls, patients with UC and CD, and patients with active disease 
and inactive disease were assessed. Absenteeism costs were estimated using the lost-
wages method26, which calculates absenteeism costs by multiplying the estimated number 
of workdays missed by the estimated average daily compensation for full-time employees 
and an average wage multiplier of 1.6127. Estimated daily earnings and benefits were 
defined as $31.93 per hour and based of the U.S. Department of Labor statistics.25 To 
define a high and low salary group, we obtained the different hourly wages for the 
employment categories from the Department of Labor, patients who made more than $32 
per hour were defined as the high salary group, whereas patients who made less than $32 
per hour were defined as the low salary group. Presenteeism costs were calculated 
assuming the hours of decreased productivity as partially non-worked hours and 




Descriptive statistics were provided for the results of the work impact questionnaire. 
Students’ t tests and one-way analysis for variance tests were performed for continuous 
data, and Fisher’s exact tests and chi-square tests for categorical data. The data were 
analyzed using Excel (Microsoft Office Excel 2010, Microsoft, Redmond, WA) and SPSS 






A total of 469 patients filled out the WPAI questionnaire. Twenty-nine patients were 
excluded because 23 forms were filled out incorrectly, and 6 patients did not have 
confirmed IBD, which left 440 patients with IBD eligible for analysis. For a subset of 379 
patients, QoL and DA were assessed during the same clinic visit. In addition, a total of 213 
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patients filled out the work impact questionnaire. DA and QoL scores were available for 
152 of those. A total of 22 controls were included as a comparison (Figure 3.2). 
 
 
Figure 3.2. Study flowchart. 
 
Out of the 440 included patients with IBD, 49.8% were male (Table 3.1). The median age 
was 37 years (range, 18-83 yr), and 73.9% had never smoked. The majority of the included 
patients (82%) were white, 7.3% were of Asian descent, and 3.4% were black or African 
American. In total, 50.2% (221) were diagnosed with CD and 49.8% (219) with UC. No 
significant differences in gender, smoking status, race, ethnicity, and disease duration 
were observed between patients with UC and CD. The median age at diagnosis for 
patients with CD was slightly younger (24; range, 8-68 year) than for patients with UC (29; 
range, 6-81 year) (P=0.002). Rectal bleeding was the most common presenting symptom 
in UC (77.3%) and abdominal pain the most common in CD (69.7%). As expected, more 
patients with CD (33.5%) have undergone abdominal surgery than patients with UC (9.1%) 
(P<0.0001). No significant differences in gender, age, intoxications, race, and ethnicity 
were observed between the IBD and the control group (Table 3.2); 13.6% of the controls 
had a chronic disease. 
 
Employment 
In total, 64.4% (283) of the total IBD cohort was employed and 35.6% (157) was not (Table 
3.3). Table 3.4 shows the industrial sectors in which patients were employed. Out of 62 
unemployed patients who indicated a reason for being unemployed, 54.8% were retired 
or a student; 14.5% were on disability; 12.9% were homemakers (manager of the 
household); 4.8% could not work due to IBD; and 3.2% recently lost their job. All of our  
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Total (n=440) CD (n=221) UC (n=219) P 
Male gender, n (%) 110 (49.8) 109 (49.8) 1.000 
Age (years), median (range) 36 (19-79) 40 (18-83) 0.174 





























Age at diagnosis (years), median (range) 24 (8-68) 29 (6-81) 0.002 
Disease duration (years), median (range) 8 (0-52) 6.5 (0-52) 0.115 
Race, n (%) 
- American Indian or Alaska Native 
- Asian 
- Black or African American 


















Ethnicity, n (%) 
- Hispanic or Latino 











Medication use, n (%) 
- Biological therapy 
- Immunomodulators 
- Steroids 
- Other medication 

















Initial symptoms (1 or more), n (%) 
- Abdominal pain 
- Diarrhea 
- Rectal bleeding 



















Initial disease extent (1 or more), n (%) 
- Upper GI tract 
- Small bowel excluding terminal ileum  










Table 3.1. Demographics of IBD population. PSC: primary sclerosing cholangitis, NA: not applicable. 
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Total (n=440) CD (n=221) UC (n=219) P 











Fistula, n (%) 
All Fistula 
- Peri-anal fistula 
- Enterocutaneous fistula 



















Extra-intestinal manifestations, n (%) 



























Surgeries, n (%) 







Table 3.1 – continued. Demographics of IBD population. PSC: primary sclerosing cholangitis, NA: not applicable. 
 
controls were employed. There was no significant difference in employment rate between 
patients with UC and CD (63.3% and 65.3%, respectively [P=0.67]). In the employed group, 
54.5% were male, whereas in the unemployed group, only 41.4% were male (P=0.009). 
Activity impairment was present in 65% of the employed group, whereas in the 
unemployed group, this was 79% (P=0.002). Mean QoL was significantly higher in 
employed patients (QoL=50 [SD 12]) than in the unemployed patients (QoL=44 [SD 15]) 
(P=0.001). No significant difference in DA was observed, with 24.3% active disease in the 
employed group versus 26.4% in the unemployed group (P=0.639). 
 
Work productivity 
Presenteeism and absenteeism were calculated in the employed patients (140 CD, 143 
CD) and in 22 employed controls (Figure 3.3). No significant differences in absenteeism 
were observed between controls, patients with UC and CD (13.6%, 22.4%, and 20.0%, 
respectively). Significantly, more presenteeism was detected in patients with CD (61.4%) 
and patients with UC (64.3%) compared with controls (27.3%) (P=0.004). Activity 
impairment was calculated as well, and similar patterns were observed with 63.6% and 
66.4% activity impairment in CD and UC, respectively, and 31.8% for controls (P=0.007). 
The strongest impairment was observed in patients with active disease. Of these, 46.6% 
experienced absenteeism, 94.8% presenteeism, and 98.9% activity impairment, compared 
with 14.4%, 54.7%, and 62.7%, respectively, of patients in remission (P<0.001). 
Absenteeism was similar between remissive patients and controls (14.4% and 13.6%, 
respectively, P=1.000), whereas controls had significantly less presenteeism than 




Total (n=462) IBD (n=440) Controls (n=22) P 
Male gender, n (%) 219 (49.8) 12 (54.5) 0.662 
Age (years), median (range) 37 (18-83) 37 (25-77) 0.439 

























Race, n (%) 
- American Indian or Alaska Native 
- Asian 
- Black or African American 
















Ethnicity, n (%) 
- Hispanic or Latino 









Table 3.2: Demographics of IBD patients versus controls. NA: not applicable. 
Total (n=440) Employed (n=283) Unemployed 
(n=157) 
P 
Age (years), median (range) 36 (20-82) 41 (18-83) 0.094 
Male gender, n (%) 154 (54.4) 65 (41.4) 0.009 








Activity impairment, n (%) 184 (65.0) 124 (79.0) 0.002 
Active disease (total n=379), n (%) 58 (24.3) 37 (26.4) 0.639 
QoL (total n=379), mean (SD) 50 (12) 44 (15) 0.000 
Table 3.3. Characteristics of employed versus unemployed IBD patients.CD: Crohn’s disease; UC: ulcerative colitis; 
QoL: Quality of life. 
Work impact 
Table 3.5 shows the limitations that patients with IBD experienced at work. Most 
commonly reported limitations were fatigue (41.8% of patients), irritability (12.2%), and a 
decreased motivation (11.7%). The most frequent reasons to miss work were doctor 
appointments (39%), abdominal pain or cramping (24.4%), and hospital/emergency 
department visits (22.1%). Remarkably, only 34.3% were able to make work adjustments 
(e.g., telecommuting or flexible hours) to avoid taking time off due to their IBD. Stress or 
pressure when taking sick time off from work due to IBD was experienced by 37.1% of 
patients, 4.3% felt superiors and/or colleagues complained or made unfair remarks about 
their performance at work in relation to their IBD, and 5.3% felt that they were 
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discriminated in the workplace as a direct consequence of their IBD. Furthermore, 26.2% 
felt that IBD had negatively affected their career path, opportunities for advancement, 
income and/or earning potential. Also, 11.2% lost a job or had to quit a job because of 
IBD, job-lock was observed in 14% of patients, and 3.3% reported to have been on 
disability at some point in the past year. 
 
Industry, n (%)  Total (n=213) 
Arts, entertainment  38 (17.8) 
Health/social care  33 (15.5) 
Education services  24 (11.3) 
Other services  23 (10.8) 
Corporate management  18 (8.5) 
Finance and insurance  15 (7.0) 
Retail trade  15 (7.0) 
Real estate, renting, leasing  10 (4.7) 
Information  9 (4.2) 
State and local government  7 (3.3) 
Construction  5 (2.3) 
Federal government  4 (1.9) 
Other  4 (1.9) 
Manufacturing  3 (1.4) 
Utilities  2 (0.9) 
Wholesale trade  2 (0.9) 
Agriculture  1 (0.5) 
Table 3.4. Patients by employment categories. 
 
 
Figure 3.3 Prevalence of absenteeism, presenteeism, and activity impairment in controls and IBD patients with 











Which of the following adjustments have you made in your 
work to avoid taking sick days off from work due to your 
IBD? n (%) 
- Working from home 
- Working part-time 
- Working flexible hours 
- I have not made any such adjustments 

































If you have missed work due to your IBD, what was the 
reason? Check all that apply. n (%) 
- Hospital/emergency department visit 
- Doctor appointment 
- Incontinence or fear of incontinence 
- Abdominal pain or cramping 
- Fear of frequent stools or bowel movements interfering 
with work activities 
- Fear of frequent stools or bowel movements bringing 
attention to my condition from colleagues 
- Fatigue, and/or not enough energy to get through the 
day 
- Worry about gas pressure, discomfort 
- Worry/fear of potential for embarrassment 
- Rectal/anal pain or burning 
- Volume of blood in bleeding episode 























































How does IBD affect your performance at work? n (%) 
- I am quiet or quieter during meetings 
- I cancel my attendance at meetings at the last minute 
- I do not participate in work social activities 
- I am irritable at work 
- I am less motivated in my work 
- My IBD does not affect my behavior at work 
- I am fatigued 


































Table 3.5. An overview of limitations patients with IBD experience at work, subdivided by 
disease activity. 
 
Unsurprisingly, significant differences were observed between patients with active disease 
versus inactive disease. Active patients experienced more fear of frequent stools or bowel 
movements interfering with work activities (P=0.017), felt more fatigued (P=0.002), made 
more adjustments to avoid taking sick days off from work due their IBD (P=0.028), and 
Presenteeism in IBD 
61 
experienced more worry and fear of potential embarrassment at the workplace (P=0.003). 
We observed that patients who reported absenteeism or presenteeism felt more 
frequently stressed about taking time off work due to their disease (78% and 50%, 
respectively, P<0.01) than those without absenteeism or presenteeism (27% and 16%, 
respectively, P<0.01). Interestingly, patients who experienced absenteeism and 
presenteeism made work adjustments significantly more often (54% and 40%, 




We estimated that total indirect costs for active patients on average were $1133 per 
week, assuming an average hourly compensation of $31.93, a 40-hour work week, and a 
wage multiplier of 1.61. This equals 55.1% of the total weekly compensation. This was 
significantly more than patients in remission, whose total indirect cost was estimated to 
be 18% of the total weekly compensation or $370.13 per week for a full-time employee 
(P<0.01). 
 
Presenteeism accounted for the majority of costs, with 33.8% of total weekly 
compensation ($695.03 per week) for active patients and 13.5% of total weekly 
compensation ($277.60 per week) for remissive patients. Absenteeism accounted for 
21.3% of total weekly compensation ($437.99 per week) in active patients and 4.5% of 
total weekly compensation for patients in remission. 
 
Indirect costs encountered for patients in remission were still significantly higher when 
compared with controls (P=0.029). For controls, average weekly indirect costs were 
estimated at 9.3% of total weekly compensation or $191.23 per week (for a full time 
employee). Average indirect cost associated with absenteeism were on average 4.8% of 
total weekly compensation or $98.70 per week, and costs associated with presenteeism 
were estimated at 4.6% of total weekly compensation or $94.59 per patient per week 
(Figure 3.4). Furthermore, patients in remission who made more than $32 per hour 
experienced absenteeism more frequently than those who made less than $32 per hour 
(24.5% and 6.9%, respectively, P=0.01). Presenteeism was similar in both salary groups 
(56.6% and 55.2%, respectively). Average total indirect costs were estimated at $789.58 in 




“Without question, the single biggest force threatening U.S. workforce productivity, as 
well as health care affordability and QoL, is the impact of chronic conditions.”28 Indeed, 
the indirect costs of care are estimated to be approximately 76% of total cost of care.2 
This discussion has become especially relevant now that our daily clinical practice is faced 
with the transition from the fee-for-services model to the value-payment model to bend 
the cost curve. Tackling both direct and indirect costs will increasingly be placed on the 
agenda of the provider, especially in the management of costly chronic disease like IBD. 
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In this study, we found that employed patients with IBD, even when in complete clinical 
remission, still experienced decreased productivity significantly more frequently than 
healthy controls: 54.7% versus 27.3%, respectively (P=0.02). This translates into a sizable 
economic impact as reflected by the indirect costs for patients although they are in clinical 
remission (18% IBD versus 9.3% controls of total compensation per week [P=0.03]). 
Disturbingly, we found that patients continue to cope with limitations at work that cause a 
lower QoL and an increase in stress, absenteeism, and presenteeism. The majority, 65.7%, 
has not made any adjustments to combat these problems, most likely due to their inability 
to deal with complaints like fatigue or with aligning their doctors’ appointments with their 
job demands. 
 
Figure 3.4. Indirect costs as a percentage of maximum weekly compensation for employees. 
*P=0.03, ** P=0.02, *** P<0.01. 
 
Interestingly, we did not observe a significant difference in absenteeism between IBD 
patients and controls, respectively 21.2% (CD 20% and UC 22.4%) compared with 13.6% 
(P=0.399). This could be attributed to improved treatments, like biological therapy, 
inducing effective clinical remission and allowing patients to resume their work.13-15,29 
Other studies found comparable absenteeism percentages ranging from 18% to 36% for 
CD and 13% to 25% for UC.1 Although the control population was small, differences for 
absenteeism, presenteeism, activity impairment, and indirect costs were significant. 
 
A limitation of this study is that controls were identified through our patients with IBD, 
which could potentially lead to bias. However, it has been shown that caregivers of 
patient with chronic diseases usually tend to have reduced productivity compared with 
controls9, which would suggest that this would only underestimate the measured effect. 
Furthermore, the included patients were selected in a tertiary care center, with 
Presenteeism in IBD 
63 
potentially more patients with difficult to treat disease. To limit the effect of this, we 
aimed to focus on the productivity of patients in clinical remission. 
From a health economical perspective, it has been shown that presenteeism makes up for 
the majority of indirect costs.2 This is the first report on indirect costs including 
presenteeism of patients with IBD in the U.S. Our cost model shows that indirect costs are 
significantly lower when patients with IBD enter a remissive state, dropping from $1333 
per week when clinically active to $370 per week when in remission. A recent study from 
Hungary showed presenteeism costs of €2508 per patient per year, which translates to 
$3191 per patient per year,30 that equals $66 per patient per week. This number is lower 
than our estimated $354 per patient per week. The difference can be explained by the 
average hourly wage that is lower in Hungary ($7) and the fact that we incorporated the 
average wage multiplier to correct for the variation in presenteeism cost among different 
kind of employment levels. 
What can we, as caregivers, do to decrease presenteeism in patients with IBD in 
remission? First of all, it is important to note that patients themselves do not appear to 
make the necessary adjustments: only 34.3% were able to do so, which confirms results 
from a recent study that showed that only 40% of patients had made any adjustment.11 
Second, these patients continue to struggle with 3 types of problems: (1) persistent 
symptoms (e.g., fatigue, irritability, cramping), (2) lack of work motivation, and (3) missed 
workdays due to medical appointments. Third, we observed additional macroeconomic 
issues: (1) career stagnation, 26.2% felt that their disease had negatively affected their 
career and (2) job-lock, which was observed in 14% of patients. It has been reported that 
chronic illness reduces job mobility by about 40% those that rely on their employer 
coverage.31 For IBD, this has not been studied previously. 
Our recommendations therefore are divided into care provider recommendations and 
employer recommendations. Care providers (e.g., physicians, nurses, social workers, 
dieticians) will need to proactively discuss and propose employment-related adjustments 
tailored to the individual. They need to encompass mental support, nutritional support, 
wellness (e.g., fitness, yoga, meditation), and elimination of unnecessary tests, 
procedures, and medical appointments. Employer recommendations include job-
coaching, an in depth discussion about career and work place related support measures. 
Surveys have shown that employees with chronic conditions are more likely to be highly 
satisfied with their jobs if they had high self-efficacy in managing their disease, perceive 
workplace support, and had less work limitations.32 This would allow employers to make 
effective adjustments leading to a decrease of presenteeism. 
In conclusion, this study shows that employed patients with IBD in clinical remission still 
have significant loss of work productivity that goes unnoticed in the majority of cases. The 
associated high indirect costs constitute a significant economic burden on health 
expenditures. A way to decrease indirect costs includes both care provider and employer 
interventions, ideally converging into an integrated approach. The development and 
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testing of practice guidelines and productivity enhancement tools will most likely have a 
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Value-based health care is an upcoming field. The core idea is to evaluate care based on 
achieved outcomes divided by the costs. Unfortunately, the optimal way to evaluate 
outcomes is ill-defined. In this study we aim to develop a single, preference based, 
outcome metric for patient value, which can be used to quantify overall health value in 
inflammatory bowel disease (IBD) management. 
 
Methods 
IBD patients filled out a choice based conjoint (CBC) questionnaire in which patients chose 
preferable outcome scenarios with different levels of disease control (DC), quality of life 
(QoL), and productivity (Pr). A CBC analysis was performed to estimate the relative value 
of DC, QoL and Pr. A patient-centered composite score was developed which was 
weighted based on the observed preferences. 
 
Results 
We included 210 IBD patients. Large differences in individual preferences were observed. 
Increases from low to intermediate outcome levels were valued more than increases from 
intermediate to high outcome levels. Overall, QoL was more important to patients than 
DC or Pr. Individual patient value scores were calculated based on observed preferences. 
This score was significantly different from a score not weighted based on patient 
preferences, especially in patients with active disease. 
 
Conclusion 
We showed the feasibility of creating a single composite outcome metric for patient value 
in IBD using CBC. Including patient preferences in the score development significantly 
changed outcomes in patients with active disease. Therefore, we propose that success in 
health care should be measured using individual patient preferences, and that providers 





Currently, a health care transformation of seismic proportions is unfolding, aimed to 
replace the broken fee-for-services model with new modalities, one of which is value-
based health care (VBHC). Although VBHC is a relatively new concept in medicine with 
clearly defined principles1, only few real-world models are currently available. Its key 
component is the quantification and continuous measurement of health value - the 
achieved health outcomes per the associated costs of care.1 By means of demonstrating 
these health value metrics, a brand new framework for competition in the health care 
space is created. Providers are incentivized to improve individual health outcomes in a 
cost-effective manner. In addition, patients are able to compare provider performance to 
choose their care providers accordingly. Lastly, payers are able to choose provider 
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networks and health systems based upon performance, and they can direct their 
members in order to achieve the most optimal health outcomes and contain costs. 
 
Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative 
colitis (UC), are chronic, debilitating disorders characterized by inflammation of the 
gastrointestinal tract. IBD is thought to be caused by a dysregulated immune response in 
response to unknown environmental triggers in a genetically susceptible host.2 IBD 
treatment is associated with significant costs, and large variations between clinical 
practices are observed.3 Because of the chronic characteristic, the high costs, and the lack 
of consistency in treatment patterns, VBHC could greatly improve the value of IBD care. 
 
The optimal health outcome on a patient level – patient value – is unfortunately ill-
defined.4 Several sets of quality measures have been developed in IBD. The American 
Gastroenterology Association (AGA) has developed a set of 8 process measures to 
estimate quality of care in IBD and is currently developing a set of outcome metrics5; the 
Crohn’s and Colitis Foundation America developed a set of 10 process measures along 
with 10 outcome measures6. Optimal health outcomes from a patient perspective are not 
necessarily equivalent to those from a provider perspective. It is increasingly recognized 
that incorporating patient preferences into their associated treatment plan through a 
process called ‘Shared Decision Making’ (SDM) offers significant benefit to both patients’ 
knowledge and patients’ experience.7 Additionally, patient reported outcomes (PROs) are 
increasingly recognized to be essential in evaluating a patients’ health status. The US Food 
and Drug Administration (FDA) recently officially incorporated PROs as a measure of 
success in clinical trials.8 The National Institute of Health (NIH) PRO Measurement 
Information System (PROMIS) project aims to develop databanks of PROs that allow 
comparisons of outcomes across multiple disease areas.9 However, to our knowledge, 
nobody has aimed to quantify a single value measure based on patient preference. 
 
Our recently launched VBHC program for IBD incorporated the VBHC principles of cost and 
outcome measurement within its care delivery infrastructure.6 The IBD program designed 
the outcome measure Value-Quotient (vQ), which incorporates patient value, as well as 
the associated provider costs of care delivery, and medication. The key objective of this 
VBHC program is to annually increase individual vQs by increasing health outcomes at 
lower costs through interventions on the patient level (e.g. improve compliance, 
participation, wellness, job coaching, and education) and provider level (e.g. constant 
process innovation, cost awareness, medication choice, task shifting, and education). 
 
Although patient value is difficult to define, a reasonable assumption is that most patients 
value a high level of disease control (DC) with preservation of their quality of life (QoL) 
and ability to perform daily activities, including (work) productivity (Pr). In collaboration 
with IBD patient focus groups, the initial design around patient value therefore consisted 
of a combination 1) DC, 2) QoL, and 3) Pr.10 Critical to both the evaluation and the 
constant improvement of this VBHC program is an improved understanding on how 
patients value various outcomes in this value-based care program and how they relate to 
each other. Incorporating these values in the constant redesign of the program may 
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ultimately result in clinical, reimbursement, and policy decisions that better reflect patient 
preferences. Aligning the value-based care program with patient preferences can 
potentially increase its effectiveness by improving adoption of, satisfaction with, and 
adherence to its coordinated care scenarios. 
Different methods are available to quantify value to consumers, which can roughly be 
divided into revealed and stated preference methods.11 Revealed preference methods 
derive preferences from actual market data, whereas stated preference methods refer to 
data obtained through questionnaires in which preferences are elicited. Value is 
preferably assessed through revealed methods, but direct data are often hard to obtain. 
Stated preference methods for measuring preference have been developed to facilitate 
this process. One form of a stated preference is choice based conjoint analysis (CBC), in 
which consumers are asked to choose from a set of products or outcomes. Using conjoint 
analysis, the value to customers of different components of a product can be assessed.11 
Although the cost component is difficult to include in the health care setting, the relative 
preferences for outcomes (components) can still be determined. Conjoint analysis has 
been used progressively in health research, mostly in the setting of SDM processes.11 In 
this study we aim to quantify the relative importance of each of the ‘patient value’ 
components: DC, QoL, and Pr using a CBC analysis for IBD patients and use this to 
construct a single, preference based, PRO metric for IBD health value. 
Methods 
Study design 
This is a prospective study evaluating patient preferences in disease outcomes using a CBC 
questionnaire and analysis. Relative importance for DC, QoL, and Pr was assessed for each 
participant. Data was collected using an online questionnaire using SSI web, version 8.3.8, 
Sawtooth Software (Orem, UT). 
Population and data collection 
Patients with an established IBD diagnosis were approached by email and supplied with a 
unique code to login to the computerized questionnaire. Patients were recruited between 
December 2014 and April 2015. The questionnaire started with a set of PROs assessing 
current symptom level, and self-reported DC, QoL, and Pr using 10-point Likert scales. The 
last 10 questions involved CBC questions eliciting patient preference for each of these 
three disease outcomes. The design of the questions was selected based on a pilot study 
including 12 patients that chose the most optimal questionnaire design (Figure 4.1). 
Additional characteristics including age, gender, disease duration, age at diagnosis, 
surgical history, and medication use were extracted from medical records. 
Definitions 
To assess and compare disease activity we utilized the mobile health index (mHI) for CD 
(mHI-CD) and UC (mHI-UC), which were calculated based on the reported symptom levels. 
These validated score assess clinical disease activity utilizing solely PROs.12 For CD the mHI 
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includes the number of liquid stools, abdominal pain (yes/no), general well-being, and 
self-assessed disease control; a score of ≥6.38 indicates active disease. The mHI-UC 
includes stool frequency, abdominal pain, rectal bleeding, and self-assessed disease 
control; a score of ≥3.2 indicates active disease.  
Figure 4.1. Example of CBC question soliciting patients’ preference for the three different attributes: disease 
control, quality of life, and work productivity. Each patient answers 10 CBC questions and is asked to choose the 
most preferable scenario for each of those ten 
Conjoint analysis 
A CBC analysis was performed to assess the relative value that patients attribute to the 3 
individual components of patient value: DC, QoL, and Pr. CBC is a decomposition method, 
which estimates the individual value of an attribute based on the overall value of a 
scenario containing multiple attributes.11 Three attributes were evaluated: DC, QoL, and 
Pr. For each attribute the worth of 4 levels were evaluated: 
I. Disease control; 10%, 40%, 70%, or 100% of disease control 
II. Quality of Life; 10%, 40%, 70%, or 100% of quality of life
III. Productivity; 10%, 40%, 70%, or 100% of productivity
Each participating patient was asked to fill out a set of 10 CBC questions. Every question 
showed two scenarios including all three attributes (i.e. DC, QoL, and Pr), with different 
attribute levels (i.e. 10%, 40%, 70%, or 100%) shown in each scenario (Figure 4.1). In each 
question patients were asked to choose their most preferable scenario. Questions in 
which one scenario has better outcomes for all three attributes than the second scenario 
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were not included in the questionnaires (i.e. in all questions a trade-off between at least 
one attribute versus the other needed to be made). 
Calculations of patient value 
We defined overall patient value on a scale from 0-100 where 100 means the highest 
possible patient value and 0 the lowest patient value possible. Individual value scores 
were calculated using individual outcomes and weights for DC, QoL, and Pr. To estimate 
DC we used the mHI, for QoL and Pr self-reported values using Likert-scales. Weights were 
assigned based on the individual importances derived from the CBC analysis. These 
weights add up to 100% per definition. For any decrease in DC, QoL, or Pr, the percentage 
decrease (relative to the maximum decrease) was calculated and subtracted from 100; 
relative to the individual weights. We also calculated patient value using arbitrary weights 
for DC, QoL, and Pr, which are more closely aligned with physician practice: DC 60%, QoL 
20%, and Pr 20% importance. 
Statistical analysis 
Patients that completed all CBC questions were included in the analysis. A Hierarchical 
Bayes (HB) model was used to estimate individual part worth utilities (i.e. preference 
scores) for each of the attribute levels. All questions were included in the HB model. 
Constraints were included in the model stating that 100% DC/QoL/Pr is better than 70%, 
70% better than 40%; and 40% better than 10% for each of the three attributes. For 
estimation of preferences 10,000 iterations of the model were used for convergence of 
the model, another 10,000 cycles were run for estimation of part-worth utilities. 
Part worth utilities were normalized to allow comparison of importances between 
patients across all three attributes. Part worth utilities are scaled on an arbitrary scale. To 
estimate the importance of improving from one level to another (i.e. improving from 40% 
QoL to 70% QoL), utility scores of the respective levels were subtracted. To assess the 
overall importance of each of the attributes (i.e. DC, QoL, and Pr), for each attribute the 
part worth utility of the 100% level is subtracted by the part-worth utility of the 10% level. 
The relative difference between those three values determines the importance of each of 
the attributes. Based on the individual patient’s highest preference, patients were 
assigned to one of three groups: 1) DC preference; 2) QoL preference; 3) Pr preference. 
Self-reported DC, QoL, Pr, and symptoms, as well as clinical characteristics such as gender, 
age, disease duration, age at diagnosis, and previous surgeries were compared between 
groups. Pearson Chi-squared and Fisher exact test were used to compare categorical data; 
Wilcoxon Mann-Whitney tests were used to compare non-parametric data. A Wilcoxon 
Signed Rank Sum test was performed to compare paired observations of patient value 
scores calculated using different weightings. 
The target inclusion number was 250 patients. To collect 1,000 representations per main 
level effect, a sample size of 200 patients is sufficient, taking into account that each 
respondent answers 10 questions, each comparing two scenarios.13 Assuming an 80% 
completion rate, 250 participants need to be included. SSI web, version 8.3.8, Sawtooth 
Software (Orem, UT), and SAS version 9.4 (Cary, NC) were used for the analysis. 
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Ethical considerations 
This study was approved by the University of Los Angeles, California Institutional Review 
Board under protocol number IRB#14-001308. All included patients consented to 
participate in this study. 
Results 
In total, 227 patients filled out the questionnaire. After exclusion of 17 incomplete 
questionnaires, 210 patients were included in the final analysis. The median time to finish 
the first CBC question was 40 (IQR 28-58) seconds, the second 19.5 (IQR 15-30.5) seconds, 
and for the next questions the median time gradually decreased to 10-12 seconds per 
question for the last 5 questions (Figure 4.2). Of the patients that finished all CBC 
questions, 107 (51%) had CD, 6 had (3%) indeterminate colitis (IC), and 97 (46%) had UC. 
For 14 (6%) of included patients only self-reported measures were available because no 
consent to look up medical information in the medical chart was acquired. Of the 
remaining 196 patients, 96 (49%) was male, and the median age was 40 years (range 20-
83). The median age at diagnosis was 29 years (range 0-55), and 59 (30%) had an 
abdominal surgery for IBD in the past (Table 4.1). Of the participating CD patients, 26% 
had active disease; for UC this was 31%. In total 16 (8%) were using oral corticosteroids at 
the time of the study, 82 (42%) were using biologics, 85 (33%) were using 
immunomodulators and 76 (39%) were using 5-ASA. 
Figure 4.2 Average and median time to complete CBC questions 
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  Maximum preference group  








n (% of total) 210 63 115 32  
Male gender, n (%) 96 (49) 26 (43) 51 (48) 19 (66) 0.13 
Diagnosis, n (%)     0.19 - Crohn's disease 107 (51) 30 (48) 57 (50) 20 (62.5)  - Indeterminate colitis 6 (3) 0 (0) 6 (5) 0 (0)  - Ulcerative colitis 97 (46) 33 (52) 52 (45) 12 (37.5)  
Age, median (range) 40 (20-83) 39 (21-71) 38 (20-83) 47 (23-80) 0.21 
Age at diagnosis, median (range) 29 (7-81) 30 (14-69) 27 (7-81) 36 (16-75) 0.037 
Disease duration, median (range) 7 (0-55) 6 (1-47) 7 (0-55) 6 (0-40) 0.36 
months in program, median (range) 42 (6-96) 43 (9-91) 41 (6-96) 43 (13-91) 0.22 
Smoking, n (%)     0.53 - Current 7 (4) 3 (5) 3 (3) 1 (3)  
- Never 143 (76) 44 (77) 80 (78) 19 (66)  - Past 39 (21) 10 (18) 20 (19) 9 (31)  
Alcohol use, n (%) 110 (63) 32 (58) 63 (66) 15 (58) 0.53 
Medication use, n (%)      - 5ASA  76 (39) 27 (45) 41 (39) 8 (28) 0.29 
- immunomodulators 65 (33) 21 (35) 38 (36) 6 (21) 0.29 
- biologics 82 (42) 25 (42) 44 (42) 13 (45) 0.95 
- ciprofloxacin/ 
metronidazole 
1 (1) 1 (2) 0 (0) 0 (0) 0.46 
- budesonide 10 (5) 2 (3) 6 (6) 2 (7) 0.67 
- systemic corticosteroids 16 (8) 6 (10) 7 (7) 3 (10) 0.63 
- rectal corticosteroids 8 (4) 3 (5) 4 (4) 1 (3) 0.89 
Surgical history, n (%)      - abdominal surgery 59 (30) 17 (28) 34 (32) 8 (28) 0.85 
- perianal surgery 12 (6) 2 (3) 8 (7) 2 (7) 0.59 
Anatomy, n (%)      - ileostomy 2 (1) 1 (2) 1 (1) 0 (0) 1.00 
- IPAA 7 (4) 2 (3) 4 (4) 1 (3) 1.00 
Perianal disease, n (%) 12 (6) 1 (2) 8 (8) 3 (10) 0.15 
Patient reported outcomes,  
median (range)      
- disease activity VAS 2 (0-10) 2 (0-10) 2 (0-10) 2 (0-10) 0.95 
- quality of life decrease VAS 1.5 (0-10) 1 (0-10) 2 (0-10) 2 (0-9) 0.98 
- productivity decrease VAS  1 (0-10) 1 (0-10) 1 (0-10) 1 (0-8) 0.73 
Active disease*, n (%) 59 (29) 21 (34) 28 (25) 10 (31) 0.41 
Characteristics CD patients      
Disease location, n (%)     0.52 - L1 27 (30) 4 (15) 16 (33) 7 (44)  
- L2 14 (15) 5 (19) 7 (14) 2 (13)  - L3 48 (53) 16 (62) 25 (51) 7 (44)  - L4 2 (2) 1 (4) 1 (2) 0 (0)  
Upper GI involvement, n (%) 6 (6) 1 (4) 3 (6) 2 (12) 0.62 
Table 4.1 Demographics and disease characteristics of included patients, and by preferred outcome. *Active 
disease defined as mHI-CD≥6.38 or mHI-UC≥3.2. 
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Characteristics CD patients (cont’d)  
Disease behavior, n (%)     0.61 - B1 57 (59) 17 (61) 32 (62) 8 (47) 
- B2 29 (30) 7 (25) 14 (27) 8 (47) 
- B3 8 (8) 2 (7) 5 (10) 1 (6) 
- B2+B3 3 (3) 2 (7) 1 (2) 0 (0) 
Patient reported outcomes, 
median (range) 
- liquid stools/day  1 (0-20) 1 (0-15) 1 (0-20) 1.5 (0-6) 0.64 
- well-being VAS 8 (0-10) 8 (0-10) 8 (4-10) 8 (5-10) 0.84 
- abdominal pain present, n(%) 35 (33) 9 (31) 21 (37) 5 (25) 0.60 







active disease*, n (%) 28 (26) 9 (31) 14 (25) 5 (25) 0.80 
Characteristics UC/IC patients  
Disease extent, n (%)     0.84 - E1 26 (28) 10 (32) 13 (25) 3 (30) 
- E2 33 (36) 9 (29) 21 (41) 3 (30) 
- E3 33 (36) 12 (39) 17 (33) 4 (40) 
Patient reported outcomes, 
median (range) 
- n stools/day 3 (0-15) 2 (0-12) 3 (0-15) 2.5 (1-9) 0.87 
- abdominal pain VAS 1 (0-8) 1 (0-7) 1 (0-8) 1 (0-6) 0.87 
- rectal bleeding VAS 1 (0-10) 0 (0-8) 1 (0-9) 1 (0-10) 0.70 







active disease*, n (%) 31 (31) 12 (36) 14 (25) 5 (42) 0.36 
Table 4.1 – continued. Demographics and disease characteristics. 
The HB estimation showed that on average, an increase in QoL from 10% to 40% was 
perceived as very valuable: twice as valuable as an increase in QoL from 40% to 70%, and 
3.9 times more valuable than an increase in QoL from 70% to 100% (Figure 4.3, Table 4.2). 
Similarly, increasing QoL from 10%-40% was valued 1.4 times as important as increasing 
DC from 10%-40%, and 2.3 times as important as increasing Pr from 10%-40%. Increases in 
DC were on average less valued by patients than increases in QoL, and increases in Pr 
were less valued than increases in QoL. Across the three attributes, patients assigned on 
average 34% importance (SD 19) to DC, 42% importance (SD 16) to QoL, and 24% 
importance (SD 17) to Pr.  
Patient preferences for DC, QoL and Pr vary widely across patients (Figure 4.4). Overall, 
preference for DC ranged from 4%-87%, QoL from 7%-78%, and Pr from 1%-79%. In total, 
63 patients (30%) had a stronger preference for DC than for QoL or Pr; 32 (15%) had a 
stronger preference for Pr than for QoL or DC; and 115 (55%) preferred improvements in 
QoL over improvements in Pr or DC (Table 4.3). No significant differences in baseline 
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demographics, medical history, current medication use, and current disease state were 
observed (Table 4.1).  
 
 
Figure 4.3 The importance patient assign to increasing DC, QoL, and Pr with 30% at different thresholds. 
Increasing any of the three attributes rom 10-40% is valued more than increases from 40%-70% and increases 
from 70%-100%. Increases in QoL are valued more than similar increases in DC and Pr. The y axis represents 
importances, which are directly related to the differences in utility scores between two levels (e.g. utility score of 
40% DC minus the utility score of 10% DC). Utility scores do not have units, are scaled arbitrarily, and can 
generally not be compared between studies. Therefore, the y-axis does not have units, but the relative size of the 
bars can be compared (e.g. a bar twice as high means twice as important). 
 
 
increase in   
Increase from-to Disease control Quality of life Productivity 
10%-40% 52 (2) 71 (2) 39 (2) 
40%-70% 33 (2) 36 (1) 25 (1) 
70%-100% 17 (1) 18 (1) 8 (1) 
Table 4.2. Differences between zero-centered utility scores between attribute levels separated for DC, Qol, and 
productivity. Utility scores do not have units, are scaled arbitrarily, and can generally not be compared between 
studies. Therefore, the differences do not have units and are scaled arbitrarily as well. However, relative 
differences between the numbers can be compared (i.e. if a difference is twice as much as another difference, it 
means that difference is twice as important). 
 
Next, the individualized patient value component of the vQ was calculated for all patients, 
which was weighted based on an individual patient’s preference. The average patient 
value score was 76 (SD 24) for CD patients, and 79 (SD 23) for UC/IC patients. When 
calculating patient value using a static weight of 60% DC, 20% QoL, and 20% Pr for all 
patients, the average score was 74 (SD 24) for CD and 78 (SD 23) for UC/IC, which is on 
average 1.4 (SD 6.2) point lower than using the personalized method in CD (P=0.067) and 
1.0 (SD 6.4) points lower in IC/UC (P=0.25). Overall, 14 (14%) of CD patients had a change 
of >10 points in their patient value score, as well as 14 (14%) UC/IC patients. 
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 Figure 4.4 Individual patient preferences for DC, QoL, and Pr. 
 









n 210 63 115 32 
% importance of vQ component, mean (SD) 









- quality of life (QoL) 42 (16) 27 (10) 54 (9) 28 (9) 
- productivity (Pr) 24 (17) 15 (10) 21 (10) 54 (12) 
Total 100% 100% 100% 100% 
Table 4.3. Average importances of DC, QoL, and Pr in each preference group. 
 
When comparing score changes based on the disease state, we found that for CD patients 
in remission the score decreased by 0.2 (SD 4.9) points from 86 (SD 14) when using the 
personalized score to 86 (SD 14) when using the static score (P=0.75), while for CD 
patients with active disease the score significantly decreased from 47 (SD 21) using the 
personalized method to 42 (SD 16) using the static method (P=0.0095). Similarly, in UC 
and IC patients in remission the score increased by 0.6 (SD 4.6) points from 89 (SD 14) 
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when using the personalized score to 90 (SD 11) when using the static score (P=0.27), 
while for patients with active disease the score decreased from 57 (SD 25) using the 
personalized method to 52 (SD 22) using the static method (P=0.0028, Table 4.4, Figure 
4.5). This resulted in a change of more than 10 points in the patient value score in 32% of 
patients with active disease in both CD and UC/IC. 
Diagnosis disease 
state  






>10 points change 
in patient value 
n mean (SD) mean (SD) P n (%) 
CD All 106 76 (24) 74 (24) 0.0669 14 (14) 
Inactive 78 86 (14) 86 (14) 0.7487 5 (6) 
Active 28 47 (21) 42 (16) 0.0095 9 (32) 
UC/IC All 101 79 (23) 78 (23) 0.2479 14 (14) 
Inactive 70 89 (14) 90 (11) 0.2706 4 (6) 
Active 31 57 (25) 52 (22) 0.0028 10 (32) 
Table 4.4. Differences between personalized method of calculating patient value and the static scoring using 60% 
weight for DC and 20% weight for QoL and Pr per disease type and disease state. 
Figure 4.5. Difference between a patient-preference weighted outcome score versus the pre-defined static 
outcome score. Example of outcomes of a UC patient with active disease, using the measured DC, QoL, and Pr 
(A), when different weightings (B) are applied. The total patient value score is 52 when it is calculated using the 
static weightings (C), and 78 when it is calculated using the patients’ preferred weightings (D). 
Discussion 
In this study we developed and tested a method to assess patient value quantitatively in a 
single outcome metric for IBD. We showed a wide variability in patient preferences for 
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disease outcomes; patients’ preferences were on average more heavily weighted on QoL, 
in contrast to traditional outcome metrics in which the focus is more heavily weighted on 
DC. This reaffirms the importance of SDM, and the incorporation of individualized 
treatment goals in the treatment plan. Interestingly, patient preferences were not linearly 
correlated with increases in DC, QoL, or Pr; increases from 10%-40% were judged to be 
more important than increases from 40%-70%, which in turn was perceived to be more 
important than increases from 70% to full DC, QoL, or Pr. This pattern was consistently 
observed across all three outcomes. On the other hand, no clinical characteristics could be 
identified that predict patient preferences. 
Because individual patients’ goals differed widely across patients we propose to measure 
outcomes accordingly. Instead of using a static composite score, we propose that 
composite scores should be weighted based on individual patient preferences. We 
showed the feasibility of constructing a single composite outcome metric using individual 
patient preferences. Indeed, outcomes were very different when using a patient 
preference weighted outcome metric, especially in patients with active disease. This 
concept is not limited to the metrics established in this Center; but conjoint analysis could 
be used to weigh and measure different sets of outcome metrics as well. 
Limitations of this study are that there is a potential for sampling error and respondent 
bias because of the recruitment strategy through email and the setting in a tertiary IBD 
referral center. Furthermore, QoL, DC, and Pr are strongly correlated with each other. 
However, regardless of these correlations, we showed that weighting these outcomes 
could result in significantly different outcomes. A major strength of this study is that to 
our knowledge this is the first attempt to quantify a single composite outcome metric 
based on patient preference using conjoint analysis. This is a proof of concept that CBC 
can be used for the purpose of quantifying a single patient-centered outcome metric, 
which could be used directly to fill in the patient value portion of the value equation. 
In conclusion, we showed that the definition of value matters in the evaluation of 
treatments. It is important to measure the right outcomes that are important to patients. 
We propose that success – on an individual patient level, as well as on a system level – 
should be defined based on individualized patient value, which incorporates the 
preferences of the patient. Moreover, these metrics should be included in provider 
scorecards and adopted into value based insurance designs. Where previous proposals 
have sought to include SDM process measures into reimbursement policies14, we propose 
to include provider incentives for annually increasing a patient-centric value metric which 
incorporates patients’ individual preferences. By striving for this, SDM needs to become 
an inherent part of patient treatment, and overall health care will be more patient 
focused and outcome driven. 
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Implementation of the 2010 Affordable Care Act (ACA) calls for a collaborative effort to 
transform the U.S. health care system toward patient-centered and value-based care. In 
order to identify how specialty care can be improved we mapped current U.S. health care 
utilization in inflammatory bowel diseases (IBD) patients using a national insurance claims 
database. 
Methods 
We performed a cross-sectional study analyzing U.S. health care utilization in 964,633 IBD 
patients between 2010 and 2012 using insurance claims data, including pharmacy and 
medical claims. Frequency of IBD-related care utilization (medication, tests, treatments) 
and their charges were evaluated. Subsequently, outcomes were put into the framework 
of current U.S. guidelines to identify areas of improvement. 
Results 
A disproportionate usage of aminosalicylates (42%) in Crohn’s disease (CD), frequent 
corticosteroid use (46%, with 9% long-term users), and low rates of corticosteroid-sparing 
drugs (thiopurines 15%; methotrexate 2.7%) were observed. Markers for inflammatory 
activity such as CRP or fecal calprotectin were not commonly used (8.8% and 0.13%, 
respectively). Although infrequently used (11%), anti-TNFα antibody therapy represents a 
major part of observed IBD charges. 
Conclusions 
This analysis shows 2010-2012 utilization and medication patterns of IBD health care in 
the U.S., and suggests that improvement can be obtained through enhanced guidelines 
adherence. 
Introduction 
The current U.S. health care system is suffering from a variety of clinical and economic 
inefficiencies.1-3 While the focus of debates on these challenges may vary, such as 
excessive administration, non-adherence to guidelines, overutilization of resources, 
uncoordinated care, and broad-based preventive failures, there is an emerging consensus 
that the U.S. health care system as currently implemented, with a persistent disconnect 
between high spending levels and discernible improvements in patient outcomes, is not 
sustainable. 
IBD are prototypic chronic diseases, affecting around 1.4 million adults and children in the 
U.S. The estimated annual disease-attributable direct costs are largely driven by hospital 
costs and medication, especially biological therapy.4,5 Like most chronic diseases, IBD care 
is beset with wide practice variations6, provider expertise differentials (primary and 
specialty), and a limited evidence base for basic, let alone integrated, standards of care 
and quality of care.7 Fragmentation and duplication of services, suboptimal follow-up, and 
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a lack of transparency in adherence to guidelines, particularly in regard to overuse and 
misuse of drugs, could as well contribute to the high spending in IBD care. 
We conducted a 2010-2012 insurance claims analysis encompassing 964,633 IBD patients. 
The primary study objective was to assess U.S. health care utilization in IBD patients on a 
national level, to establish a detailed understanding of current practices in IBD 
management. The secondary objective was to analyze charges encountered for different 
aspects of IBD management and assess their relative contribution to total IBD related 
health care costs. 
Methods 
Claims derived care analysis 
We conducted a retrospective analysis of U.S. IBD pharmacy and medical claims data, 
between 2010 and 2012, from Source Healthcare Analytics LLC (SHA). The data represent 
a significant proportion of all U.S. medical and pharmacy claims enabling 
quantitative/qualitative assessments of IBD-related practices and costs. Only fully 
adjudicated claims by both payers and providers were included. IBD patients were 
identified as having ≥1 medical claim with one of the International Classification of 
Diseases (ICD)-9 codes for CD (555.x) or ulcerative colitis (UC) (556.x) between 04/2010 
and 03/2012. Patients with diagnosis codes for both UC and CD were excluded from the 
disease specific analyses. We analyzed medical claims for patient identifiers, 
demographics, procedure details, charge, date, and physician information. Pharmacy 
claims for IBD specific drugs (Table 5.1) were analyzed for patient identifiers, 
demographics, prescription details, charge, date, insurance, and physician information. A 
summary of the claims data capture process is shown in Figure 5.1. Heat maps were 
generated based on UC and CD pharmacy claim counts in different U.S. regions, by 
physician 3-digit zip codes, divided by the assumed population sizes of these regions. 
Drug group Included drugs 
Aminosalicylates mesalamine, sulfasalazine, balsalazide, olsalazine 
Antibiotics metronidazole, ciprofloxacin 
Local acting corticosteroids budesonide 
Systemic corticosteroids prednisone, methylprednisolone 
Immunomodulators azathioprine, mercaptopurine, cyclosporine, methotrexate 
Biologics adalimumab, certolizumab pegol, infliximab, natalizumab 
Table 5.1. IBD related medication sorted by drug group 
Medications were categorized into 6 groups of ascending potency: 1) aminosalicylates; 2) 
antibiotics; 3) budesonide; 4) systemic corticosteroids; 5) immunomodulators; and 6) 
biologic therapy (Table 5.1). We determined the number of unique patients using these 
drugs between 2010 and 2012. Biologics, in particular i.v. infliximab and i.v. natalizumab, 
are commonly charged as medical claims, which were therefore included as well. For each 
drug group, the percentage prescribed by gastroenterologists was calculated. To 
determine concomitant medication use, we analyzed prescription rates in 3-month 
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timeframes. In addition, we calculated the percentage of patients using corticosteroids for 
more than 105 consecutive days. To quantify the volume of patients discontinuing 
immunomodulators or biologics, we defined stopping as not receiving a refill within 30 
days after the end date of the last prescription. 
Figure 5.1. Origin of the data sets. Medical claims and pharmacy claims are submitted by providers either directly 
to the payer or, more commonly, this process is outsourced to medical clearinghouses that subsequently process 
the claims and submit the claims to payers. Source Healthcare Analytics has access to a considerable amount of 
these claims data. We queried this database, based on diagnosis codes and specific medications. 
For the analysis of IBD-related procedures and tests, total claim counts, unique patient 
counts, and charges were extracted from the medical claims data set. IBD-related 
procedures were defined based on a pre-defined set of Current Procedural Terminology 
(CPT) and Healthcare Common Procedure Coding System (HCPCS) codes summarized in 
Table 5.2. The included CPT codes cover gastrointestinal surgical procedures, anesthesia, 
and medical procedures; laboratory, pathology, and radiological procedures; and codes 
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for evaluation and management. In addition, we included CPT category 2 codes for IBD 
specific quality measures8 and CPT category 3 codes for gastrointestinal procedures. The 
included HCPCS level II codes were A-codes for stoma care, B-codes for (par)enteral 
therapies, and J-, C-, and S-codes for IBD-specific drugs (Table 5.2). 
 
 codes explanation 
CPT codes category I   
Anesthesia 00700 – 00882 abdomen 
Surgery 43200 – 43278 
44360 – 44397 
45300 – 45392 
46600 – 46615 
endoscopies 
 44005 – 44346 
44500 – 44701 
44900 – 45190 
45395 – 45999 
49000 – 49084 
intestinal surgeries 
 46020 – 46500 
46700 – 46899 
peri-anal surgeries 
Radiology 70010 – 76499 diagnostic imaging 
 76506 – 76999 diagnostic ultrasound 
 77001 – 77032 radiologic guidance 
Pathology & Laboratory 80047 – 80076 organ or disease-oriented panels 
 80500 – 80502 consultations clinical pathology 
 81000 – 81099 urinalysis 
 82000 – 84999 chemistry 
 85002 – 85999 hematology & coagulation 
 87001 – 87999 microbiology 
 88300 – 88399 surgical pathology 
Medical procedures 90465 – 90474 immunization administration for vaccines/toxoids 
 90476 – 90749 vaccines, toxoids 
 91000 – 91299 gastroenterology 
 96360 – 96549 hydration, therapeutic, prophylactic, diagnostic 
injections & infusions, and chemotherapy & other 




99201 – 99215 office/other outpatient services 
 99217 – 99220 hospital observation services 
 99221 – 99239 hospital inpatient services 
 99241 – 99255 consultations 
 99281 – 99288 emergency dept. services 
 99291 – 99292 critical care services 
CPT codes category II   
 1036F current non-tobacco user 
 3095F DXA results 
 4037F influenza vaccine ordered and administered 




CPT codes category III 
4040F pneumococcal vaccine administered or previously 
received 
0184T excision of rectal tumor, transanal microsurgical 
approach 
0227T anoscopy high resolution with biopsies 
HCPCS level II 
A-codes A4361 – A4427 A5051-A5063 A5082-A5093 ostomy supplies 
(excluding urinary 
ostomy) 
B-codes All enteral and parenteral 
therapy 
J-, C-, and S- codes J0135, J0718, J0744 J1020 – J1040, J1094, 
J1100, J1700 – J1720, J1745, J2323, J2650, 
J2920, J2930, 7030 – J7130, J7500 – J7502, 
J7506 – J7510, J7515, J7516, J8540, J8610, 
J9250, J9260, C8957, C9249, C9279, C9283, 
C9399, S0173 
IBD related drugs and 
infusion fluids 
Table 5.2 – continued. Included IBD-related CPT and HCPCS codes in the analysis of the medical claims data set 
Charge analysis 
Since neither costs nor reimbursement rates are publicly known, costs in this study refer 
to claims-related charges and were utilized to assess the relative contribution of different 
medications and procedures to total IBD-related charges. Patient identifiers, and thus 
information regarding diagnoses, were only available for a subset of all pharmacy claims; 
therefore, de-identified claims for IBD-related medications prescribed by 
gastroenterologists were also collected for charge estimations. For each claim, physician 
and insurance information, prescription details, charges, and claim month were obtained. 
We corrected for the subset of IBD patients that is not managed by gastroenterologists, 
using the proportion of IBD medication prescribed by non-gastroenterologists in the IBD 
patient-identified pharmacy claims data set. To assess the charges of IBD-related 
procedures and tests, the medical claims data set was used. For claims without a charge, 
the average of charges per procedure with a known charge was used. 
Guidelines-derived care analysis 
We critically appraised and summarized all available U.S. guidelines, medical position 
statements, and technical reviews from the American College of Gastroenterology (ACG) 
and the American Gastroenterological Association (AGA). Where different sets of 
guidelines disagreed on specific management decisions, the most conservative measure 
was used in our analysis. The guidelines-derived data sets were structured in a way that 
would enable comparison with the claims-derived data analysis. 
Statistical analysis 
Our descriptive statistics consist of patient and physician demographics, medication and 
medical resources utilization, and charges. All outcomes were analyzed for all patients 
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with a diagnosis of IBD, and per diagnosis specifically (UC vs. CD). All statistical analyses 
were performed on the SHA-retrieved data sets using SAS software, version 9.2. 
Results 
Claims-derived care analysis 
Between 2010 and 2012, a total of 964,633 IBD patients was identified: 501,718 CD 
patients (52%) and 529,788 UC patients (55%); 7% had a diagnosis code for both UC and 
CD. The mean age of the study population was 50.8 (SD 18.1) years (CD 48.3 [SD 18.3] 
years, UC 52.6 [SD 17.7] years), and 44% was male (43% CD and 45% UC). In the pharmacy 
claims dataset a total of 413,334 IBD patients was identified that had at least 1 pharmacy 
claim for IBD related medication; 39% of these claims were processed by commercial 
insurers, 30% by a pharmacy benefit manager, 14% by Medicare, 6% by Medicaid, 8% by 
an employer group, and 3% paid cash (Table 5.3). Geographical heat maps that show the 
relative amount of claims per 3-digit zip code area are provided in Figure 5.2 for CD and 
UC. 
Insurance IBD total CD UC 
Unique patients 413,334 221,912 227,203 
Cash 3% 3% 3% 
Commercial 39% 39% 40% 
Employer Group 8% 7% 8% 
Medicaid 6% 7% 5% 
Medicare  14% 14% 14% 
Pharmacy benefit manager 30% 29% 30% 
Table 5.3. Payer analysis of pharmacy claims 
Pharmacy claims analysis 
Table 5.4 summarizes observed use of IBD medication, subdivided for CD and UC. In our 
study population, 62% of UC patients and 42% of CD patients used aminosalicylates. In 
total, 32% of all aminosalicylate claims were prescribed for CD patients. Antibiotics were 
used by 21% of patients with UC, and 25% with CD, and corticosteroids were used in 46% 
of IBD patients (CD 47%, UC 44%). Long-term use of corticosteroids was observed in 8.8% 
of patients (19% of all corticosteroid users) within the study period. Concomitant use of 
corticosteroid sparing medication, i.e., immunosuppressives, was low (15% used 
thiopurines concomitant with corticosteroids, 2.7% used methotrexate) (Table 5.5). In 
total, 18% of patients used thiopurines (CD 21%, UC 12%), 2.6% methotrexate, and 0.2% 
cyclosporine. Of UC patients receiving thiopurines, 59% continued the use of 
aminosalicylates; for methotrexate this was 31%. We observed that 54% of patients who 
used immunomodulators stopped, of whom 73% restarted again. The number of CD 
patients who used infliximab, adalimumab, certolizumab pegol, or natalizumab was 6.0%, 
9.2%, 2.5%, and 0.1%, respectively; for UC patients, these rates were 2.1%, 1.3%, 0.2%, 
and 0%, respectively. Of patients taking biologics, 48% stopped, of whom 74% restarted. 
The majority of biologics (69%), immunomodulators (63%), aminosalicylates (64%), and 
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budesonide (69%) were prescribed by gastroenterologists. Non-gastroenterologists 




Figure 5.2. Heat map of the U.S., reflecting the number of Crohn’s disease (a) and ulcerative colitis (b) patient 
claims per provider zip code over the number of individuals registered at that zip code 
 
Medical claims analysis 
A total of 12,374,156 medical claims were identified between 2010 and 2012, covering 
6,405 different claim codes. Of these codes 1,750 (27%) were IBD-related, corresponding 
with 9,818,429 claims (79% of the total claims). The most common claims were 15-minute 
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office visit (684,790 claims), 25-minute office visit (641,367 claims), complete blood count 
(514,459 claims), venipuncture (513,527 claims), and colonoscopy with biopsies (467,980 
claims). 
 
 IBD CD UC 
Aminosalicylates  53.1% 42.1% 62.3% 
Antibiotics  23.5% 25.2% 20.7% 
Budesonide  8.0% 12.0% 3.7% 
Systemic corticosteroids  46.3% 47.0% 44.4% 
Long term corticosteroids 8.8% 8.3% 8.4% 
Thiopurines  17.5% 21.3% 12.3% 
Methotrexate  2.6% 3.4% 1.6% 
Cyclosporine  0.2% 0.2% 0.2% 
Biologics 11.0% 16.8% 3.5% 
Table 5.4. Percentage of IBD/CD/UC patients using IBD drugs between 2010 and 2012. 
 
Table 5.5 on page 96. 
 
The average rate of annual outpatient clinic visits was 94%, emergency department (ED) 
visits 11%, hospitalizations 6.5%, and surgeries 2.8% (Table 5.6). The rate of outpatient 
clinic visits was higher for CD (97%) compared to UC (74%). Annual colonoscopy rates 
were 25% for CD and 34% for UC. The annual rate of imaging (ultrasound, magnetic 
resonance imaging [MRI], or computed tomography [CT] abdomen/pelvis) was 18%, of 
complete blood count 32%, and of liver enzyme tests 20% Annual rates of inflammatory 
activity assessment using biomarkers were as follows: C-reactive protein (CRP) 8.8%, 
erythrocyte sedimentation rate (ESR) 9.7%, fecal calprotectin 0.13%, fecal lactoferrin 
0.13%, and fecal leukocytes 0.32%. During the study period 1.0% of patients underwent a 
dual-energy x-ray absorptiometry (DXA) scan. Determination of the rate of thiopurine 
methyltransferase (TPMT) testing and thiopurine metabolites did not result in reliable 
results, because multiple CPT codes are used for these tests and these CPT codes are also 
used for other tests. The annual observed rate of tuberculosis (TB) skin or quantiferon 
tests, recommended for screening in patients starting with biological treatment, was 
0.8%, and of hepatitis B screening 0.8%, and annual rates of influenza and pneumococcal 
vaccinations were 1.8% and 0.5%, respectively. However, many of those might not be 
billed for independently. 
 
Charges 
Annual U.S. medical claim charges for IBD patients were in total $4.6 billion, of which 86% 
($3.9 billion) were directly related to IBD care. The medical claim with the highest share in 
these charges was infliximab (35%), followed by colonoscopy with biopsies (4.6%) and 
intravenous infusion of chemotherapy/biologics (3.5%). Furthermore, in total 22% of the 
IBD related medical claim charges were related to endoscopies and surgeries (including 
pathology and anesthesia charges), 13% to physician consultation services, and 9% were 
for laboratory tests (Figure 5.3a). Patients with a diagnosis code for CD had on average 
higher annual charges and more claims (mean annual charge of $5,004 with 6 claims on 
average) compared to UC patients (mean annual charge of $2,381, with 3 claims on 
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average). Annual IBD related pharmacy claims were estimated to account for a total of 
$2.9 billion annually. In total 54% of those were for aminosalicylates (of which 32% for CD 
patients) and 21% for biologics (Figure 5.3b). 
 
 IBD CD UC 
ED visit 10.7% 15.1% 4.5% 
Outpatient visit 93.8% 97.4% 74.2% 
Hospitalization 6.5% 7.6% 4.3% 
Endoscopy total 42.0% 34.1% 44.2% 
- Upper GI endoscopy - 5.8% - 6.2% - 4.7% 
- Colonoscopy - 31.3% - 25.0% - 33.9% 
IBD related surgery total 2.8% 3.3% 1.6% 
- resection colon/ileocecal - 1.1% - 1.2% - 0.8% 
- fistula/abscess surgery - 0.6% - 0.9% - 0.1% 
CBC 32.5% 39.5% 18.6% 
CRP 8.8% 11.2% 4.1% 
ESR 9.7% 12.0% 4.8% 
Liver enzymes 20.4% 24.9% 11.4% 
Fecal calprotectin 0.1% 0.2% 0.1% 
Fecal lactoferrin 0.1% 0.1% 0.1% 
Fecal leukocytes 0.3% 0.3% 0.3% 
Influenza vaccination* 1.8% 1.9% 1.3% 
Pneumococcal vaccination* 0.5% 0.5% 0.4% 
Hepatitis B vaccination* 0.1% 0.2% 0.1% 
TB screen* 0.8% 1.1% 0.4% 
Hepatitis B screening* 0.8% 1.0% 0.4% 
US/MRI/CT abdomen/pelvis 18.1% 22.6% 11.3% 
DXA scan 0.6% 0.8% 0.3% 
Table 5.6. Observed average annual rate for hospital visits, endoscopies, surgeries, laboratory investigations, and 
imaging. CD: Crohn’s disease, CBC: complete blood count, CRP: C-reactive protein, CT: computed tomography, 
DXA: Dual-energy X-ray absorptiometry scan, ED: emergency department, ESR: erythrocyte sedimentation rate, 
GI: gastro-intestinal tract, IBD: inflammatory bowel diseases, MRI: magnetic resonance imaging, TB: tuberculosis, 
UC: ulcerative colitis, US: ultrasound. *Might not be billed for independently. 
 
Guidelines-derived care analysis 
We identified seven guidelines/medical position statements published between 2003 and 
2010 with recommendations relevant for IBD care; four by the American 
Gastroenterological Association (AGA)9-12 (all accompanied by technical reviews13-16), and 
three by the American College of Gastroenterology (ACG)17-19. Four focused on IBD 
management10,12,17,18, two on colorectal cancer screening9,19, and one on osteoporosis 
management in gastrointestinal diseases11. None of the guidelines offered detailed 
recommendations on the annual frequency of clinic visits, lab visits, and endoscopies, with 
the exception of colorectal screening protocols. Extracted care recommendations from all 
guidelines are summarized in Table 5.7. 
 
An overview of expected rates of medication and medical resource utilization according to 
guidelines versus the observed rates is provided in Tables 5.8 and 5.9, respectively. 
Summarized, we found that although aminosalicylate treatment is not recommended in 
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CD patients, 42.1% of CD patients were prescribed aminosalicylates during the 2-year 
study period, which alone accounts for at least 17% of total pharmacy charges. 
Metronidazole and ciprofloxacin, indicated for treatment of pouchitis in UC, active 
fistulizing disease in CD, and to treat infectious complications, were prescribed to 23% of 
patients. However, the claims data did not allow a more detailed analysis on indications 
for antibiotic use.  
 
 
Figure 5.3. Origin of charges in medical claims dataset (a) and pharmacy claims dataset (b).  
*includes anesthesia and pathology.  
**The majority of infliximab and natalizumab charges is charged as a medical claim and is therefore not included 
in this graph 
 
Corticosteroid-sparing medication was used sparsely in conjunction with corticosteroid 
therapy (15% thiopurines, and 2.7% methotrexate), while long-term corticosteroid use 
was observed in 9% of patients. Though 9% of patients used corticosteroids for more than 
105 days consecutively, only 1% underwent a DXA scan. Furthermore, we found a low use 
of surrogate biomarkers for assessment of inflammation such as CRP and/or fecal 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medication Guidelines Expected Observed 
Aminosalicylates Recommended for UC, 
not/minimally 
effective for CD 
No aminosalicylates 
for CD 




for pouchitis or fistula 
Unknown 23.5% 
Budesonide Recommended for UC 
not for CD 
No budesonide in UC 3.7% budesonide in UC 
Corticosteroids For induction of 
remission, no long 
term use 







15% of corticosteroid 
users used concomitant 
thiopurines, 2.7% 
methotrexate. In total 
11.0% biologics use. 
Table 5.8. Expected medication use according to guidelines compared with observed values.  
CD: Crohn’s disease, UC: ulcerative colitis. 
 
 
Procedures Guidelines Expected Observed 
Colonoscopy Screening colonoscopy 
for UC 1x/1-3year 8 
years after diagnosis 
UC patients >8yr after 
diagnosis: 33.3% 
annual colonoscopy 







orosomucoid or CRP 
 Annual rates: 
calprotectin: 0.1%; 
lactoferrin: 0.1%; fecal 
leukocytes: 0.3%; CRP: 
8.8%; ESR: 9.7% 
DXA scan Patients >3 months 
corticosteroids 
9% of patients ≥1 
episode of long term 
corticosteroids  





1x/1-2 weeks, then 





per quarter: 8.7% 
thiopurines,  
1.1% methotrexate 
8.1% 3-monthly rate. 
(32.5% annual rate) 
Liver enzymes Patients on 
thiopurines/methotre




per quarter: 8.7% 
thiopurines,  
1.1% methotrexate 
3.4% 2-monthly rate 
(20.4% annual rate) 
Table 5.9. Expected rates of tests and procedure in the data set according to guidelines, compared with the 
observed values. CRP: C-reactive protein, DXA: Dual-energy X-ray absorptiometry scan, ESR: erythrocyte 
sedimentation rate, UC: ulcerative colitis. 
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Discussion 
In this study we report on U.S. health care utilization in IBD patients, and found 
unexpected discrepancies with U.S. guidelines. This was demonstrated by a 
disproportionate rate of aminosalicylate use in CD, common corticosteroid use (including 
long-term), and a low rate of corticosteroid-sparing drugs. In addition, we found only 
infrequent usage of surrogate biomarkers such as CRP and/or fecal calprotectin. 
 
IBD-related health expenditures are among the highest in the U.S. health care system.20 
A 2012 study based on patient-reported expenditures from 556 IBD patients estimated 
annual IBD-related costs in the U.S. to be $2.9 billion20, while another claims analysis of 
19,420 IBD patients estimated annual disease-attributable direct costs to be $6.3 billion21. 
Although we were not able to access actual costs in our study, we were able to assess the 
relative contribution of the different facets of IBD treatment to total IBD-related charges. 
We identified biologics to be a major cost component in IBD care, although their use was 
restricted to only 11% of IBD patients in the observation period. Aminosalicylates 
accounted for 54% of pharmacy claim charges, while 32% of the prescriptions were 
prescribed for CD patients, which is not supported by current guidelines. 
 
Medical insurance claims databases are increasingly used in health outcomes research, 
and these data present both opportunities and limitations.22 A major advantage is that 
claims are anonymous, plentiful, and available in electronic format. Limitations include 
the focus of claims on reimbursement, which is not designed for research purposes; no 
health outcomes or treatment goals are available, diagnoses cannot be formally 
confirmed, and medical utilization without insurance coverage, such as influenza 
vaccinations at the workplace, is not captured. Also, because only claims processed 
through medical clearinghouses could be captured in our data set, we were likely not able 
to capture all U.S. IBD patients, a fraction of claims for the identified patients might not 
have been included, and no reimbursement rates were available. 
 
An insurance claims analysis including 19,420 IBD patients by Kappelman et al5 found 
much higher utilization rates because of more stringent inclusion criteria, thereby 
excluding patients with a mild disease phenotype, patients whom our study aimed to 
include. In contrast, utilization rates reported in a Northern California study analyzing 
8,787 IBD patients were very similar to our observations, except for the number of 
outpatient visits (Table 5.10). 23 This study also reported a decline in prolonged steroid 
exposure from 14% in 1998-1999 to 9% in 2004-2005 annually in CD, and interestingly, an 
increase in UC from 11% to 14%. Infliximab use increased from 1% to 5% in CD and from 
<0.1% to 0.4% in UC.23 Our results are in line with these findings and confirm that similar 
patterns are observed on a national level. 
 
The observed discrepancies between guidelines and observed care could be explained in 
different ways. The New England Health Institute identified four major barriers to 
guideline adherence.24 
1) The current payment system is problematic, because we pay for volume of 
procedures rather than for outcomes;  
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2) a lack of information technology (IT) systems is a barrier because physicians often 
have insufficient access to guidelines at the point of care and because IT does not 
yet adequately support clinical decision-making;  
3) the culture, beliefs, and habits of physicians could be barriers because many doctors 
receive little or no comparative feedback on their performance; and  
4) the current process of development of guidelines presents an obstacle to 
adherence. In particular, the lack of transparency in guideline development leads to 
a lack of trust among physicians, while guidelines themselves often lack sufficient 
flexibility and relevance to clinical practice; many guidelines do not reflect the 
complexity and context in which real-world clinical decisions must be made.24 
 
  Our analysis Herrinton et al.29 Kappelman et al.10 
Hospitalizations CD 7.6% 8% 27% 
UC 4.3% 5% 19% 
Surgeries CD 3.3%  3.5% 5.4% 
UC 1.6%  0.6% 3.6% 
Endoscopies CD 34% - 41% 
UC 44% - 52% 
ER visits CD 15% - 36% 
UC 4.5% - 15% 
Outpatient visits CD 97% 220% 1030% 
UC 74% 180% 921% 
Table 5.10. Annual utilization rates for CD and UC patients compared with a utilization study by Herrinton et al29 
and Kappelman et al10.  
 
In summary, in our claims data set of 964,633 IBD patients, unprecedented in size, we 
found relevant discrepancies between daily care and guideline recommendations on a 
national level. The guidelines themselves, in this case for a prototypic chronic disease, 
need to be assessed and updated to enable development of optimal care-pathways that 
are both clinically and economically efficacious. Future research will need to show the 
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Value-based health care is thought to be the solution that will improve quality and 
decrease costs in health care. Many hospitals are implementing programs based on this 
strategy, but rigorous scientific reports are still lacking. Here, we present the first-year 
outcomes of a value-based health care program for inflammatory bowel disease (IBD) 
management which focused on highly coordinated care, task differentiation of providers 
and continuous home monitoring.  
 
Methods 
IBD patients treated within a value-based health care program were identified in an 
administrative claims database from a commercial insurer allowing comparisons to 
matched controls. Health care utilization including visits, hospitalizations, tests, and 
medications were compared between groups.  
 
Results 
In total, 173 IBD program patients were identified of which 100 were matched to 499 
controls. Significantly more biomarker testing was performed in the value-based health 
care group. Numerically less surgeries, hospitalizations, emergency department visits, and 
imaging were observed. More biologics were used, while both short- and long-term 
corticosteroid use was decreased. 
 
Conclusion 
These are the first results of the first year of a value-based health care program for 
inflammatory bowel disease management. Significantly more preventative measures were 




Globally, health care costs are inflating without necessarily leading to better outcomes.1 In 
order to increase quality and bend the cost curve, the introduction of value-based health 
care (VBHC) is thought to be inevitable.2 Conceptually, VBHC is focused around the idea of 
introducing value in care by dividing achieved health outcomes over the amount of dollars 
spent. Key components of VBHC are measuring outcomes and costs, and making 
subsequent changes in the care delivery processes accordingly. To facilitate this process, a 
coordinated care infrastructure is thought to be of major importance.3,4 Many institutions 
are currently adopting components of VBHC in clinical practice. Unfortunately, rigorous 
scientific reports on the outcomes of these approaches are currently lacking. 
 
IBD management accounts for significant health care costs. While initially the main cost 
driver in IBD was hospitalizations, with the introduction of the newer biologics, 
medication has also become a dominant cost driver.5 This poses a difficult dilemma since 
the most effective medication is oftentimes also the most expensive. This underlines the 
importance of delivering the right care at the right time to the right patient in order to 
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fully optimize value for each individual patient. Care coordination programs for IBD have 
been implemented in a variety of centers across the world, though reported outcomes are 
very sparse.6 The Royal Adelaide Hospital in Australia introduced a chronic care model in 
2008 which included nurse case managers, scheduled follow-up phone calls for 
symptomatic patients, and standardized protocols for blood test monitoring, which 
resulted in a decrease in IBD related hospitalizations7. The effect of remote disease 
monitoring has been studied by a variety of programs as well, such as the Danish 
Constant-Care system for ulcerative colitis (UC), which was shown to reduce relapse 
duration whereas the total number of recognized relapses increased.8 Similarly, the UC-
HAT tele-monitoring system showed no improvement in quality of life or disease activity, 
and many patients discontinued using the system.9 A meta-analysis assessing six remote 
monitoring interventions found a trend towards improvements in quality of life and a 
reduced number of office visits, but showed no significant reduction in relapses or 
hospitalizations.10 
 
The University of California, Los Angeles (UCLA) Center for IBD has implemented a VBHC 
Program which instituted its first version on February 1st, 2012. The program was designed 
around the concepts of value-based health care, including regular monitoring of 
meaningful health outcomes and the implementation of coordinated care pathways 
focusing on improving value for patients.4 Nine care pathways based on patients’ disease 
activity and treatment regimen were implemented, which include scheduled clinic visits, 
labs, and home monitoring (Table 6.1). Task differentiation was introduced, with specified 
tasks for administration, IBD nurses, and IBD specialists. Furthermore, at any time patients 
could reach out with questions to a specialized IBD nurse through email with a response 













6 weeks Week 6 Week 6 Every 2 weeks 
Corticosteroids 
Biologicals 











continuous 2x/year Every 2 months 
Every 2 
months 
Table 6.1. Care scenarios implemented at the UCLA Center for Inflammatory Bowel Diseases in 2012. 
 
Patient participation was achieved in part by completing health outcomes questionnaires 
in the out-of-hospital setting. During the initial year of the UCLA IBD Program hardcopy 
questionnaires were provided to patients during clinic visits and patients were asked to 
return these questionnaires at predefined time points by mail, fax or scanned by email, 
which were subsequently evaluated by a specialized IBD nurse. E-mail reminders were 
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sent, which also included an interactive pdf. During subsequent stages, a supporting IT 
infrastructure enabling outcome collection and reporting was developed and 
implemented in 2013; a patient-facing mobile application which improves usability for 
patients was implemented in 2014.11 These questionnaires consisted of a modified Harvey 
Bradshaw Index for Crohn’s disease (CD) patients and a modified partial Mayo score for 
UC patients and were used to assess patients’ symptoms in between clinic visits. 
 
This study aims to assess the impact of the first phase of the VBHC program (2012) on 
health care utilization and medication use in IBD patients. One of the key components of 
VBHC is the assessment of health care expenditure. In order to allow for a meaningful 
utilization assessment we chose to analyze our performance based on insurance claims 
data extracted from a commercial payer database, which captures the entire spectrum of 
health related utilization and pharmacy use. This allowed us to assess utilization patterns 
within as well as outside of our own facility, and to compare patients treated according to 






We performed a prospective case-control study assessing health care utilization patterns 
in IBD patients treated at the UCLA Center for IBD compared to patients not treated at 
UCLA for their IBD, by using an administrative claims database of Anthem California. We 
performed an intention-to-treat (ITT) analysis including all patients that enrolled in the 
UCLA IBD Center program, and a per-protocol (PP) analysis including only patients that 
were continuously treated at UCLA for at least one year. Additionally, health care 
utilization was assessed longitudinally in the UCLA IBD Center cohort before and after 
enrollment in the UCLA IBD Center. 
 
Population 
Administrative claims that were fully processed and paid by Anthem California were 
obtained between January 2012 and December 2013. Patients that visited the UCLA IBD 
Center between February 2012 (opening of the UCLA IBD Center) and December 2012 
were included in the analysis. Patients who entered in 2013 were not included to ensure 
one year follow-up in the database. Data from 2012 was used as index-data, 2013 data 
was used as outcome data. Matched controls with at least one IBD related visit with a 
non-UCLA gastroenterologist between February and December of 2012 were identified 
and matched 5:1 based on patient characteristics in 2012 using the greedy method12. 
Patients were matched based on age (+/- 10), IBD subtype (+/- 0.3 for UC claims/total IBD 
claims), adjusted Charleston comorbidity index13 (+/- 2), and relapse rate (+/- 1) in 2012. 
Because relapse rate could only be measured if pharmacy claims were available for 
analysis, patients were also fully matched based on pharmacy claims coverage in 2012. 
 
Outcomes in 2013 were compared between groups. Only patients that were covered for 
medical claims for at least 80% of the year in both 2012 and 2013 were included. Patients 
VBHC – impact on health care utilization 
107 
aged 65 years and older were excluded because these patients are eligible for Medicare 
coverage and the data is likely to be incomplete for these patients. 
 
For the PP analysis, we included only patients that visited the UCLA IBD Center at least 
once in 2012 and once in 2013 without any IBD related visits with a gastroenterologist 
elsewhere. Patients were matched to a control population with at least one non-UCLA 
gastroenterologist visit for IBD in 2012 and one in 2013, without any IBD related 
gastroenterologist visits at UCLA. 
 
Lastly, a longitudinal analysis was performed including UCLA IBD patients with at least one 
visit at the UCLA IBD Center. Health care utilization and medication use during the year 
prior to the first UCLA IBD Center visit was compared to the year thereafter, excluding the 
day of the first visit. Patients with no IBD related claims in the year prior to entering the 
program were excluded to ensure only patients with an established diagnosis were 
included in the study. Only patients that were covered for medical claims from a full year 
before to a full year after the first UCLA IBD visit were included. 
 
Outcomes 
IBD related claims were defined as a claim with an International Classification of Diseases 
(ICD)-9 diagnosis code 555.x or 556.x. IBD subtype was determined based on whether the 
majority of IBD related claims was for CD (555.x) or UC (556.x). IBD related utilization was 
identified using Current Procedural Terminology (CPT) codes (Table 6.2). Additionally, 
office visits needed to be accompanied with ICD-9 code 555.x or 556.x in the primary or 
secondary ICD-9 field. Office visits with a gastroenterologist were identified using the 
provider’s registered specialty. A UCLA IBD Center visit was defined as an IBD related visit 
at UCLA with one of the gastroenterologists associated with the UCLA IBD Center. 
 
IBD related ED visits were defined as any visit with ED as the place of service with the 
most frequent primary ICD-9 for an IBD related complaint (Table 6.3). IBD related 
hospitalizations were identified as having at least 2 subsequent days with inpatient 
hospital as the place of service and at least 10% of claims with an ICD-9 code 555.x or 
556.x, or including an IBD related surgery during the hospitalization. If the Diagnosis-
related group (DRG) associated with the hospital stay was not related to IBD (Table 6.4) 
the hospitalization was not considered related to IBD. Medication related to IBD was 
identified based on the generic name. Because biologics, particularly infliximab and 
natalizumab, are frequently billed as a medical claim, Health Care Common Procedure 
Coding System (HCPCS) codes for those drugs were included as well (Table 6.5). Relapses 
were identified based on newly started steroids, newly started biologics, or an acute IBD 
related surgery. Newly started steroids were defined as a new prescription starting at 
least 14 days after the end of the last one; for biologics this was defined as a new 









CPT codes Description 
Office visit 
99201 – 99205 
99211 – 99215 
99241 – 99245 
Office or outpatient visit for new patients 
Office or outpatient visit for established patients 
Consultations: Office and outpatient 
Colonoscopy 
45330 – 45392 
44388 – 44397 
Sigmoidoscopy and colonoscopy procedures (rigid and flexible) 
Colonoscopy via stoma 
Upper 
endoscopy 
43200 – 43202 
43235, 43239 




44005 – 44346 
 
 
44602 – 44701 
45000 – 45190 
45395 – 45999 
 
46020 – 46060 
46270 – 46288 
49000 – 49084 
Incisional and resectional procedures of bowel, intestinal transplant 
procedures, colon resection procedures, laparoscopic enterolysis, 
laparoscopic and open enterostomy procedures 
Open repair procedures intestine , other intestinal procedures 
Open and transrectal procedures of rectum 
Laparoscopic and closed procedures of rectum, open repairs of 
rectum  
Surgical incision of anus - setons and abscess drainage 
Resection of anal fistula 
Exploratory drainage procedures: abdomen/peritoneum 
Acute 
surgeries 
 All surgeries except 
- open repair procedures intestine (44602 – 44680) 





85025 – 85027 
General health panel, obstetric panel 







General health panel, CMP 






on rate (ESR) 








Toxin or antitoxin assay, enzyme immunoassay, probe technique, 
immunoassay with direct optical observation 
X-ray 72170 – 72190 
74000 – 74022 
74240 – 74260 





CT scan 72192 – 72194 
74150 – 74170 
74176 – 74178 
74261 – 74263  
Pelvis 
Abdomen 
Abdomen & Pelvis 
Intestines 
MR scan 72195 – 72197 
74181 – 74183 
Pelvis 
Abdomen 
Ultrasound 76700 – 76705 Abdomen 
Table 6.2. IBD related utilization  
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Code(s) Explanation 
555.* Regional enteritis 
556.* Ulcerative Enterocolitis 
558.9 Other and unspecified noninfectious gastroenteritis and colitis 
560.8* Other specified intestinal obstruction 
560.9 Unspecified intestinal obstruction 
565.* Anal fissure and fistula 
566 Abscess of anal and rectal regions 
567.21 Acute generalized peritonitis 
567.22 Peritoneal abscess 
567.29 Other suppurative peritonitis 
567.89 Other specified peritonitis 
567.9 Unspecified peritonitis 
568.0 Peritoneal adhesions (postoperative) (post infection) 
569.2 Stenosis of rectum and anus 
569.3 Hemorrhage of rectum and anus 
569.41 Ulcer of anus and rectum 
569.42 Anal or rectal pain 
569.49 Other specified disorders of rectum and anus 
569.5 Abscess of intestine 
569.6* Colostomy and enterostomy complications 
569.7* Complications of intestinal pouch 
569.81 Fistula of intestine, excluding rectum and anus 
569.82 Ulceration of intestine 
569.83 Perforation of intestine 
569.89 Other specified disorder of intestine 
569.9 Unspecified disorder of intestine 
578.1 Blood in stool 
578.9 Hemorrhage of gastrointestinal tract, unspecified 
579.2 Blind loop syndrome 
579.3 Other and unspecified postsurgical nonabsorption 
579.8 Other specified intestinal malabsorption 
579.9 Unspecified intestinal malabsorption 
787.91 Diarrhea 
789.0* Abdominal pain 
789.3* Abdominal or pelvic swelling mass or lump 
789.4* Abdominal rigidity 
789.6* Abdominal tenderness 
789.9 Other symptoms involving abdomen and pelvis 




DRG Type Description 
326 Surg Stomach, esophageal & duodenal proc w mcc 
327 Surg Stomach, esophageal & duodenal proc w cc 
328 Surg Stomach, esophageal & duodenal proc w/o cc/mcc 
329 Surg Major small & large bowel procedures w mcc 
330 Surg Major small & large bowel procedures w cc 
331 Surg Major small & large bowel procedures w/o cc/mcc 
332 Surg Rectal resection w mcc 
333 Surg Rectal resection w cc 
334 Surg Rectal resection w/o cc/mcc 
335 Surg Peritoneal adhesiolysis w mcc 
336 Surg Peritoneal adhesiolysis w cc 
337 Surg Peritoneal adhesiolysis w/o cc/mcc 
344 Surg Minor small & large bowel procedures w mcc 
345 Surg Minor small & large bowel procedures w cc 
346 Surg Minor small & large bowel procedures w/o cc/mcc 
347 Surg Anal & stomal procedures w mcc 
348 Surg Anal & stomal procedures w cc 
349 Surg Anal & stomal procedures w/o cc/mcc 
356 Surg Other digestive system o.r. Procedures w mcc 
357 Surg Other digestive system o.r. Procedures w cc 
358 Surg Other digestive system o.r. Procedures w/o cc/mcc 
371 Med Major gastrointestinal disorders & peritoneal infections w mcc 
372 Med Major gastrointestinal disorders & peritoneal infections w cc 
373 Med Major gastrointestinal disorders & peritoneal infections w/o cc/mcc 
377 Med G.i. Hemorrhage w mcc 
378 Med G.i. Hemorrhage w cc 
379 Med G.i. Hemorrhage w/o cc/mcc 
385 Med Inflammatory bowel disease w mcc 
386 Med Inflammatory bowel disease w cc 
387 Med Inflammatory bowel disease w/o cc/mcc 
388 Med G.i. Obstruction w mcc 
389 Med G.i. Obstruction w cc 
390 Med G.i. Obstruction w/o cc/mcc 
391 Med Esophagitis, gastroent & misc digest disorders w mcc 
392 Med Esophagitis, gastroent & misc digest disorders w/o mcc 
393 Med Other digestive system diagnoses w mcc 
394 Med Other digestive system diagnoses w cc 
395 Med Other digestive system diagnoses w/o cc/mcc 
856 Surg Postoperative or post-traumatic infections w o.r. Proc w mcc 
857 Surg Postoperative or post-traumatic infections w o.r. Proc w cc 
858 Surg Postoperative or post-traumatic infections w o.r. Proc w/o cc/mcc 
862 Med Postoperative & post-traumatic infections w mcc 
863 Med Postoperative & post-traumatic infections w/o mcc 
864 Med Fever 
870 Med Septicemia or severe sepsis w mv 96+ hours 
871 Med Septicemia or severe sepsis w/o mv 96+ hours w mcc 
Table 6.4. DRGs related to IBD. 
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DRG Type Description 
872 Med Septicemia or severe sepsis w/o mv 96+ hours w/o mcc 
917 Med Poisoning & toxic effects of drugs w mcc 
918 Med Poisoning & toxic effects of drugs w/o mcc 
919 Med Complications of treatment w mcc 
920 Med Complications of treatment w cc 
921 Med Complications of treatment w/o cc/mcc 
922 Med Other injury, poisoning & toxic effect diag w mcc 
923 Med Other injury, poisoning & toxic effect diag w/o mcc 
947 Med Signs & symptoms w mcc 
948 Med Signs & symptoms w/o mcc 
949 Med Aftercare w cc/mcc 
950 Med Aftercare w/o cc/mcc 
951 Med Other factors influencing health status 
Table 6.4 – continued. DRGs related to IBD. 
 
Drug type Included drugs / CPT codes 
5ASA  mesalamine, sulfasalazine, balsalazide, olsalazine 














adalimumab / J0135 
infliximab / J1745 
certolizumab pegol / J0718, C9294 
natalizumab / J2323, Q4079 
Table 6.5. Drugs included in the analyses. 
 
Statistical analysis 
The average number of IBD related office visits, ED visits, hospitalizations, procedures, 
labs, and imaging studies as well as the number of patients using IBD related medications 
in 2013 were compared between groups. IBD medication use was compared if patients 
were covered for pharmacy claims in the observation period. 
 
In the ITT and PP analyses, the Fisher’s exact test was used for categorical data and the 
Wilcoxon-Mann-Whitney test for continuous data. Differences in IBD subtype in the 
demographics section were assessed using Chi-square tests. In the longitudinal study, a 
Wilcoxon signed-rank test was used for continuous data and a McNemar’s test for 
categorical data. A Bonferroni correction for multiple testing was carried out. A P value 
smaller than 0.05/33=0.00015 was considered statistically significant. 
 
Ethical considerations 
This study was approved by the University of Los Angeles, California Institutional Review 






Intention to treat analysis 
In total 173 IBD patients were identified within the Anthem database that visited the 
UCLA IBD Center at least once in 2012. Of those, 16 were excluded from further analyses 
because they were aged 65 years or older and 57 patients were excluded because they 
were not covered for medical claims throughout index and analysis year (Figure 6.1). This 
resulted in inclusion of a total of 100 UCLA IBD patients that were matched to 499 non-
UCLA patients. Mean age in both groups was 39 (SD 11.6 for UCLA patients, 11.4 for 
controls). In the UCLA group 46% had UC versus 47% in the control group, and the average 
Charlson comorbidity index was 0.50 (SD 1.30) in the UCLA group versus 0.46 (1.19). There 
were no significant differences in baseline utilization and relapses in the index year 
between both groups. Numerically, we observed 32% less ED visits, 21% less 




Figure 6.1. Inclusion flowchart. 
 
In the ITT analysis we observed more than twice as much biomarker testing in the UCLA 
group, with an increase in CRP, ESR, and calprotectin testing of 116% (P=0.00003), 116% 
(P<0.00001), and 199% (P=0.00006), respectively. No significant differences in other IBD 
related health care utilization or medication use were observed. However, numeric 
reductions of more than 50% were observed for ED visits (58% ), hospitalizations (57%), 
upper endoscopies (74%), and abdominal ultrasounds (60%) (Table 6.7). Furthermore, we 
observed 58% less systemic corticosteroid use, 80% less long-term corticosteroid use, 68% 
more topical corticosteroid use, 231% more methotrexate use, and 73% more 
adalimumab use in UCLA patients (Table 6.8). 
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Age (years), avg (SD) 39 (12) 39 (11) 0.99 
IBD subtype, n (%) 
- Ulcerative colitis 









Charlson comorbidity score in 2012, avg (SD) 0.50 (1.30) 0.46 (1.19) 0.91 
days with IBD related claims in 2012, avg (SD) 8.8 (8.9) 7.8 (10.1) 0.20 
Office visits in 2012, avg (SD) 4.1 (4.3) 3.3 (2.9) 0.19 
ED visits in 2012, avg (SD) 0.21 (0.61) 0.31 (1.29) 0.25 
Hospitalizations in 2012, avg (SD) 0.11 (0.51) 0.14 (0.43) 0.12 
Surgeries in 2012, avg (SD) 0.06 (0.37) 0.07 (0.33) 0.36 
Relapses in 2012*, avg (SD) 0.86 (1.22) 0.83 (1.19) 0.91 
Insured for pharmacy claims in 2013, n (%) 375 (75) 68 (68) 0.14 
Table 6.6. Baseline demographics and IBD related utilization in index year (2012) for patients included in the ITT 
analysis.  
*only patients with insurance plans that covered prescription drugs were included in this assessment (UCLA n=77, 
non-UCLA n=384).  
 
IBD related utilization in 2013,  
average (SD) UCLA (n=100) Non-UCLA (n=499) Δ P 
Office visits 2.9 (3.0) 2.6 (3.6) +14% 0.10 
Office visits with gastroenterologist 1.6 (1.5) 1.6 (2.0) -0.8% 0.32 
ED visits 0.11 (0.35) 0.26 (1.79) -58% 0.91 
Hospitalizations 0.05 (0.22) 0.12 (0.50) -57% 0.40 
Colonoscopies 0.42 (0.57) 0.38 (0.60) +11% 0.34 
Upper endoscopies 0.020 (0.141) 0.078 (0.30) -74% 0.064 
Surgeries 0.050 (0.261) 0.056 (0.292) -11% 0.86 
Complete blood count 2.7 (3.0) 2.6 (3.7) +3.7% 0.65 
Liver enzyme tests 2.4 (2.9) 2.2 (3.3) +6.9% 0.66 
C-reactive protein 1.47 (1.95) 0.68 (1.4) +116% 0.00003 
Sedimentation rate (ESR) 1.46 (1.96) 0.68 (1.35) +116% <.00001 
Stool calprotectin 0.15 (0.386) 0.050 (0.275) +199% 0.00006 
C. difficile stool test 0.15 (0.44) 0.10 (0.43) +44% 0.10 
X-ray 0.23 (0.96) 0.27 (1.92) -15% 0.46 
CT scan 0.17 (0.47) 0.29 (1.06) -41% 0.69 
MR scan 0.08 (0.273) 0.066 (0.332) +21% 0.25 
Ultrasound 0.03 (0.171) 0.074 (0.277) -60% 0.13 
Relapses* 0.59 (1.02) 0.59 (1.28) +1.7% 0.50 
Table 6.7.Health care utilization in matched UCLA and non-UCLA patients included in the ITT analysis.  





Medication use in 2013, n (%) UCLA (n=68) Non-UCLA (n=375) Δ P 
Any IBD related medication 60 (88.2) 300 (80.0) +10% 0.13 
Topical 5-ASA 7 (10.3) 42 (11.2) -8.1% 1.00 
Oral 5-ASA 30 (44.1) 177 (47.2) -6.5% 0.69 
Metronidazole/ciprofloxacin 12 (17.6) 53 (14.1) +25% 0.46 
Topical corticosteroids 7 (10.3) 23 (6.1) +68% 0.20 
Budesonide 6 (8.8) 31 (8.3) +6.7% 0.81 
Systemic corticosteroids 8 (11.8) 106 (28.3) -58% 0.0039 
Long term corticosteroids 1 (1.5) 27 (7.2) -80% 0.10 
Thiopurines 23 (33.8) 95 (25.3) +34% 0.18 
Methotrexate 3 (4.4) 5 (1.3) +231% 0.11 
Biologics 26 (38.2) 102 (27.2) +41% 0.080 
- adalimumab 16 (23.5) 51 (13.6) +73% 0.043 
- infliximab 10 (14.7) 51 (13.6) +8.1% 0.85 
- certolizumab pegol 0 (0) 9 (2.4) -100% 0.37 
- natalizumab 0 (0) 0 (0) 0% 1.00 
Table 6.8. Number of patients using IBD medication in matched UCLA and non-UCLA patients in the ITT analysis.  
 
Per protocol analysis 
In total, 49 UCLA IBD patients were included in the PP analysis (Figure 6.1, Table 6.9), 
which were matched to 245 control patients. Increases in biomarker testing were 
confirmed with an observed 161% increase in CRP testing (P<0.00001), 134% increase in 
ESR testing (P=0.00007), and 344% increase in calprotectin testing (P=0.00011). No 
significant differences in health care utilization or medication use were detected between 
the two groups. The observed numeric differences were confirmed in the PP analysis, with 
slightly higher effect sizes: 75% less ED visits, 89% less hospitalizations, 79% less upper 
endoscopies, and no ultrasounds in the UCLA group. In addition, we observed 57% less CT 
scans and 64% less abdominal X-rays in UCLA patients. Finally, no IBD surgeries were 
observed in the UCLA group. Similar trends were observed in medication use as well with 
a 61% reduction in corticosteroid use, as well as long-term corticosteroid use, and 68% 
more rectal corticosteroid use. Additionally, 76% less budesonide use was observed in this 
cohort. More than 4 times as many UCLA patients used methotrexate compared to 
controls, and 41% more patients used adalimumab. The number of relapses was 48% less 
in UCLA patients (Figure 6.2 and 6.3, Tables 6.10 and 6.11). 
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Age avg (SD) 39 (12) 40 (12) 0.95 
IBD subtype n (%) 
- Ulcerative colitis 









Charlson comorbidity score in 2012 avg (SD) 0.47 (1.10) 0.44 (1.09) 0.85 
days with IBD related claims in 2012 avg (SD) 7.7 (8.3) 8.7 (10.2) 0.47 
Office visits in 2012 avg (SD) 3.6 (3.1) 3.4 (2.8) 0.89 
ED visits in 2012 avg (SD) 0.16 (0.59) 0.51 (3.0) 0.11 
Hospitalizations in 2012 avg (SD) 0.12 (0.63) 0.19 (0.57) 0.09 
Surgeries in 2012 avg (SD) 0.061 (0.429) 0.065 (0.332) 0.45 
Relapses in 2012* avg (SD) 0.86 (1.34) 0.84 (1.28) 0.94 
Insured for pharmacy claims in 2013 n (%) 33 (67) 179 (73) 0.42 
Table 6.9. Baseline demographics and IBD related utilization in index year (2012) for patients included in the PP 
analysis. *only patients with insurance plans that covered prescription drugs were included in this assessment 





Figure 6.2. Change in health care utilization in IBD patients treated at the UCLA IBD Center compared to controls 
(ITT analysis and PP analysis), and compared to the year before enrollment at the UCLA IBD Center in a 





Figure 6.3. Change in medication use in IBD patients treated at the UCLA IBD Center compared to controls (ITT 
analysis and PP analysis), and compared to the year before enrollment at the UCLA IBD Center in a longitudinal 
cohort. 
 
IBD related utilization in 2013, 
average (SD) UCLA (n=49) Non-UCLA (n=245) Δ P 
Office visits 2.9 (2.4) 3.1 (2.7) -8% 0.41 
Office visits with gastroenterologist 1.7 (0.8) 2.2 (1.8) -23% 0.057 
ED visits 0.16 (0.43) 0.67 (5.20) -75% 0.52 
Hospitalizations 0.020 (0.143) 0.184 (0.68) -89% 0.064 
Colonoscopies 0.43 (0.54) 0.48 (0.67) -10% 0.91 
Upper endoscopies 0.020 (0.143) 0.098 (0.36) -79% 0.15 
Surgeries 0 (0) 0.045 (0.226) -100% 0.15 
Complete blood count 2.9 (2.8) 3.3 (5.4) -11% 0.99 
Liver enzyme tests 2.7 (2.8) 2.8 (4.8) -4% 0.73 
C-reactive protein 1.98 (2.02) 0.76 (1.33) +161% <.00001 
Sedimentation rate (ESR) 1.82 (2.02) 0.78 (1.39) +134% 0.00007 
Stool calprotectin 0.163 (0.373) 0.037 (0.228) +344% 0.00011 
C. difficile stool test 0.18 (0.53) 0.14 (0.49) +32% 0.42 
X-ray 0.16 (0.62) 0.45 (2.72) -64% 0.91 
CT scan 0.20 (0.54) 0.48 (2.46) -57% 0.85 
MR scan 0.061 (0.242) 0.069 (0.285) -12% 0.99 
Ultrasound 0 (0) 0.11 (0.33) -100% 0.015 
Relapses* 0.36 (0.86) 0.70 (1.28) -48% 0.089 
Table 6.10. Health care utilization in matched UCLA and non-UCLA patients included in the PP analysis. 
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Medication use in 2013, n (%) UCLA (n=33) Non-UCLA (n=179) Δ P 
Any IBD related medication 30 (90.9) 149 (83.2) +9.2% 0.43 
Topical 5-ASA 4 (12.1) 19 (10.6) +14% 0.76 
Oral 5-ASA 17 (51.5) 91 (50.8) +1.3% 1.00 
Metronidazole/ciprofloxacin 7 (21.2) 28 (15.6) +36% 0.45 
Topical corticosteroids 4 (12.1) 14 (7.8) +55% 0.49 
Budesonide 1 (3.0) 23 (12.8) -76% 0.14 
Systemic corticosteroids 4 (12.1) 56 (31.3) -61% 0.034 
Long term corticosteroids 1 (3.0) 14 (7.8) -61% 0.48 
Thiopurines 11 (33.3) 62 (34.6) -3.8% 1.00 
Methotrexate 2 (6.1) 2 (1.1) +442% 0.12 
Biologics 12 (36.4) 52 (29.1) +25% 0.41 
- adalimumab 7 (21.2) 27 (15.1) +41% 0.44 
- infliximab 5 (15.2) 26 (14.5) +4.3% 1.00 
- certolizumab pegol 0 (0) 5 (2.8) -100% 1.00 
- natalizumab 0 (0) 0 (0) 0% 1.00 
Table 6.11. Number of patients using IBD medication in matched UCLA and non-UCLA patients in the PP analysis.  
 
Longitudinal analysis 
In total 86 UCLA patients were included in the longitudinal analysis (Figure 6.1). Biomarker 
testing using CRP increased with 78% (P=0.0025), the number of upper endoscopies 
decreased by 76% (P=0.00075), and the number of CT scans decreased by 57% (P=0.0028). 
No significant differences in other outcomes were observed between the year before and 
after enrollment in the UCLA IBD Program. Numerically, there was an increase in 
biomarker testing using ESR or calprotectin (45% and 50%, respectively) and MR scans 
(22%), and a decrease in the average number of ED visits (46%), hospitalizations (44%), 
surgeries (13%), ultrasounds (40%), and abdominal X-rays (20%). The number of relapses 
was 21% less after enrollment. Corticosteroid use decreased by 23%, long-term 
corticosteroids use by 44%, budesonide use by 17%, and topical corticosteroid use by 25% 
after enrollment in the UCLA IBD Program. No changes in methotrexate use were 
observed before and after enrollment in the UCLA IBD Program. Overall 37% more 
patients used biologics after enrollment, with a 70% increase in adalimumab use and 23% 




These are the first results of a novel and developing VBHC program for IBD management. 
We show evidence that patients treated in this VBHC program, which incorporated 1) 
constant monitoring of health outcomes; 2) highly coordinated care pathways; 3) patient 
education; and 4) task differentiation between providers, undergo more preventative 
monitoring then matched control patients and undergo less IBD related tests. This reflects 
the highly preventative nature of this program in contrast to the often observed reactive 
nature of current IBD care.14 Since this study only included Anthem members, and it only 
reports on the first development stage of the program, the size of the study population is 
relatively small and no significant differences in health care utilization or medication use 
were observed. However, it is highly promising that we did consistently observe trends 
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towards less ED visits, hospitalizations, surgeries, upper endoscopies, and most imaging 
tests, as well as less corticosteroid use (including long term corticosteroid use), and more 
biologics use.  
IBD related utilization, 
average (SD) pre-UCLA 
(n=86) post-UCLA (n=86) Δ P 
Office visits 3.9 (4.2) 3.5 (3.9) -11% 0.23 
Office visits with gastroenterologist 2.0 (1.9) 1.8 (1.9) -11% 0.15 
ED visits 0.33 (0.83) 0.17 (0.60) -46% 0.055 
Hospitalizations 0.21 (0.53) 0.12 (0.56) -44% 0.13 
Colonoscopies 0.64 (0.78) 0.43 (0.62) -33% 0.056 
Upper endoscopies 0.29 (0.53) 0.07 (0.26) -76% 0.00075 
Surgeries 0.093 (0.33) 0.081 (0.382) -13% 0.78 
Complete blood count 3.1 (3.3) 3.8 (3.5) +20% 0.087 
Liver enzyme tests 2.6 (2.9) 3.2 (2.8) +24% 0.021 
C-reactive protein 1.2 (1.9) 2.2 (2.4) +78% 0.0025 
Sedimentation rate (ESR) 1.5 (2) 2.2 (2.3) +45% 0.023 
Stool calprotectin 0.09 (0.33) 0.14 (0.54) +50% 0.69 
C. difficile stool test 0.1 (0.38) 0.16 (0.46) +56% 0.47 
X-ray 0.29 (0.91) 0.23 (0.95) -20% 0.76 
CT scan 0.53 (1.17) 0.23 (0.7) -57% 0.0028 
MR scan 0.1 (0.31) 0.13 (0.4) +22% 0.59 
Ultrasound 0.12 (0.52) 0.07 (0.26) -40% 0.55 
Relapses* 0.85 (0.99) 0.67 (1.05) -21% 0.20 
Table 6.12. Health care utilization in UCLA patients before and after enrollments in UCLA IBD program.*only 
patients with insurance plans that covered prescription drugs were included in this assessment (n=67). 
Medication use in 2013, n (%) pre-UCLA (n=67) Post-UCLA (n=67) Δ P 
Any IBD related medication 59 (88.1) 61 (91.0) 3.4% 0.73 
Topical 5-ASA 13 (19.4) 11 (16.4) -15% 0.75 
Oral 5-ASA 35 (52.2) 33 (49.3) -5.7% 0.77 
Metronidazole/ciprofloxacin 18 (26.9) 15 (22.4) -17% 0.66 
Topical corticosteroids 8 (11.9) 6 (9.0) -25% 0.73 
Budesonide 6 (9.0) 5 (7.5) -17% 1.00 
Systemic corticosteroids 22 (32.8) 17 (25.4) -23% 0.33 
Long term corticosteroids 5 (7.5) 3 (4.5) -40% 0.63 
Thiopurines 19 (28.4) 21 (31.3) 11% 0.75 
Methotrexate 3 (4.5) 3 (4.5) 0% 1.00 
Biologics 19 (28.4) 26 (38.8) 37% 0.016 
- adalimumab 7 (10.4) 12 (17.9) 71% 0.063 
- infliximab 13 (19.4) 16 (23.9) 23% 0.45 
- certolizumab pegol 0 (0) 0 (0) 0% 1.00 
- natalizumab 0 (0) 0 (0) 0% 1.00 
Table 6.13. Number of UCLA patients using IBD medication before and after entering the UCLA IBD Center. 
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Oftentimes it takes many years before these types of care redesign programs come to full 
fruition since there are many initial hurdles to overcome. First, this program was not 
designed and executed as a research project but as an implementation project which 
requires more institutional involvement and change management among all stakeholders. 
Since the medical community is traditionally most resistant to change, it may require a 
multitude of years before programs like ours to truly flourish. Second, the largest 
resistance to VBHC programs is the current fee-for-service (FFS) payment system, which 
does not incentivize the use of a VBHC program. The current payment system incentivizes 
quantity as opposed to quality care, and does not reimburse for many essential care 
components such as email communication. Third, a major upfront investment is required 
for successful implementation of a VBHC program, including the vital development of a 
secure IT infrastructure and mobile application. Consistently, typical Accountable Care 
Organizations (ACO) - i.e. provider groups that take accountability for both outcomes and 
costs in a specified patient population - experienced great difficulty performing in their 
first years. ACOs can qualify for shared savings payments through the Medicare Shared 
Savings Program (MSSP) by successfully reducing total spending and reporting quality 
measures. However, only 22% of ACOs that began participating in the MSSP in 2012 or 
2013 qualified for shared savings.15 Typically, ACOs are far less influencing the care 
delivery process compared to our VBHC programs. Due to unprecedented institutional 
support we were able to implement this program despite the challenges described and we 
expect to continue to report its advances throughout the years. We encourage the various 
groups invested in VBHC to publish early reports of their programs in order to establish a 
basis for best practices and further growth and improvements. 
 
Limitations of this study include that numeric differences in baseline utilization between 
the two groups were observed, including 32% less ED visits and 21% less hospitalizations, 
despite matching on baseline demographics including relapse rate, disease type, 
comorbidities, and age. Therefore, we might have overestimated the observed reduction 
in ED visits (58%) and hospitalizations (57%). We did not have access to objective health 
outcomes in this study due to the use of an insurance claims database. Despite the 
limitations of the dataset, we did observe large numeric differences in health care 
utilization, in three different analyses (i.e. ITT, PP, and longitudinal analysis). As expected, 
the PP analysis showed larger numeric differences in health care utilization than the ITT 
analysis. This is in concordance with the fact that these patients continued to receive care 
at UCLA, while the ITT analysis also included patients with no follow-up visits at UCLA 
and/or patients with concomitant visits elsewhere. 
 
The observed reduction in hospitalizations is in accordance with the results of the chronic 
care model at the Royal Adelaide Hospital in Australia7. In contrast, this study found 
numerically more corticosteroid use in the chronic care group as well as more 
immunomodulators. Consistent with other programs10 utilizing remote monitoring, we 
could not confirm a reduction in relapse rate, possibly due to the fact that more relapses 
are identified using remote monitoring approaches. In contrast to these programs, we did 




In order to bend the cost curve and improve care quality in IBD, VBHC is thought to be the 
most certain path going forward. Due to the initial phase of the UCLA IBD Program 
analyzed and reported here, many components of a full VBHC Program were not 
implemented yet. In 2013 an electronic system was implemented, which enables patients 
to view their care scenarios, easily communicate with a dedicated IBD nurse through 
messaging, and fill out electronic home monitoring questionnaires. Furthermore, this 
electronic system enables internal outcome reporting. In 2014 a mobile application (eIBD, 
available through iTunes and Google Play Store) was launched to facilitate this process 
even further, which to date has been used by almost 200 IBD patients. The mobile health 
index (mHI), a validated score consisting of 4 patient reported outcomes, was developed 
for implementation on the app.16 This score improves the accuracy of home monitoring as 
well as allows for continuous outcome monitoring, which is of utmost importance in a 
VBHC program. Future research will address the effects of these implementations because 
the current dataset does not include the necessary follow up for these analyses. 
 
Summarized, this is the first comprehensive utilization analysis of a VBHC program for IBD 
management. Despite the limitations of this study we feel this study gives a first insight in 
the effects of a comprehensive VBHC approach in IBD. More intense disease activity 
monitoring was confirmed and positive trends were observed, including trends towards 
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Chapter 7.  
 






Value based health care (VBHC) is thought to be the solution to fix the health care crisis. 
Health care costs are increasing globally, and restructuring of our payment system may be 
the most promising solution. The key concept of VBHC is to evaluate care by the health 
value obtained: the achieved health outcomes divided by the encountered costs.1,2 By 
rewarding high value care, an incentive is created to reduce costs and improve quality. 
However, in order to fairly reward value, value needs to be clearly defined. This value 
definition is an essential component for a well-functioning VBHC system. 
 
Chapter 1 discusses in depth the key components of VBHC, and the applicability in IBD 
management. The three key components discussed are 1) measuring the right outcomes 
and the associated costs of care; 2) reporting those outcomes and comparing them to 
outcomes from other providers; and 3) improve care delivery accordingly in a coordinated 
care infrastructure which supports the implementation of these changes. A fourth 
component – a value based insurance system, in which value of care is rewarded rather 
than volume of care – is essential to drive this cycle of improvement. While the number of 
programs incorporating key-components of VBHC is rapidly growing, the evidence 
supporting these concepts is still limited to date.3 This thesis explores the first part of this 
VBHC framework in IBD – the development, implementation, and measurement of 
outcome measures relevant for the evaluation of IBD care – and evaluates the efficacy of 
an IBD specific VBHC program implemented at the University of California, Los Angeles 
(UCLA). 
 
Inflammatory bowel diseases (IBD), consisting of Crohn’s disease and ulcerative colitis, are 
chronic inflammatory diseases of the intestines. IBD is thought to be caused by 
environmental triggers, which lead to a dysregulated immune response in a susceptible 
host.4 IBD are chronic, lifelong diseases, which affect around 1.4 million Americans. IBD 
treatment is associated with significant costs, which were traditionally mostly driven by 
hospitalizations, and more recently by the newer biological therapies.5,6 The UCLA Center 
for IBD has implemented a VBHC program in 2012, which incorporates the key concepts of 
VBHC. The program is based on a coordinated care infrastructure and is supported by a 
designated IT platform with a patient app. Patients are treated by pre-defined evidence-
based care pathways, in which health outcomes are measured frequently while IBD 
related health care utilization is tracked. The in-house developed UCLA eIBD mobile app 
allows patients to view their treatment plan, update medications, participate in eLearning, 
and communicate directly with a specialized IBD nurse. Additionally, wellness programs 
tailored for IBD patients are available. To assess the treatment results of individual 
patients, and to assess overall performance, the UCLA IBD Center developed the outcome 
metric value quotient (vQ). The vQ is calculated by dividing obtained patient value by the 
associated costs. Patient value is defined as a combination of disease control, quality of 
life, and (work) productivity.9 In Chapter 2, 3, and 4 the development and evaluation of 
IBD specific outcome metrics to assess patient value are discussed, while Chapter 5 and 6 
focus on the measurement of health care utilization in IBD care as a proxy for costs. 




As discussed in Chapter 1, quality of care can be assessed on multiple levels using 
structure, process, or outcome measures.10 Structural measures assess the availability of 
resources in a care delivery setting such as the number of beds in a hospital. Process 
measures evaluate key processes in health care delivery and can be helpful for internal 
process improvement. However, process measures do not measure what is ultimately 
important to the patient: the achieved outcomes. Therefore, outcome measures are 
increasingly recognized to be the most important metrics to assess. The evaluation of care 
using outcome metrics should incorporate outcomes in three tiers: 1) the achieved level 
of health and quality of life, 2) the level of discomfort during the recovery process, and 3) 
the sustainability of the achieved outcomes; regardless of the processes leading to these 
outcomes.11 Which outcomes are important to measure remains ill-defined, but patient 
reported outcomes are increasingly recognized to be important. The IBD Center strives to 
measure patient value regularly, to get an in-depth view on the obtained results in all 
three tiers. While clinical outcome scores can be evaluated during clinic visits, remote 
monitoring of outcomes using patient reported measures is essential to ensure regular 
evaluation of patients’ health statuses. In Chapter 2 we developed a score for remote 
monitoring of IBD disease activity that patients can use on a mobile app. We assessed how 
well different patient reported outcomes predict clinical disease activity using 
multivariable logistic regression. Two composite-scores were developed, one for Crohn’s 
disease and one for ulcerative colitis patients. Both scores consist of four patient reported 
questions that accurately predict clinical disease activity. This tool is now implemented in 
the UCLA eIBD app and allows for year-round monitoring of patient reported outcomes in 
the out-of-clinic setting. 
 
In Chapter 3 we assessed the prevalence of reduced work productivity in IBD patients. 
Reductions in work productivity can be categorized as absenteeism or presenteeism. 
Absenteeism refers to missed work hours due to for example sickness, or doctor’s visits. 
Presenteeism refers to reduced productivity while at work. We showed that absenteeism 
rates are significantly higher in patients with active disease (47%) than in patients with 
remissive disease (14%). Similarly, more presenteeism was observed in patients with 
active disease (95%) than in patients in remission (55%). No difference in absenteeism 
rates was observed between patients in remission and healthy controls (both 14%). 
However, patients in remission still experience significantly higher rates of presenteeism 
(55%) than healthy controls (27%). The most common reported cause for reduced 
productivity was fatigue (42%), and only 34% of patients were able to make adjustments 
in their work schedule to avoid taking time off.12 
 
To further quantify the patient value component of the vQ, we assessed patient 
preference for the three outcomes incorporated in the vQ: disease control, quality of life, 
and productivity, in Chapter 4. Using a choice-based conjoint analysis we showed that 
there is a large variation in individual preferences between patients. Overall, quality of life 
is perceived to be more important than both disease control and productivity, and 
increases from low outcome levels to intermediate outcome levels are valued more than 
increases from intermediate to high levels. Furthermore, we constructed a composite 
patient value metric weighted based on observed patient preferences for disease 
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outcome (i.e. quality of life outcomes were weighted more heavily than disease control 
outcomes if a patient valued quality of life more than disease control). Use of these 
patient-centric patient value scores resulted in significantly different outcomes, both on 
the individual patient level, and on the aggregate provider level. Incorporation of patient 
preferences in the treatment plan, a process called shared decision making, has been 
shown to increase both patients’ knowledge as well as the patients’ experience.13 Because 
of the importance of shared decision making and the observed differences in the 
observed patient value metric when incorporating patients’ preferences, we suggest that 
physicians should be rewarded accordingly in value-based insurance designs. 
 
To quantify the complete vQ, costs need to be assessed as well. In Chapter 1 different 
methods to estimate costs are discussed. Charges, the amounts listed on hospital bills that 
are charged to the insurance, are most readily available. However, charges often correlate 
poorly with the actual reimbursements which in turn don’t correlate well with the actual 
costs of care.14 To truly understand the costs of care, a method called time driven activity 
based costing (TDABC) can be used. This technique assigns costs, based on the time and 
materials required, to each step in the process. TDABC has successfully been shown to 
measure costs and identify waste in care processes.15 While TDABC offers a good solution 
to estimate costs of specific processes of care, it is hard to assess overall costs in care due 
to the time intensive nature of the development of TDABC models. Therefore, we chose to 
focus on health care utilization instead. Utilization data can be obtained from payer 
databases, hospital databases, or medical clearing houses. We developed methods to 
extract meaningful utilization patterns using insurance claims and applied those in 
Chapter 5 and 6. Next to the direct costs, indirect costs should eventually be incorporated 
in the vQ as well. It has been shown that indirect costs due to losses in work productivity 
represent a major percentage of overall health care related costs.16 In Chapter 3 we 
confirmed high indirect costs in IBD as well, mostly due to presenteeism.12 
 
In Chapter 5, US health care utilization in IBD care is evaluated in depth using an insurance 
claims analysis. Using a database with 964,633 IBD patients, we showed that utilization 
patterns are inconsistent with current guideline-based recommendations. We showed 
that 42% of Crohn’s disease patients are managed using aminosalicylates, which are 
shown to be non-effective in this population while accounting for 54% of prescription drug 
costs in IBD management. Additionally, 46% of patients were shown to use 
corticosteroids, of which 9% used corticosteroids for more than 90 consecutive days. 
Nonetheless, corticosteroid sparing medications were prescribed infrequently, in contrast 
to current guideline-based recommendations. Lastly, we observed only infrequent usage 
of biomarker testing for disease control.7 Non-adherence to guidelines, leading to 
underuse of necessary care and overuse of unnecessary care, is known to be a major 
contributor to excessive health care costs in the US.8 In Chapter 5 we confirmed that 
overutilization and underutilization are significant problems in IBD management as well, 
which indicates that implementation of VBHC components in IBD management could 




To facilitate the care delivery process and allow for structural implementation of 
improvements, a coordinated care infrastructure is important. Additionally, a coordinated 
care infrastructure can facilitate the routine collection of outcome measures in a 
systematic manner. In Chapter 1 different models for care coordination are explored. 
Positive results have been shown for disease-specific infrastructures17 as well as for 
population health infrastructures such as the U.S. patient-centered medical home18 and 
primary care based systems19. For IBD specifically only one evaluation of a coordinated 
care infrastructure has been published, in which a reduction in hospitalizations and costs 
after implementation was shown.20 In Chapter 6 we evaluated the UCLA IBD Center’s 
VBHC infrastructure by comparing patients treated at the UCLA IBD Center to a matched 
control population of patients treated by gastroenterologists elsewhere. We found 
significantly more biomarker testing and numeric reductions in the number of ED visits, 
hospitalizations, surgeries, upper endoscopies, and radiology tests in UCLA patients. 
Additionally, UCLA patients received more biologics and less short and long term 
corticosteroids, which is thought to result in better long term outcomes. 
 
Finally, in order to promote VBHC, physicians will need to be reimbursed for delivering 
high value. A large variety of insurance designs have been developed that incentivize 
either cost savings, such as capitated payments and shared saving contracts, or that 
incentivize high quality care, such as pay for performance programs. More recently, 
insurance designs rewarding the combinations of high quality and low costs have been 
implemented, such the U.S. Accountable Care Organization model. The reported results of 
these programs are mixed and the number of reports is still very limited.21 Generally, 
value-based insurance designs can target physicians or patients by reimbursing high value 
care more generously than low value care, which is discussed in depth in Chapter 1. 
Additionally, in Chapter 4 a method to incorporate patient preference in reimbursement 
strategies is discussed. 
 
 
General discussion and future perspectives 
 
The essence of VBHC is to improve patients’ outcomes at lower costs. This thesis attempts 
to construct the value quotient (vQ) for IBD: a metric for value which incorporates patient 
value, defined as a combination of disease control, quality of life, and productivity in the 
numerator, and divides it by the associated IBD-related costs in the denominator. In this 
thesis we showed the feasibility of monitoring clinical disease control remotely using a 
mobile app, we showed the impact of IBD on work productivity, and we developed a 
patient-centric composite score that incorporates all three outcomes as well as individual 
patient preferences. However, metrics for long term outcomes still need to be 
incorporated in the vQ. Although ideally this would be done by measuring disease 
outcomes long-term, this is not practical for short-term improvements. Process measures 
that are associated with long term outcomes and that are well-grounded in the medical 
literature offer a feasible short term alternative. Future research is needed to assess 
which process measures would be appropriate in this context, and to develop a 
quantifiable way to include these in the vQ. 
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The cost component of the vQ can be split into direct and indirect costs. Though in this 
thesis no direct costs were estimated in dollar amounts, we did develop and apply 
methods to assess health care utilization in IBD. To fully quantify the vQ, methods to 
reliably and efficiently estimate direct costs need to be developed. TDABC offers a very in 
depth view of costs associated with care, but is a very time intensive method that needs 
to be repeated for every process involved in care delivery. Utilization-based cost-models 
based on published costs could be a more practical approach. The development of a 
procedure database with TDABC-derived cost estimations would be of major value to 
facilitate further research in this field. Indirect costs are another major contributor to 
disease-associated costs. We were able to estimate indirect costs and showed that 
presenteeism is the major cause of indirect costs in IBD. This suggests that incorporation 
of rehabilitation and work-integration strategies in IBD care could vastly improve the 
value of care. Future research needs to be done to identify successful interventions that 
improve work productivity. 
 
Full VBHC implementation requires benchmarking of outcome and costs data, and 
subsequent improvement of the care processes, which can be facilitated by value-based 
insurance contracting. This thesis adds to the still limited evidence-base for VBHC, by 
showing preliminary results of a VBHC program specifically designed for IBD. Although the 
scientific evidence is limited, a VBHC approach might be the only option to safeguard the 
existence of a sustainable and accessible health care system, given the growing costs of 
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Nederlandse samenvatting (Dutch summary) 
 
Samenvatting en perspectief 
Value based healthcare (VBHC) – in het Nederlands te vertalen als ‘op waarde gebaseerde 
zorg’ – is een potentiële oplossing voor de financiële crisis in de gezondheidzorg. 
Wereldwijd nemen de kosten voor gezondheidszorg toe, en een anders georganiseerde 
financiering lijkt daar een goede oplossing voor te kunnen bieden. Het belangrijkste idee 
achter VBHC is dat zorg wordt beoordeeld en vergoed op basis van de waarde die 
geleverd wordt: de behaalde resultaten gedeeld door de gemaakte kosten.1,2 Het 
vergoeden van hoogwaardige zorg is een drijfveer om de kosten te verlagen en de 
kwaliteit te verbeteren. Om de waarde van de zorg objectief te kunnen belonen, moet die 
waarde wel scherp gedefinieerd worden. Die waardedefinitie is een essentiële component 
van een VHBC-systeem. 
 
Hoofdstuk 1 van dit proefschrift behandelt in detail de belangrijkste componenten van 
een VBHC-systeem, en de toepasbaarheid van VHBC op de behandeling van inflammatoire 
darmziekten (IBD). De drie belangrijkste componenten zijn: 1) het meten van de 
resultaten van de zorg en de daaraan verbonden kosten; 2) het rapporteren van de 
resultaten en kosten en het vergelijken daarvan met die van andere zorgaanbieders; en 3) 
het verbeteren van de zorg aan de hand van de resultaten en kosten in een gecoördineerd 
zorgsysteem dat de implementatie van verbeteringen faciliteert. Een vierde element, een 
value-based insurance systeem – ofwel een op waarde gebaseerd verzekeringssysteem – 
waarin zorg vergoed wordt op basis van de behaalde waarde in plaats van op basis van het 
geleverde volume, is essentieel om deze verbeteringscyclus in stand te houden. Hoewel 
het aantal ziekenhuizen dat onderdelen van VBHC implementeert wereldwijd snel groeit, 
is het bewijs dat deze concepten ook echt werken nog zeer beperkt.3 Dit proefschrift 
focust op de eerste component van dit VBHC-kader specifiek voor IBD-gerelateerde zorg – 
de ontwikkeling en implementatie van resultaatindicatoren relevant voor IBD – en 
evalueert de effectiviteit van een VBHC-programma voor IBD bij de Universteit van 
Califonia in Los Angeles (UCLA). 
 
Inflammatoire darmziekten (IBD) – de ziekte van Crohn en colitis ulcerosa – zijn 
chronische ontstekingsziekten van de darmen. De gangbare opvatting is dat IBD 
veroorzaakt wordt door onbekende omgevingsfactoren, die leiden tot een 
ongecontroleerde immuunreactie bij patiënten die daar een aanleg voor hebben.4 IBD is 
een chronische, levenslange ziekte, die bij ongeveer 1,4 miljoen Amerikanen is 
vastgesteld. Behandeling van IBD gaat gepaard met aanzienlijke kosten, die van oudsher 
vooral werden veroorzaakt door ziekenhuisopnames, en meer recent vooral door nieuwe 
biologische therapieën.5,6 Het IBD Centrum van UCLA is in 2012 een VBHC programma 
begonnen, waarin de belangrijkste concepten van VBHC zijn opgenomen. Het programma 
is ontwikkeld rondom een gecoördineerd zorgsysteem en wordt ondersteund door een 
speciaal ontwikkeld IT-platform met een mobiele app voor patiënten. Patiënten worden 
behandeld volgens vastgelegde zorgpaden op basis van recente inzichten en richtlijnen. In 
het systeem wordt de gezondheidsstatus van patiënten regelmatig gemeten, en wordt het 
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aantal IBD-gerelateerde doktersbezoeken, laboratoriumonderzoeken en behandelingen 
bijgehouden. Via de bij UCLA ontwikkelde eIBD mobiele app kunnen patiënten hun 
behandelplan bekijken, veranderingen in hun medicijngebruik registreren, deelnemen aan 
interactief onderwijs, en rechtstreeks communiceren met een gespecialiseerde IBD-
verpleegkundige. Tevens zijn er wellness-programma’s beschikbaar, specifiek ontwikkeld 
voor IBD patiënten. Om de resultaten van de zorg voor individuele patiënten, en 
daarnaast die van het programma in totaal te beoordelen, heeft het UCLA IBD Centrum de 
value quotient (vQ) ontwikkeld. De vQ wordt berekend door de verkregen patient value – 
de waarde van de resultaten voor de patiënt – te delen door de bijbehorende kosten. 
Patient value wordt gedefinieerd als een combinatie van de mate waarin de ziekte onder 
controle is, de kwaliteit van leven, en de (arbeids)productiviteit.9 In de hoofdstukken 2, 3 
en 4 wordt de ontwikkeling en de evaluatie van IBD-specifieke resultaatindicatoren voor 
patient value besproken, terwijl de hoofdstukken 5 en 6 gericht zijn op het meten van het 
zorggebruik in IBD als een benaderingsmethodiek voor de gemaakte kosten. De indirecte 
kosten van IBD bespreken we in hoofdstuk 3. 
 
De kwaliteit van zorg kan vanuit meerdere niveaus worden gemeten met behulp van 
structuur-, proces- of resultaatindicatoren.10 Structuurindicatoren meten de beschikbare 
middelen in een zorgomgeving, zoals het aantal bedden in een ziekenhuis. 
Procesindicatoren meten de implementatie van belangrijke processen in de 
gezondheidszorg en kunnen goed worden gebruikt voor interne procesverbetering. 
Procesindicatoren meten echter niet wat uiteindelijk van belang is voor de patiënt: de 
resultaten. Daarom worden resultaatindicatoren in toenemende mate het belangrijkste 
geacht om the evalueren. De evaluatie van zorg op basis van resultaatindicatoren kent 
drie verschillende aspecten: 1) de mate van gezondheid en kwaliteit van leven die bereikt 
is; 2) de mate van ongemak tijdens het herstelproces; en 3) de duurzaamheid van de 
behaalde resultaten, ongeacht hoe deze resultaten behaald worden.11 Hoe de resultaten 
bepaald moeten worden is onduidelijk, maar patient reported outcomes – ofwel 
resultaten die door de patiënt gerapporteerd worden – worden steeds belangrijker 
gevonden. Het UCLA IBD Centrum streeft ernaar om de patient value frequent te meten, 
en zo goed zicht op de resultaten op alle drie aspecten te krijgen. Klinische resultaten 
kunnen tijdens doktersbezoeken worden geëvalueerd, maar het op afstand monitoren van 
zorgresultaten door middel van patient reported outcomes is essentieel om een frequente 
evaluatie van de gezondheidsstatus van patiënten te waarborgen. In hoofdstuk 2 hebben 
wij een index voor het op afstand monitoren van de IBD ziekteactiviteit ontwikkeld, die 
patiënten kunnen gebruiken op een mobiele app. We hebben onderzocht hoe goed 
verschillende patient reported outcomes de klinische ziekteactiviteit van de ziekte 
voorspellen met behulp van multivariabele logistische regressie. Twee indices werden 
ontwikkeld, één voor patiënten met de ziekte van Crohn en één voor patiënten met colitis 
ulcerosa. Beide indices zijn gebaseerd op vier door de patiënt te beantwoorden vragen, 
die de klinische activiteit van de ziekte nauwkeurig voorspellen. Deze index is nu 
geïmplementeerd in de UCLA eIBD patiënten app en zorgt voor continue monitoring door 




In hoofdstuk 3 onderzochten we de vermindering van de arbeidsproductiviteit van IBD-
patiënten. Verlaging van arbeidsproductiviteit kan worden gecategoriseerd als 
ziekteverzuim of als presenteïsme. Ziekteverzuim betreft gemiste werkuren als gevolg van 
bijvoorbeeld ziekte of doktersbezoeken. Presenteïsme verwijst naar verminderde 
productiviteit tijdens het werk. We lieten zien dat het ziekteverzuim significant hoger is bij 
patiënten met ziekteactiviteit (47%) dan bij patiënten met met goed gecontroleerde IBD 
(14%). Evenzo was er meer presenteïsme bij patiënten met actieve ziekte (95%) dan bij 
patiënten in remissie (55%). Er was geen verschil in verzuimpercentages tussen patiënten 
in remissie en de gezonde controlegroep (14% beide). Wel trad bij patiënten in remissie 
aanzienlijk meer presenteïsme op (55%) dan bij de gezonde controlegroep (27%). De 
meest genoemde oorzaak van verminderde productiviteit was vermoeidheid (42%). 
Verder was slechts 34% van de patiënten in staat om aanpassingen te maken in hun 
werkschema om ziekmelding te voorkomen.12 
 
Om de patient value component van de vQ verder te kwantificeren, onderzochten wij in 
hoofdstuk 4 de voorkeur van patiënten voor de drie onderdelen van de vQ: de mate 
waarin de ziekte onder controle is, de kwaliteit van leven en de productiviteit. Met behulp 
van een conjoint analyse hebben we laten zien dat er grote variatie is tussen patiënten in 
hun individuele voorkeuren. Over het algemeen wordt kwaliteit van leven door patiënten 
als belangrijker ervaren dan ziektecontrole of productiviteit. Daarnaast wordt een 
verbetering van een laag naar een gemiddeld niveau als belangrijker ervaren dan een 
verbetering van een gemiddeld naar een hoog niveau. Vervolgens hebben we een nieuwe 
resultaatindicator voor patient value gecreëerd, met gewichtsfactoren afhankelijk van de 
gemeten voorkeuren van de individuele patiënt (bijvoorbeeld wanneer een patiënt 
kwaliteit van leven als belangrijker ervaart dan ziektecontrole, dan krijgt kwaliteit van 
leven een hoger gewicht). Het gebruik van deze patiëntgerichte score voor patient value 
resulteerde in significant andere resultaten, zowel op het niveau van de individuele 
patiënt als op het niveau van de zorgverlener. Het is bekend dat het meenemen van 
patiëntvoorkeuren in een behandelplan – shared decision making – leidt tot meer ziekte-
inzicht bij, en een prettiger ervaren behandeling door de patiënt.13 Gezien dit belang van 
shared decision making en gezien de waargenomen verschillen in de patient value 
wanneer patiëntenvoorkeur hierin wordt opgenomen, stellen wij voor artsen ook op basis 
hiervan te beoordelen en te honoreren in value based insurance designs. 
  
Om de vQ volledig te kwantificeren, moeten ook de kosten worden gemeten. In 
hoofdstuk 1 worden verschillende methodes besproken om zicht te krijgen op deze 
kosten. Gemakkelijk te verkrijgen zijn de facturen die door de ziekenhuizen aan de 
verzekeraar en patiënt worden gestuurd. De factuurbedragen correleren in de V.S. echter 
vaak slecht met de daadwerkelijke vergoedingen, die op hun beurt niet goed correleren 
met de werkelijke kosten van de zorg.14 Om echt inzicht te krijgen in de kosten van de zorg 
kan de methode van time-driven activity-based costing (TDABC) worden gebruikt. Deze 
techniek kent kosten toe aan elke stap in het zorgproces, gebaseerd op de tijd en het 
materiaal die voor elke stap nodig zijn. TDABC kan met succes kosten meten en 
inefficiënties in het zorgproces aantonen.15 Hoewel TDABC een goede oplossing kan zijn 
voor het berekenen van de kosten van specifieke processen, is het moeilijk om door 
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middel van deze methode de totale kosten van de zorg te berekenen omdat het 
ontwikkelen van TDABC modellen erg tijdrovend is. Daarom hebben wij ervoor gekozen 
om ons te concentreren op het meten van de hoeveelheid geleverde zorg als een indicator 
voor de kosten. Gegevens over de hoeveelheid geleverde zorg zijn beschikbaar via 
databases van verzekeraars, ziekenhuizen en financiële intermediairs in de 
gezondheidszorg. Wij hebben methodes ontwikkeld om in dit soort data patronen te 
onderkennen die medisch gezien betekenisvol zijn. In hoofdstuk 5 en 6 passen wij deze 
toe. Naast de directe kosten, moeten ook indirecte kosten uiteindelijk worden 
meegenomen in de kwantificatie van de vQ. Het is bekend dat indirecte kosten als gevolg 
van verlies van arbeidsproductiviteit een groot percentage uitmaken van de totale kosten 
van de gezondheidszorg.16 In Hoofdstuk 3 bevestigen wij dat dit ook in de IBD-zorg het 
geval is, wat met name te wijten is aan presenteïsme.12 
 
In hoofdstuk 5 evalueren we het gebruik van gezondheidszorg voor IBD in de V.S. door 
middel van een analyse van verzekeringsclaims. Met behulp van een database met 
964.633 IBD-patiënten hebben we aangetoond dat de huidige zorgpatronen strijdig zijn 
met de actuele richtlijnen. We lieten zien dat 42% van de patiënten met de ziekte van 
Crohn wordt behandeld met aminosalicylaten, hoewel deze bewezen ineffectief zijn voor 
deze populatie, maar wel verantwoordelijk voor 54% van de kosten van voorgeschreven 
IBD-medicatie. Ook lieten wij zien dan 46% van de patiënten corticosteroïden gebruikten, 
waarvan 9% meer dan 90 opeenvolgende dagen. Desondanks bleek het gelijktijdig gebruik 
van steroïd-sparende medicatie laag, wat wederom tegenstrijdig is met de richtlijnen. Ten 
slotte bleek dat biomarker-testen voor het monitoren van ziektecontrole weinig gebruikt 
worden.7 Het niet-naleven van richtlijnen, wat leidt tot onderbenutting van noodzakelijke 
zorg en overmatig gebruik van onnodige zorg, levert een belangrijke bijdrage aan de 
excessieve kosten van de gezondheidszorg in de V.S..8 In hoofdstuk 5 bevestigen wij dat 
ook in de IBD-zorg zowel overgebruik als onderbenutting belangrijke problemen zijn, wat 
aangeeft dat het invoeren van VBHC-componenten in IBD de waarde van IBD-zorg sterk 
kan verhogen. 
 
Om de zorgverlening te vergemakkelijken en verbeteringen structureel door te voeren is 
een gecoördineerd zorgsysteem belangrijk. Bovendien vergemakkelijkt een dergelijk 
systeem het routinematig en systematisch verzamelen van resultaten. In hoofdstuk 1 
worden verschillende modellen voor zorgcoördinatie besproken. Positieve resultaten zijn 
aangetoond in systemen voor specifieke ziektebeelden7 en in gezondheidszorgsystemen 
op nationaal niveau, zoals het patient-centered medical home (PCMH) in de V.S.18 en 
andere systemen gebaseerd op eerstelijns zorg19. Specifiek voor IBD is er slechts één 
publicatie over een gecoördineerd zorgsysteem, waarin minder ziekenhuisopnamen en 
lagere kosten werden gemeten na implementatie.20 In hoofdstuk 6 evalueerden wij de 
resultaten van het bij het UCLA IBD Centrum geïmplementeerde systeem. Patiënten van 
het UCLA IBD Centrum werden vergeleken met een controlegroep van patiënten van 
andere gastro-enterologen. Bij UCLA-patiënten vond significant meer 
laboratoriumonderzoek plaats met biomarkers, maar zij hadden een geringer aantal 
bezoeken aan de spoedeisende hulp, ziekenhuisopnames, operaties, gastroscopieën en 
radiologisch onderzoek. Daarnaast kregen UCLA patiënten meer biologische medicatie en 
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minder korte en lange termijn corticosteroïden, wat aannemelijkerwijs betere resultaten 
oplevert op de lange termijn. 
 
Om VBHC verder te bevorderen, zullen artsen moeten worden gehonoreerd voor het 
leveren van hoogwaardige zorg. Verscheidene verzekeringsmodellen zijn ontwikkeld die 
verschillende componenten van value belonen. Sommige modellen stimuleren 
kostenbesparingen, bijvoorbeeld door de zorgverlener niet meer te honoreren boven een 
bepaald bedrag of door de winst te delen tussen de verzekeraar en zorgverlener. Andere 
modellen stimuleren de zorgkwaliteit, zoals programma's waarin zorgverleners extra 
vergoedingen krijgen wanneer ze aan bepaalde kwaliteitseisen voldoen. Meer recent zijn 
er verzekeringsmodellen geïmplementeerd die de combinatie van hoge kwaliteit én lage 
kosten belonen, zoals in het Accountable Care Organization model in de V.S. – een model 
waarin meerdere partijen in de zorgverlening gedeelde verantwoordelijkheid nemen voor 
zowel resultaten als kosten van de zorg. De eerste resultaten van deze value-based 
insurance designs zijn gemengd en er is nog weinig over gepubliceerd.21 In het algemeen 
kunnen value-based contracten zich richten op zowel artsen als patiënten door 
hoogwaardige zorg ruimer te vergoeden dan laagwaardige zorg, wat besproken is in 
hoofdstuk 1. De in hoofdstuk 4 besproken methode waarmee de voorkeur van de patiënt 
gemeten wordt, kan opgenomen worden in deze verzekeringsmodellen.  
 
 
Algemene discussie en toekomstperspectieven 
 
De essentie van VBHC is het verbeteren van patiëntgerichte resultaten tegen lagere 
kosten. Dit proefschrift heeft als doel de value quotient (vQ) voor IBD te construeren: een 
breuk met in de teller patient value, gedefinieerd als een combinatie van de mate waarin 
de ziekte onder controle is, de kwaliteit van leven en (arbeids)productiviteit, en in de 
noemer de bijbehorende IBD-gerelateerde kosten. In dit proefschrift lieten wij zien dat het 
haalbaar is om ziekteactiviteit op afstand te monitoren met behulp van een mobiele app, 
we toonden de impact aan van IBD op arbeidsproductiviteit, en we ontwikkelden een 
score die alle drie aspecten van patient value meeneemt met gewichtsfactoren passend 
bij de individuele voorkeuren van de patiënt. Statistieken van resultaten op lange termijn 
moeten echter nog in het vQ worden opgenomen. Idealiter zou dit gebeuren door patient 
value over langere tijd te meten. Voor verbeteringen op korte termijn is het meten van 
resultaten op lange termijn echter niet praktisch. Procesindicatoren, waarvan we op basis 
van de medische literatuur mogen aannemen dat zij geassocieerd zijn met resultaten op 
lange termijn, zouden een haalbaar alternatief kunnen zijn. Verder onderzoek is nodig om 
te beoordelen welke procesindicatoren bruikbaar zijn voor dit doel, en om een methode 
te ontwikkelen om deze indicatoren kwantitatief in de vQ op te nemen.  
 
De kostencomponent van de vQ kan worden opgesplitst in directe en indirecte kosten. 
Hoewel in dit proefschrift geen directe kosten in dollars zijn bepaald, hebben we wel 
methodes ontwikkeld om de hoeveelheid IBD-zorg nauwkeurig te meten. Om de vQ 
volledig te kwantificeren moeten methodes worden ontwikkeld waarmee we die directe 
kosten betrouwbaar en efficiënt kunnen schatten. TDABC biedt een goed inzicht in 
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zorgkosten, maar is een tijdrovende werkwijze die moet worden herhaald voor elk proces 
in de zorgverlening. Kostenmodellen die zijn gebaseerd op de hoeveelheid geleverde zorg 
vormen een meer praktische aanpak. Niettemin zou de ontwikkeling van een database 
met kosten van afzonderlijke werkprocessen gebaseerd op TDABC van grote waarde zijn 
voor verder onderzoek op dit gebied. Indirecte kosten vormen een ander belangrijk 
onderdeel van ziekte-gerelateerde kosten. We konden indirecte kosten schatten en 
toonden aan dat presenteïsme de belangrijkste oorzaak is van indirecte kosten in IBD. Dit 
suggereert dat de integratie van revalidatie en reïntegratie op de werkvloer de waarde 
van de zorg sterk kan verbeteren. Toekomstige studies zullen moeten uitmaken wat 
succesvolle interventies zijn die de arbeidsproductiviteit verhogen. 
 
Volledige VBHC implementatie vereist vergelijking van de resultaten en de kosten tussen 
verschillende zorgverleners, en verbetering van de zorgprocessen aan de hand daarvan. 
Meer innovatie hierin kan worden gestimuleerd door het invoeren van value based 
insurance contracten. Dit proefschrift draagt bij aan de nog beperkte bewijsvoering voor 
VBHC, door het tonen van de voorlopige resultaten van een VBHC programma speciaal 
ontworpen voor IBD. Hoewel het wetenschappelijk bewijs beperkt is, denken wij dat VBHC 
een kansrijke optie is om een duurzaam en toegankelijk gezondheidszorgsysteem te 
waarborgen, gezien de toenemende kosten van de zorg wereldwijd. De uitdaging zal zijn 
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